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Abstract 
 
The main body of this thesis deals with a small-scale structural genomics project for proteins 
from the bacterium, Burkholderia pseudomallei. Potential pathogenicity determinants were 
selected based on their possession of at least one of two criteria. The first was their 
expression in the pathogenic Burkholderia pseudomallei but not the closely related, non-
pathogenic Burkholderia thailandensis. The second required their expression be controlled as 
part of a stress response, which controls other known virulence factors. Of the nine selected 
targets, five were successfully overexpressed, purified and crystallised and the structure of 
one was determined. The selected targets were all of unknown function and initial sequence 
analysis highlighted a number of interesting characteristics for certain targets.  
BPSL1958 contains a highly repetitive sequence conserved at both the protein and DNA 
level, suggesting the gene was created in a recent duplication event and there has not been 
enough time for the sequence of the individual repeats to drift.  
Four of the selected targets, BPSS0211 – BPSS0214, formed an operon, of these BPSS0212 
and BPSS0213 were homologous, with BPSS0211 also representing the C-terminal domain 
of the two proteins. The structure of BPSS0211 was determined to 2.17 Å using multiple-
wavelength anomalous dispersion experimental phasing. BPSS0211 is a small protein 
annotated as containing a conserved domain of unknown function, DUF1843. The tertiary 
structure of BPSS0211 entails two alpha helices stacked together which assemble to form a 
tetramer comprising a dimer of dimers. The pattern of conservations between residues in 
DUF1843 within BPSS0211, BPSS0212 and BPSS0213 is such that interactions between the 
three proteins would be possible. The proposed function of DUF1843 is as an oligomerisation 
domain, allowing the formation of homo and hetero, dimer and tetramer, complexes of three 
proteins encoded within the BPSS0211-BPSS0214 operon. 
Other work included involves the determination of the structure of thioredoxin from 
Burkholderia pseudomallei as part of an on-going project into this system. The structure was 
solved to 1.07 Å using molecular replacement and agreed well with previously solved 
thioredoxin structures from other organisms. 
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1.0 Burkholderia pseudomallei is the causative agent of melioidosis 
This section provides an introduction about the bacterial pathogen Burkholderia pseudomallei 
and its biological relevance as the causative agent of the human disease melioidosis. 
Melioidosis is defined as any disease caused by infection with the bacterium Burkholderia 
pseudomallei and was first reported as the cause of death in the post-mortem of a morphine 
addict in Rangoon, Burma in 1911. Detailed microbiological studies identified a new 
organism, Burkholderia pseudomallei, which fulfilled Koch’s postulates as the causative 
agent of the disease [1, 2]. 
1.1 Taxonomy 
The Burkholderia genus was created recently in 1992 with the transfer of seven species from 
the Pseudomonas genus [3]. It now consists of over sixty species occupying a large range of 
ecological niches [4] with highly diverse genomes [5]. The evolutionary history of the genus 
is complex, with high levels of lateral gene acquisition and transfer between species inside 
the genus, broader bacteria and some eukaryotic organisms [6]. The phylogeny has been 
mapped using various techniques [7, 8] one of which is the sequence divergence of the recA 
gene in the individual species [9] (figure 1.1). The genus consists of two genetic lineages 
with one representing mainly pathogenic bacteria and the other predominantly non-
pathogenic environmental isolates often symbiotically associated with plant species. The 
pathogenic group can be split into three further sub-groups. The Burkholderia cepacia 
complex contains a number of opportunistic pathogens that can be responsible for lung 
infections in cystic fibrosis sufferers. The phyto-pathogenic sub-group contains a number of 
plant pathogens, some of which are responsible for disease in important food crops. The last 
sub-group, the pseudomallei group, is the most important in terms of human disease and 
contains the three species, Burkholderia pseudomallei, mallei and thailandensis.  
1.1.1 The pseudomallei group 
Burkholderia pseudomallei and mallei are the causative agents of the human disease 
melioidosis and the equine disease glanders respectively. Burkholderia mallei is unable to 
persist outside of a host while pseudomallei and thailandensis occupy the same 
environmental soil niche in endemic areas. Burkholderia thailandensis is a non-pathogenic 
species, being more than 10,000 fold less virulent than pseudomallei in model organisms 
[10]. The three closely related species are thought to have recently evolved from a common 
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Figure 1.1 Phylogenetic tree for the Burkholderia genus based on recA sequences. The tree is rooted using the 
recA gene from Pseudomonas aeruginosa PAO1 and includes 27 Burkholderia species (those in bold represent 
the pseudomallei group) and 11 other closely related organisms. Bootstrap values and genetic distance are 
shown. Figure adapted from “Development of a recA gene-based identification approach for the entire 
Burkholderia genus” [9]. 
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Australian ancestor followed by an introduction into South East Asia and further divergence 
into numerous strains [11, 12]. Understanding the difference between these closely related 
species and strains would answer important questions, providing a window into the differing 
level of pathogenicity, host specificity, virulence determinants and the ability of the bacteria 
to persist in the environment. 
1.2 Bacteriology 
Burkholderia pseudomallei are gram-negative, non-spore-forming, aerobic, motile, rod-
shaped bacteria (figure 1.2). The bacteria exist in the environment as a soil-dwelling 
saprophyte as well as a pathogen of a number of organisms.  Melioidosis has been identified 
in a wide range of animals including mammals, birds, fish and reptiles with varying levels of 
severity [13]. Burkholderia pseudomallei are also capable of infecting certain plant species 
including tomatoes providing a further environmental reservoir [14]. The organism is highly 
resilient in the environment with the ability to survive in a wide range of harsh conditions in 
both soil and liquid media [15]. The bacteria can not only survive but continue to grow under 
a diverse range of temperature [16], acid and alkali pH [17], and severe dehydration 
conditions [16]. Burkholderia pseudomallei are also able to survive extreme nutrient 
deprivation [18] with the bacteria still maintaining viability after at least sixteen years in 
distilled water [19]. Burkholderia pseudomallei can survive exposure to disinfectant and 
antiseptic solutions [20, 21] and exhibit a tolerance to chlorinated water with levels used in 
water supplies proving only bacteriostatic [22] although elevated levels are effective at killing 
the bacteria [23]. Burkholderia pseudomallei are also naturally resistant to a large number of 
antibiotics including cephalosporins, penecillins, rifamycins, aminoglycosides, quinolones 
and macrolides [15]. 
1.2.1 Colony morphology 
Clinical and environmental isolates of the bacteria exhibit a diverse morphology with seven 
colony types (figure 1.3) when plated out on Ashdown’s agar [24]. Morphology is not strain 
dependant with switching between types being inducible under certain conditions and 
reversible within the same strain. Different morphotypes have different proteomic profiles 
[25] and levels of virulence [26]. Environmental strains almost always display colony 
morphology I and there is a relationship between isolate morphology and patient history. 
Morphology I is the most commonly identified in samples from initial infections, with 
morphologies II and III being represented more often from relapse patients [26]. The level of 
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phenotypic change may provide a mechanism for the bacteria to persist in the host in a latent 
infection or survive antibiotic treatment and subsequently cause relapse in patients. 
Figure 1.2 Schematic diagram showing the cellular structure  of Burkholderia pseudomallei. 
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Figure 1.3 The seven different colony morphologies of Burkholderia pseudomallei. Colonies were 
morphotyped based on appearance, size and pigmentation. The percentages indicate the proportion of each form 
in a collection of 212 clinical isolates after growth for four days on Ashdown’s agar. Figure adapted from 
“Biological relevance of colony morphology and phenotypic switching by Burkholderia pseudomallei” [24]. 
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1.3 Epidemiology 
Melioidosis is endemic throughout the tropical regions of South East Asia and Northern 
Australia where Burkholderia pseudomallei is found in the environment [15] (figure 1.4). It is 
thought that the extent of the disease in these areas as well as worldwide is misrepresented, 
with many cases going unrecognised due to lack of awareness and diagnostic facilities in 
affected areas, particularly amongst rural communities [27]. There is evidence for emerging 
areas of endemicity around the globe, probably due to wider awareness of the disease in 
many areas particularly tropical regions of Africa, the Americas, and a growing area of South 
East Asia and the wider South Pacific [28, 29]. 
1.3.1 Cellular basis of disease 
Burkholderia pseudomallei is an intracellular pathogen with the ability to invade, survive and 
multiply inside host phagocytic and non-phagocytic cells [30] (figure 1.5).  Before the 
bacteria can enter into a host epithelial cell it must first interact with the cells surface through 
adhesion. This is mediated by flagella based motility, the bacterial capsule and through the 
use of type IV pili. The bacteria are taken up into vacuoles, by phagocytosis or invasion, 
which they can later escape from into the host cells cytoplasm. Once inside host cells 
Burkholderia pseudomallei are able to survive, avoiding the bacteriocidal activities of 
immune cells and the induction of autophagy. The bacteria utilise a form of ARP2/3 
independent actin based motility to travel inside host cells [31]. This form of motility also 
allows the bacteria to travel between cells and is involved in the formation of multinucleated 
giant cells. Burkholderia pseudomallei is capable of inducing cell lysis through apoptosis or 
caspase-1-dependent cell lysis [32]. This releases the bacteria from the cell allowing invasion 
of further host cells. The bacteria are able to spread to other areas of the body by transport 
either in the lymphatic or circulatory systems. 
1.3.2 Modes of acquisition 
Infection with Burkholderia pseudomallei usually occurs through cutaneous inoculation or 
inhalation of infected soil or water. The disease can be obtained through ingestion [33] and it 
has also been rarely recorded as transmitting through human to human contact, either 
sexually or during childbirth [34, 35]. Outbreaks of melioidosis are known to exhibit seasonal 
variability with an increased frequency during the rainy season due to increased contact with 
the bacterium through agricultural activity and extreme weather events [30]. Several clinical 
risk factors are known to provide a predisposition to developing melioidosis particularly 
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Figure 1.4 Map representing a summary of known global melioidosis endemicity in 2005. Figure adapted from 
“Melioidosis: Epidemiology, pathophysiology, and management” [15]. 
 
 
 
Figure 1.5 The intracellular lifestyle of Burkholderia pseudomallei. Bacteria enter into host cells inside primary 
phagosomes by invasion or phagocytosis. During phagosomal maturation bacteria secrete effectors that lead to 
the disruption of vacuolar membranes and escape into the host cells cytosol. Here the bacteria can multiply, 
induce cell lysis, engage actin based motility and spread to other cells by inducing cell fusion or pushing 
through the cell membrane and entering neighbouring cells in a secondary vacuole. Figure adapted from 
“Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei” [30]. 
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diabetes mellitus, thalassemia and renal disease [15]. In rural rice farming communities in 
Thailand, the majority of the population are seropositive for Burkholderia pseudomallei [36]. 
However seropositivity does not provide protection against further infection, and it is unclear 
what proportion of people testing positive have cleared their systems of the bacteria or are 
harbouring a latent infection. 
1.3.3 Clinical manifestation 
Melioidosis can present as a wide range of disease states from acute septicaemia to a chromic 
localised infection which has earned it the nickname ‘the great mimicker’ [37]. The disease 
can affect almost any organ or tissue resulting in an acute or chronic disease state. Pneumonia 
represents the most common clinical manifestation of melioidosis either resulting from initial 
infection via inhalation of the bacterium or following septiceamic spread from another 
infected site. Chronic lung infection is also common presenting a tuberculosis type disease. 
Other possible sites of infection include the liver, spleen, genito-urinary tract (leading to 
prostatic abscess), skin, soft tissues, bones and skeletal muscle. Disease manifestation varies 
throughout the world possibly due to different strains of Burkholderia pseudomallei existing 
in the environment. There is a high incidence of acute suppurative parotiditis amongst 
paediatric cases in Thailand, with the condition being almost absent in Australia, while 
encephalomyelitis and genito-urinary infections are common in Australia but uncommon 
throughout South East Asia. The disease also can exist in an asymptomatic state for long 
periods of time with clinical manifestations often occurring decades after initial infection, 
usually triggered by a weakening of the host defence by other diseases. 
1.3.4 Current treatment 
Current best practice treatment for melioidosis lasts twenty weeks and is divided into two 
stages, an initial high intensity intravenous phase of treatment followed by a prolonged oral 
eradication phase. Initial treatment varies by region but at its core involves a high dose of 
intravenous ceftazidime for at least ten days or until improvement occurs. It is not uncommon 
for the intravenous stage of treatment to proceed for over a month before the fever has 
subsided for more than two days and the eradication phase can begin. Without treatment 
acute melioidosis has a mortality rate exceeding 80 %, the initial treatment alone reduces 
overall mortality by more than 50 % [38]. The eradication phase also varies by region but 
typically consists of a two drug combination of trimehoprim and co-trimoxazole with the 
possible addition of chloramphenicol and doxycycline for the initial eight weeks of the 
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treatment [15, 39]. Relapse into the disease state is common amongst patients and is caused 
by the reactivation of the original infection following failure to clear the infection. The major 
factors that contribute to relapse are the initial severity of the disease and a failure to adhere 
to the full course of antibiotic treatment, due to the prolonged course, cost and adverse side 
effects associated with the treatment [15]. A full course of antibiotic treatment results in a 
relapse rate of approximately 10 % with this increasing to 30 % in patients who fail to 
complete at least 8 weeks of eradication phase antibiotic treatment [39].  
1.3.5 New treatments are required 
The current treatment for melioidosis is far from ideal with the mortality rate remaining high, 
the prolonged course and cost of treatment, and the emergence of a number of ceftazidime 
resistant strains [40-42]. The need for a better understanding of the organism and the creation 
of new treatments is clear. There is a possibility that bactriophage could be utilised as an 
effective treatment in the future with the identification of a specific podovirus capable of 
lysing several clinically relevant strains of Burkholderia pseudomallei but not other species 
of the Burkholderia genus [43]. 
1.3.6 Vaccine development 
Several approaches are being undertaken in order to develop effective vaccines for use 
against melioidosis [44, 45]. Several live attenuated mutants have been used as vaccines in 
mice models providing high levels of resistance. However these are unlikely to be developed 
for human use due to fear of reversion and the bacteria’s ability to establish a persistent latent 
infection which can remain dormant for prolonged periods of time. Inactivated whole cell 
vaccines studies in mice using either Burkholderia pseudomallei or the non-pathogenic 
thailandensis have resulted in protective immunity, however as with all inactivated whole cell 
vaccines there is potential for undesirable side effects. A number of individual protein targets 
have been tested for their ability to induce immunity in mice models with some success. The 
use of naturally derived outer-membrane vesicles has also shown promise as a potential 
vaccine [46]. The use of Burkholderia pseudomallei DNA as a potential vaccine has been 
tested successfully in mice though potential DNA vaccines against other organisms that 
showed promise in mice were found to be ineffective in human trials. The use of monoclonal 
antibodies specific to the bacteria lipopolysaccharide and capsular polysaccharide for passive 
immunisation in mice has been shown to offer protection from infection with the bacterium 
[47]. Overall the hope of finding a long lasting, totally effective vaccine against Burkholderia 
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pseudomallei seems unlikely as repeated exposure to environmental isolates of the bacterium 
in people inhabiting the endemic areas does not prevent further infection [39]. However, even 
if a vaccine was not totally effective at preventing disease incidence it could represent a cost 
effective public health initiative particularly if administered to at risk groups due to the high 
cost of treatment [45]. 
1.4 Burkholderia pseudomallei as a potential bioweapon 
Burkholderia pseudomallei’s ability to survive a large range of conditions, it’s high mortality 
rate, difficulty to treat and lack of an effective vaccine has led to it being considered as a 
potential bioweapon. The United States Centre for Disease Control has classified 
Burkholderia pseudomallei as a category B potential biological threat. This places the 
organism in the second highest priority category alongside other potentially air or water 
borne pathogens and threats to global food and water safety [48]. 
1.5 Genomics 
The first reported full genome sequence was for the clinical isolate strain K96243 and 
comprised two chromosomes of 4.07 and 3.17 megabase pairs (figure 1.6 a) [49]. The gene 
nomenclature used in this study is based on this genome sequence with the 3,460 genes on 
the larger chromosome being designated BPSL____ and the 2,395 genes on the smaller 
chromosome BPSS____. The two chromosomes were found to contain genes broadly 
involved in different roles, with the larger chromosome encoding many of the core functions, 
and the smaller chromosome genes involved in adaptation and survival in different niches, 
although genes from all functional classes were found on both chromosomes (figure 1.6 b). 
The genome contains 16 identifiable genomic islands making up 6.1 % of the total genome 
with properties suggesting recent lateral gene acquisition by Burkholderia pseudomallei. A 
statistical analysis of the K96243 evolutionary history found very high levels of lateral gene 
acquisition with 109 genomic islands of different predicted ages highlighting the importance 
of horizontal gene transfer in the evolution of this species [6]. The genome contains a large 
proportion of genes of unknown function, accounting for over 20 % of annotated genes 
within the genome, demonstrating the need for studies into the basic biology of Burkholderia 
pseudomallei. 
36 
 
(a) 
(b) 
 
 
Figure 1.6 Genome sequence of Burkholderia pseudomallei strain K96243. a Schematic representation of the 
large and small chromosomes with the genomic islands shown as red segments. Genes are colour coded by 
predicted function: dark blue, pathogenicity/adaptation; black, energy metabolism; red, information transfer; 
dark green, surface-associated; cyan, degradation of large molecules; magenta, degradation of small molecules; 
yellow, central/intermediary metabolism; pale green, unknown; pale blue, regulators; orange, conserved 
hypothetical; brown, pseudogenes; pink, phage plus IS elements; grey, miscellaneous. b Distribution of genes 
belonging to different functional classes within the Burkholderia pseudomallei genome sequence expressed as a 
percentage of the total genes on each chromosome. Figure adapted from “Genomic plasticity of the causative 
agent of melioidosis, Burkholderia pseudomallei” [47]. 
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2.0 Molecular pathogenicity determinants of Burkholderia 
pseudomallei 
The Burkholderia pseudomallei genome contains a multitude of genes that encode factors 
involved in the bacterium’s pathogenicity or survival. This section details those which have 
been annotated in the genome and/or experimentally characterised. 
2.1 Quorum sensing 
Cell density dependent cell to cell communication systems allow bacteria to co-ordinate gene 
expression through the use of small signalling molecules. One system used by many species 
of bacteria involves the use of N-acyl-homoserine lactones (AHLs).  Burkholderia 
pseudomallei contains three LuxI genes, responsible for AHL synthesis, and five LuxR genes, 
which act as transcriptional regulators. These systems control the expression of a number of 
genes including metalloproteases, phospholipase C and DspA. The system is also important 
for the production of biofilms [50]. Mutants in any of the LuxI or LuxR genes are less 
virulent with increased survival times of infected mice and an increased lethal dose 50 % in 
hamster models [51]. There is evidence for the requirement of the Bpe-OprB multidrug efflux 
pump for secretion of AHLs from inside the cell [52] [53]. A second quorum sensing system 
has also been identified in Burkholderia pseudomallei involving the production, release and 
detection of 4-hydroxy-3-methyl-2-alkylquinolones (HMAQs) [54]. The function this second 
system plays in regulation and virulence is yet to be determined. 
2.2 Alternate sigma factors 
The multisubunit RNA polymerase of eubacteria is required to associate with a sigma factor 
in order to initiate transcription. The sigma factor is responsible for promoting recognition of 
the transcription start site allowing translation to start. Alternative sigma factors control the 
expression of many genes associated with response to a variety of stresses and of virulence 
factors in some pathogenic bacteria. Burkholderia pseudomallei contains seventeen sigma 
factors in its genome, two of which, RpoE (BPSL2434) and RpoS (BPSL1505) have begun to 
be characterised. RpoE is required for response to several environmental stresses including 
heat, osmotic shock and H2O2 [55-57]. The response regulator also has a role in the 
production of biofilms [55] and has been linked to pathogenesis by some genes it controls 
[57] and as knockout mutants have reduced survival in macrophage cell lines [55]. The 
transcription of RpoS is controlled by growth phase with an up regulation upon entering 
stationary phase [58]. RpoS is required for resistance to carbon starvation, acidic conditions 
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and oxidative stress but not heat or osmotic shock [58, 59]. It has been directly linked to 
pathogenicity as it is required for cellular invasion, the formation of multinucleated giant 
cells and inhibition of inducible nitric oxide synthase expression within macrophage [60]. 
The system is also required for the induction of host cell apoptosis [61]. RpoS also plays a 
role in regulating the production of AHLs in quorum sensing and several genes are under the 
control of both systems [62]. 
2.3 Capsule 
Bacterial capsules consist of an organised layer, usually consisting of polysaccharides, 
arranged outside the cell wall. There are three morphologically distinct forms of 
Burkholderia pseudomallei based on its polysaccharide capsule [63]. One form displays no 
capsule with two others having capsules of differing thickness. The thicker capsular form 
(0.10 – 0.25 µm) most likely represents the initial stage of biofilm formation with the thinner 
morphology (0.09 µm) the usual unicellular form. Four separate capsular polysaccharide 
structures (CPS) have been observed [64-68] and their biosynthetic clusters have been 
identified in the genome [69] (BPSL2786 – BPSL2810, BPSS0417 – BPSS0429, BPSS1825 
– BPSS1835 and BPSL2769 – BPSL2785). CPS I is found in Burkholderia pseudomallei and 
mallei with CPS II – IV found in pseudomallei and thalandensis. The distribution of capsule 
biosynthetic clusters in the three species suggests CPS I may be involved in pathogenicity 
with CPS II – IV playing a role in survival in the environment. CPS I protects against C3b 
complement deposition on the bacterial surface and provides resistance to phagocytosis [70]. 
Experiments involving mutants of CPS I synthetic pathway have shown it is required for 
survival and growth in serum with mutants deficient in CPS I biosynthesis being severely 
attenuated in hamster models [71]. CPS III is also required for virulence with mutants being 
attenuated in mouse models [72] although its function is not known. CPS II is upregulated in 
nutrient deprived conditions suggesting a role in survival in the environment but it is not 
required for virulence in hamster models [69]. It is unclear what if any role CPS IV plays in 
pathogenicity or environmental survival. 
2.4 Lipopolysaccharide 
Lipopolysaccharide (LPS) is the major component in the outer cell membrane of gram 
negative bacteria. It consists of a lipid A component covalently linked to polysaccharide 
moiety which varies between bacterial species. Burkholderia pseudomallei possesses a 
unique LPS structure [73] with an unbranched repeating unit of alternating glucose and talose 
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residues in the form -3)-β-D-glucopyranose-(1–3)-6-deoxy-α-L-talopyranose-(1-  with the 
talose subunits acetylated on the 2’ and 3’ positions [67]. Mutants in the LPS synthetic 
pathway are attenuated in mouse, hamster, guinea pig and rat models with the bacteria 
becoming particularly susceptible to the alternative complement pathway, and cationic 
microbial peptides [74]. Intact LPS is also required for bacteria survival in nutrient deprived 
aqueous conditions [75]. 
2.5 Biofilm formation 
Burkholderia pseudomallei are able to form biofilms [76] although different strains have 
different abilities to form them and production does not correlate with virulence [77]. Cells 
grown under biofilm inducing conditions have an increased antibiotic resistance although this 
appears to be due to other genes regulated under the same conditions [78]. Mutants unable to 
produce usual biofilms are not attenuated in mouse models showing it is not required for 
virulence [77]. However the presence of bacteria in biofilms in infected lung tissue suggests a 
role in persistence, not only in harsh environmental conditions, but also in allowing survival 
inside the host. Biofilm production may therefore partially account for the ability of 
Burkholderia pseudomallei to exist as a latent infection for prolonged periods of time. 
2.6 Antibiotic resistance 
Burkholderia pseudomallei are resistant to a wide array of antibiotics with a number of 
antibiotic resistance mechanisms. The Burkholderia pseudomallei genome encodes for seven 
β-lactamases including five Ambler class B (BPSL0374, BPSL1561, BPSL2708 BPSS1915 
and BPSS2119) and one of each Ambler class A (BPSS0946) and Ambler class D 
(BPSS1997) β-lactamase genes providing resistance against a range of beta lactam based 
antibiotics. There is a putative aminoglycoside acetyltransferase (BPSS0262) encoded in the 
genome possibly responsible for some of the bacteria’s resistance to aminoglycosides 
alongside other systems. 
2.6.1 Efflux pumps 
There are a number of multi-drug efflux pumps encoded in the genome sequence including 
ten members of the RND family. There are seven putative systems (BPSL0307 – BPSL0309, 
BPSL1269 – BPSL1266, BPSL1566 – BPSL1569, BPSL2234 – BPSL2235, BPSL2871 – 
BPSL2872 and BPSS1041 – BPSS1043) of unknown function and three fully characterised 
systems, AmrAB-OprA (BPSL1802 – BPSL1805), BpeAB-OprB (BPSL0813 – BPSL0816) 
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and BpeEF-OprC (BPSS0290 – BPSS0294) [79]. The AmrAB-OprA efflux pump is specific 
for the extrusion of aminoglycosides and macrolides [80]. The BpeAB-OprB multi-drug 
efflux pump is also responsible for the extrusion of aminoglycosides and macrolides [52] and 
a number of clinical isolates found to be sensitive to aminoglycosides contained mutants in 
this system [81]. However a separate study on the BpeAB-OprB system from a different 
strain of Burkholderia pseudomallei found no extrusion of aminoglycosides but instead 
macrolides, fluoroquinolones, tetracyclines, acriflavine, and, to a lesser extent, 
chloramphenicol [82]. The BpeEF-OprC system is involved in the efflux of chloramphenicol 
and trimethoprim [83]. There is also a homolog of the NorM multidrug efflux pump 
(BPSL2468) in the genome. While this is uncategorised in Burkholderia pseudomallei it has 
been shown to be responsible for polymixin efflux in the closely related Burkholderia 
vietnamiensis [84]. 
2.7 Intracellular survival 
Burkholderia pseudomallei is able to inhabit both phagosomal and non-phagosomal cells and 
encodes several genes involved in intracellular survival within its genome. The bacteria are 
resistant to human defensin proteins found in epithelial cells when exposed in vitro [85]. 
Burkholderia pseudomallei is also able to inhibit DNA and protein synthesis in host cells 
using at least one uncategorised secreted exotoxin [86]. The environment inside phagocytic 
cells is challenging, particularly inside phagosomes which the bacteria are able to survive 
inside. The bacteria have mechanisms which enable it to be highly resistant to reactive 
oxygen and nitrogen intermediates produced inside macrophage and neutrophil cells, such as 
superoxide anion, hydrogen peroxide, hydroxy radicals, singlet oxygen and nitric oxide. One 
method to protect against reactive oxygen species is the production of superoxide dismutase 
enzymes that catalyse the conversion of superoxide into hydrogen peroxide, which can then 
be further detoxified by the production of catalse enzymes. The K96243 genome sequence 
contains two superoxide dismutase genes, a Fe2+ dependent sodB gene (BPSL0880) and 
Cu2+/Zn2+ sodC (BPSL1001). SodB is currently uncategorised while the SodC protein has 
been confirmed as possessing superoxide dismutase activity and mutants in this gene are 
more susceptible to extracellular superoxide [87]. Mutants deficient in SodC also showed 
decreased survival in macrophage cell lines and were attenuated in BALB/c mouse models of 
infection [87]. The genome also encodes four catalase genes, three of which have been 
categorised katG (BPSL2865), katB (BPSS0993) and katE (BPSS2214) and a further putative 
catalase (BPSL0071). Burkholderia pseudomallei can produce a non-specific DNA binding 
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protein, dpsA (BPSL2863) capable of binding to and protecting DNA from oxidative stress 
[88]. The genome also encodes a putative hmpA gene (BPSL2840), which is important in 
resisting oxidative stress in other bacterial species. Burkholderia pseudomallei are also 
resistant to killing by reactive nitrogen species. The genome encodes two alkyl 
hydroperoxide reductase genes (BPSL1264 and BPSS0492) which have a peroxynitritase 
activity protecting against reactive nitrogen species [89]. Many of the genes involved in 
response to intracellular stress are regulated by the alternative sigma factor RpoS. OxyR is 
also involved in the regulation of oxidative stress response and alongside RpoS, is required 
for the expression of KatG and DspA [59]. HmpA and SodB were found to be significantly 
differentially expressed between primary and relapse clinical isolates from melioidosis 
patients with greater levels found in relapse isolates showing the importance of these 
mechanisms for long term survival in the host [25]. 
2.8 Flagella 
Burkholderia pseudomallei possess a polar tuft of two to four flagella that provide motility; 
however its role in virulence is unclear with conflicting data. Mutants deficient in fliC, the 
flagellin gene, have been observed as significantly less invasive into cultured human lung 
cells [90]. However a separate study using a different initial strain of the bacteria found fliC 
mutants were able to invade and replicate inside cultured human lung cells normally but were 
avirulent in mouse models when introduced intranasally but not intraperitoneally [91]. 
Similarly fliC mutants are not significantly attenuated in hamster or rat models when 
introduced intraperitoneally [92]. These data suggest that the flagella may play a role in 
initial epithelial attachment but deficiencies in flagella production can be overcome by other 
means. 
2.9 Actin motility and multi nucleated giant cell formation 
Once inside a host cell Burkholderia pseudomallei are able to induce continuous actin 
polymerisation from one pole of the cell providing intracellular motility. The bacteria uses a 
novel Arp2/3 independent method mediated by BimA (BPSS1492) [31, 93]. BimA locates to 
the bacterial surface at one cell pole and stimulates polymerisation of actin by acting as a 
nucleation promoting factor mimic [31]. Actin polymerisation can result in membrane 
protrusions which allow for cell to cell spread, with the bacteria entering neighbouring cells 
contained within a secondary phagosome [94]. 
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Burkholderia pseudomallei are able to induce the formation of multinucleated giant cells 
although the mechanism by which this occurs is poorly understood. The bacteria are able to 
produce multinucleated giant cells both in phagocytic and non-phagocytic cell lines and have 
been observed in infected tissues from melioidosis patients [94-97]. Actin polymerisation 
mobility is important in the formation of multinucleated giant cells [94, 96]. In macrophage 
cell lines multinucleated giant cell formation has been shown to be similar to 
osteoclastogenesis [95]. This process is mediated by the production of LfpA (BPSS2074) 
[95]. 
2.10 Pili and fimbriae 
The genome of Burkholderia pseudomallei K96243 contains eleven genes encoding type IV 
pili proteins (BPSL0782, BPSL1821, BPSL1899, BPSL2752, BPSL2756, BPSL3008, 
BPSL3170, BPSS1593, BPSS1595, BPSS2185, and BPSS2186) including the pillin gene 
(BPSL0782). The type IV pili is involved in microcolony formation which leads to increased 
association with cultured human cell lines [98]. Pillin deletion mutants are less virulent in 
nematode and mouse models as well as displaying reduced adherence to human epithelial 
cells in vitro [99]. The genome also encodes six type I fimbriae (BPSL1007 – BPSL1008, 
BPSL1626 – BPSL1629, BPSL1799 – BPSL1801, BPSL2026 – BPSL2031, BPSS0091 – 
BPSS0094 and BPSS0120 – BPSS0121) although no fimbriae have been observed in electron 
micrographs of the bacterium [100] and any role in pathogenicity is unknown. 
2.11 Secretion systems and effectors 
Burkholderia pseudomallei are able to produce and secrete a number of proteins with a role 
in pathogenicity including lipases, proteases, haemolysins and siderophores [101].  
2.11.1 Proteases and lipases 
The Burkholderia pseudomallei genome encodes a number of secreted proteases although 
their role in virulence appears to be minor. Different strains of Burkholderia pseudomallei 
exhibit different level of proteolytic activity in cell free supernatant, however there is no 
correlation between protease activity and virulence in mouse models of infection [102]. 
MprA (BPSS1993) is a serine metalloprotease [103]; the protein is produced as a pro-enzyme 
that is autoproteolytically processed to produce the active form of the enzyme [104]. The 
protease is able to do extensive damage to cell lines however; MprA is not required for 
virulence in mouse models [105]. A second calcium-dependent serine protease has also been 
43 
 
characterised [106]. This protease causes localised tissue damage and necrosis if injected into 
guinea pig or rabbit models [106, 107]. Burkholderia pseudomallei can also produce at least 
one collagenase enzyme [108]. The genome also encodes further uncharacterised proteases 
with homologs in pathogenic bacteria species including a homolog of Pseudomaonas 
aeruginosa LasA elastase (BPSL0624) and MucD Ser protease (BPSL0808). The 
Burkholderia pseudomallei genome encodes two characterised (BPSL0338 and BPSL2403) 
and one uncharacterised (BPSS0067) phospholipase C enzymes which are secreted via the 
twin arginine translocase general secretory system. BPSL0338 and BPSL2403 are non-
hemolytic with neither being required for virulence; however BPSL2403 was found to be 
involved in cytotoxicity of HeLa cells [109]. In contrast mutants deficient in the 
uncategorised BPSS0067 were severely attenuated in hamster models [110]. 
2.11.2 Siderophores 
Burkholderia pseudomallei is able to produce siderophores to increase iron uptake into the 
cell [111]. One system involves the biosynthesis of malleobactin by mbaA (BPSL1776) and 
mbaF (BPSL1774) with fmtA (BPSL1775) transporting the siderophore across the membrane 
[112]. Malleobactin is able to remove iron from both transferrin and lactoferrin acquiring it 
for the bacteria [113]. Putative hydroxamate (BPSL1779 – BPSL1774) and pyochelin 
(BPSS0581 – BPSS0588) biosynthetic genes have also been annotated in the genome [114]. 
2.11.3 Type II secretion system 
The general secretory system (T2SS) is responsible for secreting a number of the effector 
proteins from the cell including several of the proteases, lipases and phospholipase C proteins 
[115]. However mutants for the secretory system are not seriuosly attenuated in hamster 
models suggesting these proteins play only a minor role in pathogenicity [102]. 
2.11.4 Type III secretion system 
The Burkholderia pseudomallei genome encodes for three separate type III secretion systems 
(T3SS), T3SS1 (BPSS1390 – BPSS1409) and T3SS2 (BPSS1592 – BPSS1630) are 
homologous to systems found in Ralstonia solanacearum, a plant pathogen, and T3SS3 
(BPSS1534 – BPSS1553) which is homologous to one found in pathogenic Salmonella 
species. T3SS1 and T3SS2 are involved in the infection of tomato plants with deletion 
mutants being seriously attenuated [14]. An initial study using deletion mutants of the SctU 
subunit, a major component of the inner membrane assembly, for the three systems found 
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only T3SS3 to be an important pathogenicity determinant in mouse and hamster models 
[116]. T3SS3 has been shown to have a role in survival and persistence inside macrophages, 
escape from endocytic vesicles, multinucleated giant cell formation and induction of host cell 
apoptosis [117] [118]. More recently a role for T3SS1 has been suggested in mice models 
using SctN (BPSS1394) deletion mutants with the system being involved in preventing usual 
phagosomal maturation [119]. Three proteins, BipB (BPSS1532), BipC (BPSS1531), BipD 
(BPSS1529), form the T3SS3 tip complex required for translocation of proteins across the 
host cell membrane. The tip complex is required for multinucleated giant cell formation and 
induction of host cell apoptosis [118] and mutants are attenuated in mice models [120]. Four 
type III secretion system effector molecules have been identified to date, BopA (BPSS1524), 
BopC (BPSS1516), BopE (BPSS1525) and Cif (BPSS1385). The BopA protein has been 
shown to be involved in avoidance of autophagy [121]. BopE acts as a guanidine nucleotide 
exchange factor for host cell Rho family of GTPases inducing host cell ruffling and actin 
rearrangements [122]. The T3SS3 effector proteins, BopA and BopE have been shown to 
exhibit effects in cell lines but deletion mutants do not appear to be significantly less virulent 
in animal models of infection [116]. This could be due to each molecule playing only a small 
role but together, alongside other virulence factors, the combined effects of these proteins 
could be large. BopC represents another T3SS3 effector protein with deletion mutants being 
less invasive into epithelial cells [123] although experiments to determine the pathogenicity 
of deletion mutants have not yet been conducted. The Cif protein targets the eukaryotic cell 
cycle irreversibly blocking the cycle at the G2/M and G1/S transitions [124] which may be 
important in the production of multi nucleated giant cells. 
2.11.5 Type VI secretion system 
There are six type VI secretion system (T6SS) gene clusters in the Burkholderia 
pseudomallei K96234 genome [125]. T6SS I mutants are unable to form multinucleated giant 
cells, escape from phagosomes, grow inside macrophage cell lines and have reduced 
cytotoxicity of macrophages [126, 127]. T6SS I mutants are severely attenuated in hamster 
models [127]. T6SS V expression was upregulated following macrophage invasion [125]. 
T6SS I mutants were attenuated in the cockroach model of infection with mutations in T6SS 
II – VI showing no loss of virulence [128]. No secreted effector molecules for any of the 
T6SSs have been identified to date. 
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2.12 Toxin 
BLF1 (BPSL1549) represents a major toxin in Burkholderia pseudomallei. The protein acts 
as a potent cytotoxin against human cell lines, is lethal when injected into mice and insertion 
mutants are severely attenuated in mouse models [129]. The toxin inhibits the helicase 
activity of translation factor eIF4A by a glutamine deamidation reaction preventing protein 
expression [129]. It is unclear how this toxin is exported from the cell or enters into host cells 
as it lacks a signal sequence or translocation domain. BLF1 was found to be expressed at a 
significantly higher level in clinical isolates from primary as opposed to relapsing melioidosis 
patients [25] suggesting a role in initial infection. 
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3.0 Project aims, target selection and sequence analysis 
This section describes the target selection of a number of proteins of unknown function for 
study in a small-scale structural genomics project. An initial in silico analysis was performed 
on the selected proteins, to ascertain their suitability and merit for this study. 
3.1 Project aims  
Developments in DNA sequencing led to the production of vast amounts of data in the form 
of whole genome sequences. Concurrent advances in the technologies required for structure 
elucidation, from gene cloning, through protein production and purification, to 
crystallographic techniques, have been combined to provide a high-throughput approach to 
elucidating the structural and functional characteristics of the proteins encoded by the 
sequenced genomic DNA. The aims of this project were to identify potential pathogenicity 
determinants of unknown function from Burkholderia pseudomallei, and elucidate their 
structures with the intention of ascribing a function based on structural analysis or informed 
functional studies. 
3.2 Target selection 
The targets in this study represent potential pathogenicity determinants of unknown function 
from the bacterium Burkholderia pseudomallei. Targets were selected based on two 
characteristics, differential expression by a pathogenic species and a closely related non-
pathogenic species, and proteins whose expression is under the control of the RpoS stress 
response. BLF1 (BPSL1549), a protein found to represent a major toxin of Burkholderia 
pseudomallei [129], has recently been worked on and characterised within the Sheffield 
crystallography research group and shares both of these characteristics, validating this target 
selection strategy. 
3.2.1 Proteomic comparison 
A comparison of protein expression between Burkholderia pseudomallei and the closely 
related, non-pathogenic bacterium Burkholderia thailandensis found fourteen genes that were 
significantly differentially expressed between the two organisms during stationary phase 
growth [130] (figure 3.1). Six of these genes were homologs of previously known virulence 
factors from other bacteria. Four of the remaining genes were annotated as hypothetical 
proteins of unknown function, BPSL1549, BPSL1958, BPSS0683 and BPSS0212.  
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Burkholderia pseudomallei Burkholderia thailandensis 
 
Figure 3.1 2D gel electrophoresis of protein extracts from stationary phase Burkholderia pseudomallei and 
Burkholderia thailandensis. The red circled spots represent genes that were highly differentially expressed 
between the two organisms with the blue circles representing the genes of unknown function that were selected 
as potential targets for this study. Spot 79 is BPSL1549, spot 81 is BPSL1958, spot 83 is BPSS0212 and spot 84 
is BPSS0683. Figure adapted from “Comparative proteomic profiles and the potential markers between 
Burkholderia pseudomallei and Burkholderia thailandensis” [130].  
pH 4                                                 pH 7 pH 4                                                 pH 7 
3.2.2 Genes under the control of RpoS 
A proteomic analysis of RpoS+ and RpoS- strains followed by a genomic analysis identified 
68 genes under direct or in-direct control of RpoS-dependent promoter sites [131]. Eight of 
these were annotated as hypothetical proteins of unknown function under the direct control of 
RpoS, BPSL0599, BPSL1549, BPSL3012, BPSS0212, BPSS0213, BPSS0683, BPSS1588 
and BPSS2055. BPSS0212 and BPSS0213 exist as part of an operon also containing 
BPSS0211 and BPSS0214. Along with the four selected genes heavily expressed in 
Burkholderia pseudomallei and not in Burkholderia thailandensis, BPSL0599 and BPSS0213 
were also identified as being highly expressed during stationary growth but below the 
threshold for assignment as differentially expressed [132]. 
3.3 Initial in silico analysis of targets 
Combined the two approaches to target selection gave eleven unique protein targets, with five 
sharing both selection criteria. Two of the targets have been studied previously within the 
Sheffield crystallography group, BPSL1549 and BPSS0683, leaving nine proteins of interest 
for this study.  
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3.3.1 Blast and literature search 
Blast searches were conducted to find potential homologs in other organisms of known 
function or structure. BPSL0599 represents a member of the BMA_0021 family of conserved 
hypothetical proteins found in several Burkholderia species. Proteins of this family are often 
found in thiazole/oxazole-modified microcin biosynthetic clusters, suggesting a possible role 
in bacteriocin biosynthesis. BPSL1958 homologs are found only in Burkholderia 
pseudomallei, mallei and a single strain of thailandensis (MSMB43) known to contain genes 
from other Burkholderia species not normally found in Burkholderia thailandensis including 
the toxin BLF-1. It is unknown if this strain represents a possible human pathogenic strain of 
Burkholderia thailandensis. BPSL1958 contains a highly repetitive sequence of a 52 amino 
acids repeated six and three quarter times (figure 3.2 a). The repetitive nature is also apparent 
at the DNA level (figure 3.2 b) suggesting the gene was created in a recent duplication event 
and there has not been enough time for the sequence of the individual repeats to drift. 
BPSL3012 is a member of the YacF family of proteins found in many organisms. The 
function of proteins in this family is unknown but there is a structure in the protein data bank 
for a homolog from Vibrio parahaemolyticus (pdb 2OEZ) [133]. The protein BPSL3012 is 
known to be associated with the outer membrane or periplasmic space [134] [135].  A 
BLAST search on the proteins in the BPSS0211 – BPSS0214 operon shows that there are 
homologs of these proteins in several Burkholderia species as well as a number of related 
plant pathogens. The BLAST search predicts that BPSS0212 and BPSS0213 both contain two 
separate domains of unknown function, DUF1842 and DUF1843, with the shorter BPSS0211 
also representing DUF1843. When the amino acid sequences are aligned it is apparent that 
BPSS0212 and BPSS0213 are homologs of each other with BPSS0211 representing a 
homolog of the C-terminal domain of the two proteins (figure 3.3). BPSS0212 and 
BPSS0213 are associated with the outer membrane or periplasmic space [134] [135] and are 
also up regulated by RpoE, another alternative sigma factor involved in stress response [57]. 
The two proteins were found to be significantly differentially expressed between clinical 
isolates from primary and relapse melioidosis patients suggesting a role in initial infection 
[25]. BPSS0214 is also of unknown function and is usually, but not always, found associated 
with the other members of the operon. The protein is predicted to contain a radical-SAM 
domain, found in a diverse range of proteins involved in processes such as methylation, 
isomerisation, sulphur insertion, and protein radical formation [136]. BPSS1588 has 
homologs, all of unknown function, in Burkholderia mallei, thailandensis, oaklahomis and 
gladioli and is also found in Shewella denitrificans. BPSS2055 has homologs in Burkholderia 
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mallei, thailandensis, oaklahomis and ubonensis all of unknown function. It is also found in a 
variety of other bacterial species including the pathogenic Yersinia pseudotuberculosis and 
Yersinia pestis. clustalw [137] , boxshade [138]   
 
(a) Amino acid sequence alignment 
Repeat1      1 MAKLAASNQFGIPNQTDVFAVDGNGSLRVSWVVSAGAWNGPAQIGPAGLFPS 
Repeat2      1 RAAVASSNQFGIPNQTDVFAVGRDGALNVAWVVSADRWNGPTPISAAGLFPA 
Repeat3      1 GAAIAASNQFGIPNQTDVFAVSDSGALNVAWVVSAERWNGPIPISAAGHFPA 
Repeat4      1 GAPLATSNQFGIPNQTDVFVVDNKGALNVAWVVGAGSWNGPIPISPPGLFPP 
Repeat5      1 GAAVAASNQFGIPNQTDVFVVDNQGALNVAWVVGADRWNGPVPISPAGLFPP 
Repeat6      1 GAAVAASNQFGIPNQTDVFAVGRDGALRVAWVVSAGNWNGPVSISPTNLFPS 
Repeat7      1 GAAVAASNQFGIPNQTDVFAADSDGVLHVAWVVSAGNWNGPISIA------- 
consensus    1 .*..*.*************...  *.*.*.***.*. ****..*.......   
 
 
(b) DNA sequence alignment 
Repeat1      1 ATGGCAAAATTAGCAGCTTCAAATCAATTCGGCATTCCCAATCAGACCGACGTATTTGCC 
Repeat2      1 CGCGCGGCGGTTGCGTCGTCGAACCAATTCGGCATCCCGAATCAGACCGACGTGTTCGCC 
Repeat3      1 GGCGCGGCGATCGCGGCGTCGAACCAGTTCGGCATCCCGAATCAGACCGACGTGTTTGCC 
Repeat4      1 GGCGCGCCGCTCGCGACATCGAACCAGTTCGGCATCCCGAATCAGACTGACGTGTTCGTC 
Repeat5      1 GGCGCGGCGGTCGCCGCATCGAACCAGTTCGGCATTCCGAATCAGACCGACGTGTTCGTC 
Repeat6      1 GGCGCGGCGGTTGCGGCATCGAACCAGTTCGGTATCCCGAACCAGACCGACGTGTTTGCC 
Repeat7      1 GGCGCGGCGGTTGCGGCATCGAACCAGTTCGGCATCCCGAATCAGACCGACGTGTTCGCC 
consensus    1 ...**.....* **..*.**.**.**.*****.**.**.**.*****.*****.**.*.* 
 
Repeat1     61 GTTGACGGCAACGGCTCGCTGCGCGTTTCCTGGGTGGTCAGCGCCGGCGCCTGGAACGGC 
Repeat2     61 GTCGGCCGCGACGGCGCGCTGAACGTCGCGTGGGTGGTCAGCGCCGATCGCTGGAACGGA 
Repeat3     61 GTGAGCGACAGCGGCGCGTTGAACGTGGCGTGGGTCGTCAGCGCCGAGCGCTGGAACGGA 
Repeat4     61 GTCGACAATAAAGGCGCGTTGAACGTGGCATGGGTTGTCGGCGCCGGCAGTTGGAACGGC 
Repeat5     61 GTCGACAACCAGGGCGCGTTGAACGTCGCCTGGGTCGTCGGCGCGGATCGCTGGAACGGG 
Repeat6     61 GTCGGCCGCGACGGCGCACTACGCGTTGCCTGGGTGGTCAGCGCCGGCAATTGGAACGGC 
Repeat7     61 GCCGATAGCGACGGCGTCCTGCACGTCGCGTGGGTGGTCAGCGCCGGCAATTGGAACGGG 
consensus   61 *...........***....*...*** .*.*****.***.****.*.....********. 
 
Repeat1    121 CCCGCTCAGATCGGGCCGGCGGGGCTCTTCCCGTCC 
Repeat2    121 CCGACCCCGATCAGCGCCGCGGGCCTTTTCCCGGCC 
Repeat3    121 CCGATTCCAATCAGCGCGGCGGGCCACTTCCCGGCG 
Repeat4    121 CCGATTCCGATCAGCCCTCCCGGGCTGTTCCCTCCC 
Repeat5    121 CCGGTTCCGATCAGCCCTGCCGGGCTCTTCCCGCCC 
Repeat6    121 CCCGTGTCGATCAGCCCGACGAACCTTTTCCCGTCC 
Repeat7    121 CCGATTTCCATTGCGTGA------------------ 
consensus  121 **.......**............ .. ...... .. 
 
Figure 3.2 Sequence alignments for BPSL1958. a Amino acid sequence alignment of the repeated elements of 
BPSL1958. Identical residues are shaded black with similar amino acids shaded grey. b DNA sequence 
alignment of the seven repeated elements of BPSL1958. Both alignments have been produced using ClustalW 
[134] and BOXSHADE [135] and the consensus is shown. Residues that are completely conserved are shown as 
(*), more than half shown as (.) and less than half left blank. 
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BPSS0211     1 ------------------------------------------------------------ 
BPSS0212     1 MSEDLRVGLFPVRYLVGTGLPGAPQLVLDLMVDTVDHSVVGRAAVSQAVSPPLNFHADVW 
BPSS0213     1 ---MATTGLFPVQLRVATPNLGAPVLWLNLLVNTVEKTASGFARITQTVYPPMHFRARVV 
consensus    1        .....   ...   ... . . ... .....  . . ... . ... ... .  
 
BPSS0211     1 ------------------------------------------------------------ 
BPSS0212    61 GSYVFRLGPPPRRDGSGAIVQISLQGNQGGPQSNSMITFYGELLLKGDGKTGVASYRYYS 
BPSS0213    58 GPFHQMRIDPH----APQSVTLTLSGSPTGPVAPQVVILELNALLNEGWQSGTANYRYFY 
consensus   61 . .      .         . ... .   ..    ..      ..     .. . ....  
 
BPSS0211     1 -----------------------------MSQAQGHPVTPYGVAIHQAIADGDLAQMKSL 
BPSS0212   121 NGSWHEVENVPVKADPELVPIEPGPVIGQSSMSAIGSAAMYGVAIQSAAASGDLAHMRTL 
BPSS0213   114 ESRWHSIEHAIVSKDNSRIPLDPP---------SEHVMPMYGVGLQEARASGDLSRMKAL 
consensus  121    .. ..   .  .   .....       .    . . .***... * *.***..*..* 
 
BPSS0211    32 RTQAQALLAQQGNLATALELLEVEIAKLERRK 
BPSS0212   181 SAYARQQLESRDEIAAALSELKAEIAKLESRQ 
BPSS0213   165 AQQAEQQLADHDVIAAELQKLEAEIARLEARR 
consensus  181   .* ..*. .. .*..*  *..***.** *. 
 
 
Figure 3.3 Amino acid sequence alignment of BPSS0211, BPSS0212 and BPSS0213. Identical residues are 
shaded black with similar amino acids shaded grey. The alignment has been produced using ClustalW [134] and 
BOXSHADE [135] and the consensus is shown. Residues that are completely conserved are shown as (*), more 
than half shown as (.) and less than half left blank. 
  
3.3.2 Primary sequence prediction 
The SignalP program [139] was used to predict if any targets had a potential signal sequence. 
One target, BPSS1588, was predicted to have an N-terminal signal sequence for export from 
the cell (figure 3.4). This was taken into account when designing primers to create a construct 
without the signal sequence. 
Figure 3.4 Signal sequence prediction for BPSS1588. The prediction was conducted using the SignalP 
programme [136]. The S-score is based on the likelihood of any residue appearing in a signal sequence while the 
C-score is the cleavage site score predicting a position where cleavage is likely  to occur. The Y-score represents 
a combination of the two other scores giving the most accurate estimate of the cleavage site in this case after 
alanine 23 in the protein. 
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Hydropathy plots calculated for the target genes using Protscale [140] to predict if the 
proteins were all theoretically soluble suggested none of the targets contained integral 
transmembrane helicies (figure 3.5).  
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Figure 3.5 Hydropathy plots for the target genes from Burkholderia pseudomallei. The figure was created using 
Protscale [137] with a window size of 19 residues and the Kyte and Doolittle hydrophobicity scores. A value of 
1.5 or over would indicate a possible transmembrane helix. As this threshold value is not reached for any of the 
targets it suggests all target proteins do not contain a membrane spanning helix. 
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3.3.3 Secondary structure analysis and threading 
Secondary structure prediction and threading were also carried out on the target proteins 
using the Phyre 2 server [141]. The results were largely uninformative, with the exception of 
BPSL1958, BPSL3012 and BPSS1588. Secondary structure prediction on BPSL1958 showed 
an abundance of beta sheet in the protein with no predicted helices. Threading analysis 
predicts the protein folding into a six (figure 3.6 a) or seven (figure 3.6 b) bladed beta-
propeller with each of the repeats forming a single blade. BPSL3012 was predicted to have a 
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similar secondary structure and fold to the homologous protein, YacF, in the PDB (figure 3.6 
c). The threading results for BPSS1588 were inconclusive for the majority of the protein 
however they highlighted the presence of a putative CUB-like collagen binding domain 
within the protein (figure 3.6 d). 1ofz [142] 2c4d [143] 2oez [133] 1nqj [144] 
 
(a) BPSL1958 (6 bladed) model (b) BPSL1958 (7 bladed) model 
Residues 13 – 316 (357), PDB 1ofz [139] Residues 9 – 349 (357), PDB 2c4d [140] 
 
 
(c) BPSL3012 model (d) BPSS1588 model 
Residues 2 – 249 (251), PDB 2oez [131] Residues 212 – 315 (466), PDB 1nqj [141] 
 
 
Figure 3.6 PHYRE 2 threading results for BPSL1958, BPSL3012 and BPSS1588. The images show the 
predicted folds of the proteins. The represented residues of the target protein, with the total number of residues 
in parenthesis, are listed alongside the PDB entry onto which they have been threaded. 
 
3.4 Structure solution strategy 
The overall strategy for structure solution consisted of cloning genes from genomic DNA into 
a suitable vector for protein expression in Escherichia coli followed by purification, 
crystallisation and data collection. The primary sequence of the target proteins was 
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considered in order to decide on a possible phasing strategy for structure solution (table 3.3). 
BPSL3012 has a homolog with 32 % identity in the PDB which would likely allow phasing 
by molecular replacement. BPSL0599 and BPSS1588 contain a high proportion of tyrosine 
residues which could allow experimental phases to be obtained using iodine soaking 
experiments and iodine SAD data collection. BPSS0212, BPSS0213 and BPSS0214 contain a 
high proportion of methionine residues which would allow phases to be obtained through the 
incorporation of seleno-L-methionine into the protein and selenium MAD data collection. 
Alternatively the large number of cysteine residues in BPSS0214 could allow experimental 
phases to be obtained using mercurial compound soaking and co-crystallisation experiments 
and mercury MAD data collection. BPSL1958 contains no naturally occurring methionines, 
cysteines or tyrosines presenting a possible problem for obtaining experimental phase 
information. The strategy was therefore to create a number of mutants containing either 
cysteine or methionine residues to enable phasing. For the three homologous proteins 
BPSS0211, BPSS0212 and BPSS0213 it was hoped that once BPSS0212 or BPSS0213 was 
solved the others could be phased using molecular replacement. 
 
Protein 
Number of residues 
Phasing methods 
Total Methioninea Cysteine Tyrosine 
BPSL0599 120 0 3 6 C, Y 
BPSL1958 357 0 0 0 MR (M, C)b 
BPSL3012 251 9 2 7 MR, M, C, Y 
BPSS0211 63 1 0 1 (MR)d, M, Y 
BPSS0212 212 5 0 8 (MR)d, M, Y 
BPSS0213 196 5 0 5 (MR)d, M, Y 
BPSS0214 491 9 16 14 MR, M, C, Y 
BPSS1588c 443 (466) 3 (4) 4 (4) 17 (18) M, C, Y 
BPSS2055 422 14 4 9 M, C, Y 
 
a
 This is excluding the N-terminal residue which is frequently removed by the cellular machinery. 
b
 These methods are only available following mutation.  
c
 Numbers are for truncated protein, those in parenthesis represent the full length protein. 
d
 These methods are only available following resolution of a related structure. 
 
Table 3.3 Summary of possible phasing techniques for the target proteins. Possible techniques considered 
included (MR) phasing using a molecular replacement model, (M) phasing using selo-L-methionine 
incorporation experiments, (C) phasing using mercurial compound soaking or co-crystallisation experiments, 
(Y) phasing using iodine soaking experiments. The preferred method(s) for each target is in bold.  
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Chapter two 
Results from a small-scale structural genomics project conducted for 
proteins from the bacterial pathogen, Burkholderia pseudomallei 
 
 
 
 
Section 4 DNA to soluble protein: Producing material for protein studies 
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Section 9 Studies on the protein BPSS0213 
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4.0 DNA to soluble protein: Producing material for protein studies 
This section describes the cloning of target genes from genomic DNA into plasmid vectors 
and the overexpression of target proteins in Escherichia coli cells. 
4.1 Cloning 
Target genes were amplified from Burkholderia pseudomallei strain D286 genomic DNA, 
taken from a melioidosis patient at Kuala Lumpur Hospital, by PCR using BioMix Red 
(Bioline), varying concentrations of DMSO and specific primers for each gene (Eurofins) 
(table 4.1). DMSO was included in the PCR reactions in an attempt to improve the 
production of the desired genes with reduced background contaminants, due to the high GC 
content of the Burkholderia pseudomallei genome [49, 145]. Altering the concentration of 
DMSO was shown to have an effect on amplification and the conditions resulting in the best 
amplification without other contaminating fragments were selected (figure 4.1). PCR 
products were purified using agarose gel electrophoresis and a QIAquick® Gel Extraction Kit 
(Qiagen) by standard protocols. A miniprep was performed using a QIAprep® Miniprep kit 
(Qiagen) from DH5α cells containing pET21a plasmid to obtain vector DNA. The purified 
PCR products and plasmid were then digested using NdeI and either BamHI or EcoRI 
restriction enzymes (NEB) depending on the site present in the primer sequence (table 4.1). 
Vector DNA was purified by gel extraction and then treated with antartic phosphatase (NEB), 
to prevent singularly digested plasmids self-ligating, and inserts were purified using a 
QIAquick® PCR purification kit (Qiagen). Vector and insert DNA were ligated together 
using T4 DNA ligase (NEB) before being transformed into competent DH5alpha cells 
(VWR) and plated on LB-agar with the addition of 100 µg ml-1 carbenicillin for selection. 
Plasmids were recovered by miniprep, sequenced (Geneservice) and compared to the 
expected sequence from the genome (table 4.2). As different strains of bacteria were used for 
sequence analysis (K96243) and PCR amplification (D286) a number of mutations were 
accepted. 
4.1.1 Site-directed mutagenesis 
BPSL1958 mutants were required in order to enable experimental phases for the structure 
resolution to be obtained. Sites chosen for cysteine mutagenesis were polar residues (with the 
exception of the C-terminal alanine), and predicted to be solvent exposed in the tertiary 
structure of the threading models (figure 4.2), while those for methionine mutagenesis were 
all isoleucine to minimise the change in amino acid side chain properties. A QuikChange site 
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             bpsl0599            bpsl1958            bpsl3012            bpss0211            bpss0212 
 
                                               
 
                            bpss0213               bpss0214                bpss1588                bpss2055 
 
Figure 4.1 Agarose gels showing the amplification of genes by PCR from Burkholderia pseudomallei genomic 
DNA. Circled bands were excised from the gel for purification. bpss2055 amplified best without the addition of 
DMSO, bpsl1958, bpsl3012 and bpss0213 with the addition of 2.5 % DMSO and bpsl0599, bpss0211, 
bpss0212, bpss0214 and bpss1588 with the addition of 5 % DMSO. 
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Oligoname (restriction site) Sequence 
bpsl0599 F (NdeI) 5’-ATATATATCATATGGCCGAGAACAACGCC-3’ 
bpsl0599 R (EcoRI) 5’-ATATATATGAATTCTCAGCAGCAGGTGAA-3’ 
bpsl1958 F (NdeI) 5’-ATATATCATATGGCAAAATTAGCAGCTTC-3’ 
bpsl1958 R (EcoRI) 5’-ATATATGAATTCTCACGCAATGGAAATCG-3’ 
bpsl3012 F (NdeI) 5’-ATATATATCATATGATTCTTTACGAGTAT-3’ 
bpsl3012 R (BamHI) 5’-ATATATATGGATCCTTACAGATTGCAGAG-3’ 
bpss0211 F (NdeI) 5’-ATATATATCATATGAGTCAAGCACAGGGC-3’ 
bpss0211 R (BamHI) 5’-ATATATATGGATCCCTACTTCCTCCGCTC-3’ 
bpss0212 F (NdeI) 5’-ATATATCATATGATGTCCGAAGATCTTCG-3’ 
bpss0212 R (BamHI) 5’-ATATATGGATCCTCACTGCCGGCTTTCGA-3’ 
bpss0213 F (NdeI) 5’-ATATATATCATATGGCAACTACCGGTCTC-3’ 
bpss0213 R (BamHI) 5’-ATATATATGGATCCTCAGCGGCGCGCTTC-3’ 
bpss0214 F (NdeI) 5’-ATATATATCATATGAGCACAACGGACGC-3’ 
bpss0214 R (BamHI) 5’-ATATATATGGATCCTCACCCGCCGCCGAA-3’ 
bpss1588 F (NdeI) 5’-ATATATATCATATGTCGACCCTCGTCGCG-3’ 
bpss1588 R (BamHI) 5’-ATATATATGGATCCTTACTTGCGGCCGAG-3’ 
bpss2055 F (NdeI) 5’-ATATATATCATATGCAGAACTGGCAGCC-3’ 
bpss2055 R (BamHI) 5’-ATATATATGGATCCTCAGCGGCCGCCACG-3’ 
 
Table 4.1 Primers used for the PCR amplification of genes from genomic DNA designed using the K96243 
genome sequence. 
 
Target Mutations compared to strain K96243 genomic DNA 
bpsl0599 no mutations 
bpsl1958 S312Aa 
bpsl3012 no mutations 
bpss0211 no mutations 
bpss0212 Q187Rb 
bpss0213 no mutations 
bpss0214 L81Q, E174D and F388Sb 
bpss1588 no mutations 
bpss2055 D322Ga 
 
a
 Multiple plasmids from different colonies produced following transformation were sequenced resulting in the 
same sequence. 
b
 A single plasmid sequence was obtained. 
 
Table 4.2 Summary of sequencing results for target genes. The mutations found could represent PCR errors or a 
difference in the genomic DNA of the strains used for selection (K96243) and as a template in the PCR reaction 
(D286). The chance of the mutation arising from PCR error is reduced for genes where multiple constructs were 
sequenced. 
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Figure 4.2 Selection of residues for site directed mutagenesis in BPSL1958. The sequence has been split into 
the seven repeats representing the blades of the predicted β-propeller fold and the secondary structure prediction 
from the PHYRE2 server is assigned. These individual blades contain four β-strands in the threaded model 
which are roughly highlighted in orange for each blade. Residues selected for mutation to cysteine residues are 
highlighted in red and are generally polar amino acids appearing in linking regions between strands. Residues 
selected for mutation to methionine residues are highlighted in green and are all isoleucine in the original 
sequence. 
 
directed mutagenesis kit (Stratagene) was used with specific primers (Eurofins) (table 4.3) to 
create cysteine and methionine mutants. For the first batch of cysteine mutants the wild type 
gene was used as a template for the mutagenesis. In subsequent reactions to create the 
methionine and the remaining cysteine mutants, the K3C mutant was used as it allowed for an 
improved purification strategy (section 6.1.2). The highly repetitive sequence of BPSL1958 
created problems during mutagenesis despite sites being carefully chosen based on the 
relative level of difference between the seven repeats. Colonies were screened by colony PCR 
using T7F and T7R primers to check the size of the resultant gene before sequencing 
(Geneservice) to confirm which of the desired mutations had been produced. The following 
mutants were successfully produced: K3C, S128C, A357C, K3C-D244C, K3C-H340C, K3C-
I44M, K3C-I356M, K3C-I44M-I252M and K3C-I44M-I252M-I356M. 
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Oligoname Sequence 
bpsl1958 K3C F 5’-GGAGATATACATATGGCATGTTTAGCAGCTTCAAATCAATTCGGC-3’ 
bpsl1958 K3C R 5’-GCCGAATTGATTTGAAGCTGCTAAACATGCCATATGTATATCTCC-3’ 
bpsl1958 R53C F 5’-CTCTTCCCGTCCTGCGCGGCGGTTGCGTC-3’ 
bpsl1958 R53C R 5’-GACGCAACCGCCGCGCAGGACGGGAAGAG-3’ 
bpsl1958 R89C F 5’-GTCAGCGCCGATTGCTGGAACGGACCGAC-3’ 
bpsl1958 R89C R 5’-GTCGGTCCGTTCCAGCAATCGGCGCTGAC-3’ 
bpsl1958 S128C F 5’-CCGTGAGCGACTGCGGCGCGTTGAACG-3’ 
bpsl1958 S128C R 5’-CGTTCAACGCGCCGCAGTCGCTCACGG-3’ 
bpsl1958 H153C F 5’-GCGCGGCGGGCTGCTTCCCGGCGGGCG-3’ 
bpsl1958 H153C R 5’-CGCCCGCCGGGAAGCAGCCCGCCGCGC-3’ 
bpsl1958 K180C F 5’-GACGTGTTCGTCGTCGACAATTGTGGCGCGTTGAACGTGGC-3’ 
bpsl1958 K180C R 5’-GCCACGTTCAACGCGCCACAATTGTCGACGACGAACACGTC-3’ 
bpsl1958 D244C F 5’-CGTCGGCGCGTGTCGCTGGAACGG-3’ 
bpsl1958 D244C R 5’-CCGTTCCAGCGACACGCGCCGACG-3’ 
bpsl1958 S312C F 5’-CCTTTTCCCGTGCGGCGCGGCGGTTGC-3’ 
bpsl1958 S312C R 5’-GCAACCGCCGCGCCGCACGGGAAAAGG-3’ 
bpsl1958 H340C F 5’-GACGGCGTCCTGTGCGTCGCGTGGGTGGTC-3’ 
bpsl1958 H340C R 5’-GACCACCCACGCGACGCACAGGACGCCGTC-3’ 
bpsl1958 A357C F 5’-GGCCGATTTCCATTTGTTGAGATCCGAATTCGAGCTCCG-3’ 
bpsl1958 A357C R 5’-CGGAGCTCGAATTCGGATCTCAACAAATGGAAATCGGCC-3’ 
bpsl1958 I44M F 5’-CGGCCCCGCTCAGATGGGGCCGGCGGGGC-3’ 
bpsl1958 I44M R 5’-GCCCCGCCGGCCCCATCTGAGCGGGGCCG-3’ 
bpsl1958 I64M F 5’-GAACCAATTCGGCATGCCGAATCAGACCG-3’ 
bpsl1958 I64M R 5’-CGGTCTGATTCGGCATGCCGAATTGGTTC-3’ 
bpsl1958 I108M F 5’-GGCCGGCGCGGCGATGGCGGCGTCGAACC-3’ 
bpsl1958 I108M R 5’-GGTTCGACGCCGCCATCGCCGCGCCGGCC-3’ 
bpsl1958 I252M F 5’-CGGGCCGGTTCCGATGAGCCCTGCCGGGC-3’ 
bpsl1958 I252M R 5’-GCCCGGCAGGGCTCATCGGAACCGGCCCG-3’ 
bpsl1958 I356M F 5’-CGGGCCGATTTCCATGGCGTGAGAATTCG-3’ 
bpsl1958 I356M R 5’-CGAATTCTCACGCCATGGAAATCGGCCCG-3’ 
 
Table 4.3 Primers used for the site-directed mutagenesis of BPSL1958 to create cysteine and methionine 
mutations. 
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4.2 Overexpression 
Plasmids containing correctly sequenced genes were used to transform BL21 (DE3) or Tuner 
(DE3) competent cells (Novagen) (table 4.4) for overexpression. A small-scale over 
expression trial was performed for all genes to find post induction conditions that would 
produce soluble protein. Successful conditions were identified for the production of 
BPSL0599, BPSL1958, BPSS0211, BPSS0212 and BPSS0213 (table 4.4).  
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BPSL0599 BL21(DE3) 20 1.0 3 
BPSL1958 BL21(DE3) 9a 1.0 30 
BPSL1958 A357C, K3C-D244C and K3C-H340C BL21(DE3) 8a 1.0 30 
BPSL1958 K3C and S128C Tuner(DE3) 8a 1.0 30 
BPSL1958 K3C-I44M-I252M-I356M (Seleno-Met) Tuner(DE3) 10 1.0 48 
BPSS0211 BL21(DE3) 37 1.0 3 
BPSS0211 (Seleno-Met) BL21(DE3) 37 1.0 18 
BPSS0212 BL21(DE3) 12a 1.0 24 
BPSS0212 (Seleno-Met) BL21(DE3) 12 1.0 48 
BPSS0213 BL21(DE3) 15a 1.0 24 
 
a
 cold shock prior to induction 
 
Table 4.4 Post-induction conditions for the soluble overexpression of target proteins. 
 
BPSL0599 was found to overexpress as two separate molecular weights. Purified protein was 
analysed by mass spectrometry (Simon Thorpe, University of Sheffield) showing that the two 
products were the full length protein and a smaller fragment clipped by the cellular 
machinery (figure 5.3). The remaining proteins, BPSL3012, BPSS0214, BPSS1588 and 
BPSS2055 could only be produced as part of the insoluble cellular fraction. Mutant 
constructs of BPSL1958 overexpressed under the same conditions as for native BPSL1958. 
Larger scale growths were conducted to obtain enough cell paste from which to purify the 
proteins of interest. For BPSL1958, BPSS0212 and BPSS0213 it was necessary to adjust the 
overexpression protocol once the expression had been scaled up. It was required for the 
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cultures to be incubated on ice for 20 minutes, immediately prior to the addition of IPTG. 
Without this extra step the proteins were produced primarily in the insoluble fraction. 
4.2.1 Seleno-methionine 
Seleno-methionine protein was produced for BPSL1958 K3C-I44M-I252M-I356M, 
BPSS0211 and BPSS0212 in order to obtain experimental phasing. For the production of 
seleno-methionine incorporated protein, cells were grown in LB media before being 
transferred to minimal media supplemented with seleno-methionine prior to induction of 
protein expression. For BPSS0211 and BPSS0212 the same overexpression conditions for 
native protein were applied with a longer post induction incubation time (table 4.4). For 
BPSL1958 K3C-I44M-I252M-I356M it was necessary to conduct a further small-scale 
expression trial using minimal media supplemented with seleno-methionine for suitable 
conditions to be found for overexpression (table 4.4). 
4.3 Summary of cloning and overexpression 
The nine initial targets were successfully cloned into pET21a vectors and transformed into 
expression strains where five were successfully expressed as soluble proteins. Mutant forms 
of BPSL1958 were produced by site directed mutagenesis and expressed as part of the cells 
soluble fraction. Seleno-methionine incorporated cell paste was also produced for BPSL1958 
K3C-I44M-I252M-I356M, BPSS0211 and BPSS0212. The following five sections deal with 
subsequent work conducted for the successfully expressed protein targets. 
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5.0 Studies on the protein BPSL0599 
This section describes the purification, and crystallisation of the target BPSL0599. 
5.1 Protein purification for BPSL0599 
Approximately 2 g of cell paste was resuspended in 30 ml 50 mM TRIS pH 8.0 and disrupted 
by sonication. Cell debris and insoluble proteins were removed by centrifugation at 70,000 g 
for 15 minutes and the supernatant was loaded onto a DEAE-HiTrap column equilibrated 
with 50 mM TRIS pH 8.0. A 75 ml gradient from 0 to 500 mM NaCl was then applied to the 
column and 2.5 ml fractions were collected (figure 5.1 a). Peak fractions were combined and 
concentrated to 1.5 ml using a Vivaspin concentrator with a 10 kDa MWCO. This was then 
loaded onto a 1.6 x 60 cm Superdex 200 gel filtration column equilibrated in 50 mM TRIS 
pH 8.0 and 500 mM NaCl and eluted using the same buffer collecting 2 ml fractions (figure 
5.1 b). Fractions were analysed by SDS-PAGE (figure 5.2) and those containing BPSL0599 
were combined. At this stage the sample, which contained a mixture of the two BPSL0599 
fragments produced during overexpression (sections 4.2 and 5.1.1),  was split with half of the 
sample being concentrated to 12 mg ml-1 and having its buffer exchanged for 10 mM TRIS 
pH 8.0 for use in crystallisation trials. The remaining sample was diluted 20 fold using 50 
mM MES pH 6.3 and applied to a ResourceQ column equilibrated with 50 mM MES pH 6.3. 
A 120 ml gradient from 0 to 250 mM NaCl was then applied to the column and 2.5 ml 
fractions were collected (figure 5.1 c) and analysed by SDS-PAGE (figure 5.2). This final 
step allowed for the two molecular weight components of the sample to be partially 
separated. The buffer was exchanged for 10 mM TRIS pH 8.0 and the two protein samples 
were concentrated to 10 mg ml-1 for use in crystallisation trials.  
 
 
 
 
Figure 5.1 Chromatogram traces for the purification of BPSL0599. a DEAE purification step showing column 
loading and elution. 2.5 ml fractions were collected starting at the beginning of the gradient at 33 ml. b Gel 
filtration purification step showing elution with 2 ml fractions collected after the void volume of 42 ml. c 
ResourceQ purification step showing loading and elution with 2.5 ml fractions collected starting at the 
beginning of the gradient at 22 ml. For all traces, green highlighted regions indicate volumes taken for 
subsequent purification steps or as pure protein. 
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(a) BPSL0599 DEAE purification step 
 
(b) BPSL0599 Superdex 200 purification step 
  
(c) BPSL0599 ResourceQ purification step 
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Figure 5.2 SDS-PAGE gels showing the purification of BPSL0599. The theoretical molecular weight of 
BPSL0599 is 13.8 kDa but it appears in two forms. The highlighted bands indicate the protein in fractions taken 
for subsequent purification steps or as one of the three protein samples used in crystallisation trials. 
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5.1.1 Purification analysis 
The elution profile from the gel filtration column shows a single broad peak roughly 
corresponding to a trimeric form of the protein (figure 5.1 b). The mixed sample was sent for 
mass spectrometry (Simon Thorpe, University of Sheffield) to identify the two components. 
The larger protein is the full length BPSL0599 without its N-terminal methionine with the 
smaller protein representing a clipped fragment of BPSL0599 (figure 5.3). SDS-PAGE 
analysis of the purified samples shows they were of differing levels of purity (figure 5.2). The 
mixed sample contained approximately 45 % of each with 10 % other contaminants. The pure 
fragment sample contained only the fragment and approximately 5 % other contaminants. 
The full length sample was about 60 % pure with 35 % of the smaller fragment and 5 % other 
contaminants.  
 
 
 
Figure 5.3 Mass spectrometry results for the mixed sample of purified BPSL0599. The molecular weight of 
13637.0 Da represents the full length protein without its N-terminal methionine (residues 2 – 120) with the 
12149.0 Da molecule being a clipped form of the protein (residues 2 – 106 or 3 – 107). 
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5.2 Protein crystallisation for BPSL0599 
Five initial 96 condition robot screens, the AmSO4, JCSG+, PACT, Pegs and Classics suites, 
were conducted using the three samples of purified protein (a mixed sample, and two samples 
predominantly containing the two different molecular weight proteins). 200 nl of protein was 
mixed with 200 nl of well solution and the trays were incubated at 17 ºC. Initial hits were 
obtained for the two single species samples, in condition Pegs G4 containing 200 mM 
calcium acetate and 20 % (w/v) PEG 3350 and for the full length sample in condition JCSG 
G11 containing 100 mM BIS-TRIS pH 5.5 and 2 M ammonium sulphate (figure 5.4). The 
initial hits are yet to be tested for X-ray diffraction or optimised to produce better crystals. 
 
  
(2-120) – Pegs G4 – Robot screen 
200 mM Calcium acetate 
20 % (w/v) PEG 3350 
Drop size 200 nl protein + 200 nl well solution 
(2-106) – Pegs G4 – Robot screen 
200 mM Calcium acetate 
20 % (w/v) PEG 3350 
Drop size 200 nl protein + 200 nl well solution 
 
 
 
 
 
 (2-120) – JCSG G11 – Robot screen  
100 mM BIS-TRIS pH 5.5 
2 M  Ammonium sulphate 
Drop size 200 nl protein + 200 nl well solution 
 
 
Figure 5.4 Photographs of BPSL0599 crystals. 
100 µm 100 µm 
100 µm 
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6.0 Studies on the protein BPSL1958 
This section describes the purification, crystallisation, data collection and attempts to solve 
the structure for the target BPSL1958. 
6.1 Protein purification for BPSL1958 
6.1.1 Native protein purification 
Approximately 3 g of cell paste was resuspended in 30 ml 25 mM TRIS pH 9.0 and disrupted 
by sonication. Cell debris and insoluble protein were removed by centrifugation at 70,000 g 
for 15 minutes and the supernatant was loaded onto a DEAE-Sepharose fast flow column 
equilibrated with 25 mM TRIS pH 9.0. A 200 ml gradient from 0 to 500 mM NaCl was then 
applied to the column and 8 ml fractions were collected (figure 6.1 a). Fractions were 
analysed by SDS-PAGE (figure 6.2) and BPSL1958 was found to interact weakly with the 
column eluting at the end of the loading step. Fractions containing the protein were pooled 
and concentrated to 1.5 ml using a Vivaspin concentrator with a 10 kDa MWCO. This was 
then loaded onto a 1.6 x 60 cm Superose 6 gel filtration column equilibrated in 50 mM TRIS 
pH 8.0 and 500 mM NaCl and eluted using the same buffer collecting 2 ml fractions (figure 
5.1 b). Peak fractions were combined, the buffer was exchanged for 10 mM TRIS pH 8.0 and 
the protein was concentrated to 8 mg ml-1 for use in crystallisation trials using the Vivaspin 
concentrator. The overall yield of protein was low with only 0.7 mg being obtained which 
was estimated by SDS-PAGE to be over 95 % pure (figure 6.2). 
6.1.2 Mutant protein purification 
The mutant BPSL1958 proteins, K3C, S128C, A357C, K3C-D244C and K3C-H340C, 
created in order to allow phasing experiments for structure determination (sections 3.4 and 
4.1.1),  were purified using the same techniques as the native protein. Between 4 and 8 g of 
cell paste were used for each purification and the overall yields of mutant proteins were low, 
typically less than 2 mg in total. However BPSL1958 mutants containing the K3C mutation 
eluted from the DEAE column later than the native protein, suggesting slightly tighter 
binding, with most of the protein not eluting before the start of the NaCl gradient (figure 6.3). 
This is likely due to the loss of a positive charge on the proteins surface represented by the 
lysine to cysteine mutation. 
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(a) BPSL1958 DEAE purification step 
 
 
(b) BPSL1958 Superose 6 purification step 
 
Figure 6.1 Chromatogram traces for the purification of BPSL1958. a DEAE purification step showing column 
loading and elution. 8 ml fractions were collected starting at the beginning of the gradient at 45 ml. b Gel 
filtration purification step showing elution with 2 ml fractions collected throughout. For both traces, highlighted 
regions indicate the eluant taken for subsequent purification step or as pure protein. 
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Figure 6.2 SDS-PAGE gel showing the purification of BPSL1958. The molecular weight of BPSL1958 is 36.1
kDa and the highlighted bands indicate the protein in fractions taken for subsequent purification steps or as pure 
protein. 
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6.1.3 Seleno-methionine mutant protein purification 
The BPSL1958 K3C-I44M-I252M-I356M quadruple mutant seleno-methionine protein was 
purified using the same techniques as the other K3C mutant proteins. The overall yield was 
very low with only 0.5 mg being obtained which was concentrated to 8 mg ml-1 for use in 
crystallisation trials. 
6.1.4 Purification analysis 
The purified native protein was analysed by N-terminal sequencing (Arthur Moir, University 
of Sheffield) confirming it was BPSL1958 without its N-terminal methionine. During the 
purification the protein was found to elute significantly later than expected from the Superose 
6 gel filtration column (figure 6.1 b) with a predicted molecular weight of approximately 10 
kDa, not the expected 36.1 kDa. This suggests the protein interacts with the matrix of the 
column causing it to elute anomalously. 
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BPSL1958 K3C DEAE purification step 
 
 
 
 
Figure 6.3 Chromatogram trace and SDS-PAGE analysis of BPSL1958 K3C DEAE purification. The trace 
shows loading and elution with 8 ml fractions collected starting at the beginning of the gradient at 104 ml. The 
highlighted region indicates the volume taken for the subsequent purification step. The SDS-PAGE gel shows 
fractions from the DEAE purification step of BPSL1958 K3C. The highlighted region indicates the fractions 
taken for subsequent purification steps. 
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6.2 Protein crystallisation for BPSL1958 
6.2.1 Native protein crystallisation 
Two initial 96 condition screens, the Classics and Pegs suites, were conducted using purified 
BPSL1958 at 8 mg ml-1. 200 nl of protein was mixed with 200 nl of well solution and the 
trays were incubated at 17 ºC. A single hit was found in the Classics robot crystal screen in 
well H11 (figure 6.4) containing 100 mM HEPES pH 7.5, 20 % (w/v) PEG 10,000 and 8 % 
(v/v) ethylene glycol. This condition was repeated in a single hanging drop experiment using 
a 5 µl protein, 5 µl well solution drop to obtain larger single crystals for data collection. 
 
v 
 
Classics H11 – Robot screen  
100 mM HEPES pH 7.5 
20 % (w/v) PEG 10000 
8 % (v/v) Ethylene glycol 
Drop size 200 nl protein + 200 nl well solution 
Classics H11 – Hanging drop 
100 mM HEPES pH 7.5 
20 % (w/v) PEG 10000 
8 % (v/v) Ethylene glycol 
Drop size 5 µl protein + 5 µl well solution 
 
Figure 6.4 Photographs of BPSL1958 crystals. 
100 µm 100 µm 
 
6.2.2 BPSL1958 K3C and S128C mutant protein crystallisation 
Three initial 96 condition robot screens, the JCSG+, PACT and Pegs suites, were conducted 
using purified BPSL1958 K3C at 7 mg ml-1 and BPSL1958 S128C at 8 mg ml-1 on their own 
and mixed with a five times molar excess of EMTS. 200 nl of protein was mixed with 200 nl 
of well solution and the trays were incubated at 17 ºC. The only hit was found for BPSL1958 
K3C in the Pegs robot crystal screen containing EMTS (figure 6.5) with no protein crystals 
being formed in any conditions for the S128C mutant protein. The single crystal was found in 
condition D8, 100 mM TRIS pH 8.5 and 25 % (w/v) PEG 4000. Attempts to optimise the 
crystals by altering the PEG concentration (20 – 35 % (w/v)) and pH (7.0 – 9.0) using 1 µl 
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protein solution and 1 µl well solution initially failed producing no crystals or precipitate. A 
further single experiment using the initial conditions and a drop size of 8 µl protein solution 
and 2 µl well solution produced several large crystals of the K3C mutant protein. Following 
this success, four further screens, the JCSG+, PACT, Pegs and Classics suites, were 
conducted for BPSL1958 S128C using protein at 8 mg ml-1 mixed with a ten times molar 
excess of EMTS. For these screens 500 nl of protein solution was mixed with 200 nl of well 
solution and the trays were incubated at 17 ºC. Several hits were found (figure 6.5) in 
conditions Pegs D5 containing 100 mM HEPES pH 7.5 and 20 % (w/v) PEG 10,000, Classics 
A5 containing 100 mM HEPES pH 7.5, 10 % (v/v) isopropanol and 20 % (w/v) PEG 4,000, 
Classics H3 containing 100 mM tri-sodium citrate pH 5.6, 200 mM ammonium acetate and 
30 % (w/v) PEG 4,000, Classics H4 containing 100 mM TRIS pH 8.5, 200 mM magnesium 
chloride and 30 % (w/v) PEG 4,000, and Classics H8 containing 100 mM MES pH 6.5, 200 
mM ammonium acetate and 30 % (w/v) PEG 5,000 MME. Optimisation trials were 
conducted for all initial BPSL1958 S128C crystal hits by altering the pH and concentration of 
components. For condition Pegs D5, the pH (7.0 – 8.0) and PEG concentration (15 – 30 % 
(w/v)) were varied. For condition Classics A5, the pH (7.0 – 8.0), isopropanol concentration 
(0 – 20 % (v/v)) and PEG concentration (15 – 30 % (w/v)) were varied. For condition 
Classics H3, the pH (5.0 – 6.0), and PEG concentration (20 – 40 % (w/v)) were varied. For 
condition Classics H4, the pH (8.0 – 9.0), and PEG concentration (20 – 40 % (w/v)) were 
varied.  For condition Classics H8, the pH (6.0 – 7.0), and PEG concentration (20 – 40 % 
(w/v)) were varied. Optimisation screens for conditions Pegs D5 and Classics A5 were 
successful with the other optimisation screens failing to produce crystals that appeared 
superior to the initial hits on inspection. The best crystals were found in the optimised 
condition 100 mM HEPES pH 7.5, 5 % (v/v) isopropanol and 12 % (w/v) PEG 4,000, and 
these crystals were selected for data collection.  
6.2.3 BPSL1958 K3C-D244C, K3C-H340C and A357C mutant protein crystallisation 
Four initial 96 condition robot screens, the JCSG+, PACT, Pegs and Classics suites, were 
conducted using purified BPSL1958 K3C-D244C, K3C-H340C and A357C all at 8 mg ml-1  
mixed with a five times molar excess of EMTS. The screens were conducted using both a 200 
nl of protein mixed with 200 nl of well solution and 500 nl of protein mixed with 200 nl of 
well solution drop size and the trays were incubated at 17 ºC. Hits were found in a number of 
conditions for the three mutants (figures 6.6). Three conditions familiar to all three mutants 
and also BPSL1958 S128C were Classics H3, H4 and H8. Crystals were also found for 
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K3C – Pegs D8 – Robot screen  
100 mM TRIS pH 8.5 
25 % (w/v) PEG 4000 
Drop size 200 nl protein + 200 nl well solution 
S128C – Pegs D5 – Robot screen  
100 mM HEPES pH 7.5 
20 % (w/v) PEG 10000 
Drop size 500 nl protein + 200 nl well solution 
  
S128C – Classics A5 – Robot screen  
100 mM HEPES pH 7.5 
20 % (w/v) PEG 4000 
10 % (v/v) Isopropanol 
Drop size 500 nl protein + 200 nl well solution 
S128C – Classics H3 – Robot screen  
200 mM Ammonium acetate 
100 mM Tri-sodium citrate pH 5.6 
30 % (w/v) PEG 4000 
Drop size 500 nl protein + 200 nl well solution 
  
S128C – Classics H4 – Robot screen  
200 mM Magnesium cholride 
100 mM TRIS pH 8.5 
30 % (w/v) PEG 4000 
Drop size 500 nl protein + 200 nl well solution 
S128C – Classics H8 – Robot screen  
200 mM Ammonium sulphate 
100 mM MES pH 6.5 
30 % (w/v) PEG 5000 MME 
Drop size 500 nl protein + 200 nl well solution 
 
Figure 6.5 Photographs of BPSL1958 K3C + EMTS and BPSL1958 S128C + EMTS crystals. 
100 µm 100 µm 
100 µm 100 µm 
100 µm 100 µm 
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K3C-D244C – Classics H3 – Robot screen  
200 mM Ammonium acetate 
100 mM Tri-sodium citrate pH 5.6 
30 % (w/v) PEG 4000 
Drop size 500 nl protein + 200 nl well solution 
K3C-D244C – Classics H4 – Robot screen  
200 mM Magnesium cholride 
100 mM TRIS pH 8.5 
30 % (w/v) PEG 4000 
Drop size 500 nl protein + 200 nl well solution 
  
K3C-D244C – Classics H8 – Robot screen  
200 mM Ammonium sulphate 
100 mM MES pH 6.5 
30 % (w/v) PEG 5000 MME 
Drop size 500 nl protein + 200 nl well solution 
 
K3C-H340C – Classics D8 – Robot screen  
100 mM HEPES pH 7.5 
1.4 M Tri-sodium citrate 
Drop size 500 nl protein + 200 nl well solution 
  
K3C-H340C – Classics H3 – Robot screen  
200 mM Ammonium acetate 
100 mM Tri-sodium citrate pH 5.6 
30 % (w/v) PEG 4000 
Drop size 500 nl protein + 200 nl well solution 
K3C-H340C – Classics H4 – Robot screen  
200 mM Magnesium cholride 
100 mM TRIS pH 8.5 
30 % (w/v) PEG 4000 
Drop size 500 nl protein + 200 nl well solution 
 
 
100 µm 
100 µm 
100 µm 100 µm 
100 µm 
100 µm 
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K3C-H340C – Classics H8 – Robot screen  
200 mM Ammonium sulphate 
100 mM MES pH 6.5 
30 % (w/v) PEG 5000 MME 
Drop size 500 nl protein + 200 nl well solution 
A357C – Classics D8 – Robot screen  
100 mM HEPES pH 7.5 
1.4 M tri-sodium citrate 
Drop size 500 nl protein + 200 nl well solution 
  
A357C – Classics F11 – Robot screen  
200 mM Sodium acetate 
100 mM Sodium cacodylate pH 6.5 
30 % (w/v) PEG 8000 
Drop size 500 nl protein + 200 nl well solution 
A357C – Classics H3 – Robot screen  
200 mM Ammonium acetate 
100 mM tri-sodium citrate pH 5.6 
30 % (w/v) PEG 4000 
Drop size 500 nl protein + 200 nl well solution 
  
A357C – Classics H4 – Robot screen  
200 mM Magnesium cholride 
100 mM TRIS pH 8.5 
30 % (w/v) PEG 4000 
Drop size 500 nl protein + 200 nl well solution 
A357C – Classics H8 – Robot screen  
200 mM Ammonium sulphate 
100 mM MES pH 6.5 
30 % (w/v) PEG 5000 MME 
Drop size 500 nl protein + 200 nl well solution 
Figure 6.6 Photographs of BPSL1958 K3C-D244C + EMTS, BPSL1958 K3C-H340C and  BPSL1958 A357C + 
EMTS crystals. 
100 µm 
100 µm 
100 µm 
100 µm 
100 µm 100 µm 
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BPSL1958 K3CH340C and A357C in condition Classics D8 containing 100 mM HEPES pH 
7.5 and 1.4 M tri-sodium citrate with a further two hits for BPSL1958 A357C in conditions 
Classics F11 containing 200 mM sodium acetate, 100 mM sodium cacodylate pH 6.5 and 30 
% (w/v) PEG 8,000, and Classics H6 containing 200 mM sodium acetate, 100 mM TRIS pH 
8.5 and 30 % (w/v) PEG 4,000. As many of the initial hit conditions were overlapping 
between the different mutants, optimisation screens were conducted around all hit conditions, 
found for any of the mutants or the native protein (Pegs A5 and D8, Classics A5, D8, F11, 
H3, H4, H6, H8 and H11), for BPSL1958 K3C-D244C, K3C-H340C and A357C. These were 
conducted, as for the other mutants, by varying the pH and concentration of the components. 
For condition Classics D8, the pH (7.0 – 8.0), and tri-sodium citrate concentration (1.0 – 2.0 
M) were varied. For condition Classics F11, the pH (6.0 – 7.0), and PEG concentration (20 – 
40 % (w/v)) were varied. For condition Classics H6, the pH (7.0 – 8.0), and PEG 
concentration (20 – 40 % (w/v)) were varied. For condition Classics H11, the pH (7.0 – 8.0), 
ethylene glycol concentration (0 – 15 % (v/v)) and PEG concentration (10 – 30 % (w/v)) 
were varied. Unfortunately attempts to optimise crystallisation conditions for the three 
mutants produced either no crystals or crystals of a similar quality to the robot trials. The 
most successful initial hits for BPSL1958 K3C-H340C and BPSL1958 A357C were Classics 
H4 and Classics F11 respectively, and crystals from these conditions were selected for data 
collection. 
6.2.4 BPSL1958 K3C-I44M-I64M-I356M Seleno-methionine protein crystallisation 
An initial screen around the successful crystallisation condition for the K3C single mutant, 
Pegs D8 with EMTS, by varying PEG concentration (20 – 30 % (w/v)) produced no crystals. 
Three forms of seeding were also attempted for the seleno-methionine protein using crystals 
of BPSL1958 K3C EMTS as seeds and the initial hit condition, Pegs D8 with EMTS. Macro-
seeding was conducted by removing a crystal, briefly washing it in the well solution and 
placing into a drop containing 8 µl of seleno-methionine protein solution and 2 µl of well 
solution and suspended above wells containing crystallisation solution. Micro-seeding was 
attempted by looping crystals which were placed into a 10 µl drop of crystallisation solution 
on a clean coverslip. The crystals were ground up using a glass rod until they could no longer 
be seen with a microscope. The drop was then serially diluted to form six 90 µl solutions that 
were diluted 101 – 106 times from the original drop. 1 µl of these solutions were added to 
drops containing 7 µl of seleno-methionine protein solution and 2 µl of well solution and 
suspended above wells containing crystallisation solution. The final method was streak-
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seeding which was attempted in two forms. The first was by using the 102 diluted solution 
from micro-seeding trials. A hair was dipped into the solution before being drawn across a 
drop containing 8 µl of seleno-methionine protein solution and 2 µl of well solution that had 
been allowed to equilibrate for five days and resuspended above wells containing 
crystallisation solution. The second method used a hair to rub against the edge of a formed 
crystal which was then drawn across a drop similarly to the first method. Some success was 
obtained through the streaking experiments using the micro-seeding solution, although 
crystals did not appear large enough for data collection (figure 6.7). 
 
 
Pegs D8 – Streak-seeded 
100 mM TRIS pH 8.5 
25 % (w/v) PEG 4000 
Drop size 8 µl protein + 2 µl well solution 
 
Figure 6.7 Crystals of seleno-methionine BPSL1958 K3C-I44M-I64M-I356M  + EMTS. 
100 µm 
 
6.3 BPSL1958 native data  
6.3.1 Native data collection 
Native crystals were selected for data collection based on their size and overall definition 
from the successful optimisation trial. Crystals were looped and placed into a cryoprotectant 
solution consisting of the well solution with an increased concentration of 30 % (v/v) 
ethylene glycol. They were then looped again and flash frozen in a stream of gaseous 
nitrogen at 100 ºK and mounted onto the detector. Initial diffraction analysis was conducted 
in order to determine the diffraction quality of several crystals using an in-house Rigaku 
MM007 rotating anode generator and a MAR 345 research image plate. Two images were 
collected 90º apart with 1º oscillation. A number of crystals that diffracted beyond 2.5 Å on 
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the home source were saved and taken to a synchrotron at the I02 beamline of the Diamond 
light source, Oxford. Two initial test images were taken 90º apart with 1º oscillation to ensure 
crystal centering and to obtain a collection strategy using the auto-indexing and collection 
strategy components of Mosflm [146]. For the data set 420 images were collected with 0.25º 
oscillation per image using X-rays of 12658 eV at a crystal to detector distance of 255 mm 
using an ADSC Q315r detector. Data extending to 1.7 Å were collected (figure 6.8). 
 
 
 
Figure 6.8 Diffraction image of the native crystal of BPSL1958. 
 
6.3.2 Native data processing 
The X-ray diffraction datasets were auto-processed at Diamond through the xia2 system 
using the 3dii mode [147]. Data were indexed and integrated by XDS and scaled by XSCALE 
[148]. The data indexed to a primitive orthorhombic space group with the unit cell parameters 
a = 63.7 Å, b = 99.3 Å, c = 108.2 Å (table 6.1). The space group was designated as most 
likely being P212121 based on the apparent systematic absence of odd axial reflections for all 
three axes. Matthews coefficients calculated using Mattprob [149] showed the asymmetric 
unit was predicted to contain one, two or three protein molecules, with two being 
overwhelmingly the most likely, giving a Matthews coefficient of 2.37 and a solvent content 
of 48 % (table 6.2).  
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Dataset Native protein crystal 
Space group Orthorhombic P 
Unit cell parameters  
a (Å) 63.7 
b (Å) 99.3 
c (Å) 108.2 
Energy (eV) 12658 
Resolution range (Å) 45.14 – 1.73 
Unique reflections 70099 (15397) 
Rmerge 0.059 (0.680) 
Rpim 0.040 (0.531) 
Completeness (%) 97.1 (80.7) 
Multiplicity 2.2 (1.9) 
Mean (I)/σ(I) 13.7 (2.0) 
 
Table 6.1 Data collection statistics for the native BPSL1958 crystal. Numbers in parentheses indicate values for 
the highest resolution shell. 
 
Molecules in 
the AU 
Probability 
(based data 
resolution) 
Probability 
(all proteins 
in the pdb) 
Vm (Å3 / Da) Solvent 
content (%) 
Molecular 
weight (Da) 
1 0.0029 0.0203 4.74 74.04 36110 
2 0.9944 0.9753 2.37 48.07 72220 
3 0.0027 0.0045 1.58 22.11 108330 
 
Table 6.2 Matthews coefficient calculations and probabilities for native crystals of BPSL1958. The results show 
a possibility of one, two or three protein molecules inhabiting the asymmetric unit.  
 
6.4 Phasing by molecular replacement for BPSL1958 
The two threading models for the six or seven bladed β-propeller proteins output by the Phyre 
2 server [141] (figure 3.6) were used to create possible search models for molecular 
replacement using the native diffraction data. The two models were cut back to a poly alanine 
chain using chainsaw [150] before use for an automated search in Phaser [151]. The data 
were input and Phaser was run in P212121 and all alternative related space groups. 
Unfortunately the best results for both search models were of a poor quality with low Z-
scores for both the rotation and translation searches. The resulting refined models were also 
unconvincing after refinement with REFMAC5 [152] suggesting a solution had not been 
found (table 6.3).  
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 6-Bladed model 7-bladed model 
Space group P2221 P222 
Rotation function Z-score 3.8 4.8 
Translation function Z-score 8.2 5.9 
R 61.7 62.0 
 
Table 6.3 Best molecular replacement solutions for BPSL1958 using threaded homology models.  
 
6.5 BPSL1958 mutant data 
6.5.1 K3C mutant EMTS co-crystallisation data collection 
The initial robot trial hit was selected for data collection. The crystal was looped and placed 
into a cryoprotectant solution consisting of the well solution with the addition of 30 % (v/v) 
ethylene glycol. They were then looped again and flash frozen in a stream of gaseous 
nitrogen at 100 ºK and mounted onto the detector. Initial diffraction analysis was conducted 
in order to determine the diffraction quality of the crystal using an in-house Rigaku MM007 
rotating anode generator and a MAR 345 research image plate. Two images were collected 
90º apart with 1º oscillation and the diffraction was found to be of good quality. The crystal 
was saved and data was collected using a synchrotron at the I04 beamline of the Diamond 
light source, Oxford. Two initial test images were taken 90º apart with 1º oscillation to ensure 
crystal centering and to obtain a collection strategy using the auto-indexing and collection 
strategy components of Mosflm [146]. A fluorescence scan at the mercury LIII edge was 
conducted to select X-ray energies at which to collect data in a MAD experiment (figure 
6.9a). Four energies were selected based on the fluorescence absorbance spectrum profile. 
The peak (maximised f’’) and inflection point (minimised f’) were selected as 12287 eV and 
12284 eV, and a high and low energy remote dataset were selected as 12260 eV and 12295 
eV respectively. For each wavelength 720 images were collected with 0.5º oscillation per 
image at a crystal to detector distance of 414 mm using an ADSC Q315r detector. Data 
extending to approximately 2.1 Å were collected for each X-ray energy (figure 6.10). 
6.5.2 S128C mutant EMTS co-crystallisation data collection 
Crystals were selected for data collection based on their size and overall definition from the 
successful optimisation trials. Crystals were looped and placed into a cryoprotectant solution 
consisting of the well solution with the addition of 30 % (v/v) ethylene glycol. They were 
then looped again and flash frozen in a stream of gaseous nitrogen at 100 ºK and mounted 
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Figure 6.9 Mercury LIII-edge fluorescence scans for the BPSL1958 (EMTS) mutant crystals. 
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(c) Fluorescence against energy 
for BPSL1958 A357C
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(d) Fluorescence against energy 
for BPSL1958 K3C-H340C
onto the detector. Several crystals were saved and data was collected using a synchrotron at 
the I24 beamline of the Diamond light source, Oxford. Two initial test images were taken 90º 
apart with 1º oscillation to ensure crystal centering and to obtain a collection strategy using 
the auto-indexing and collection strategy components of Mosflm [146]. A fluorescence scan 
at the mercury LIII edge was conducted to select X-ray energies at which to collect data in a 
MAD experiment (figure 6.9b). Three energies were selected based on the fluorescence 
absorbance spectrum profile. The peak (maximised f’’) and inflection point (minimised f’) 
were selected as 12294 eV and 12289 eV respectively and the high energy remote 
(maximised ∆f’ from inflection) was selected as 12500 eV. For each wavelength 450 images  
were collected with 0.2º oscillation per image at a crystal to detector distance of 400 mm 
using a Pilatus 6M detector. Data extending to approximately 2.0 Å were collected for each 
X-ray energy (figure 6.10).  
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BPSL1958 K3C peak dataset BPSL1958 S128C peak dataset 
  
  
BPSL1958 A357C peak dataset BPSL1958 K3C-H340C peak dataset 
 
Figure 6.10 Diffraction images of crystals of four mutants of BPSL1958. 
 
6.5.3 A357C mutant EMTS co-crystallisation data collection 
Crystals were selected for data collection based on their size and overall definition from the 
initial robot trials. Crystals were looped and placed into a cryoprotectant solution consisting 
of the well solution with the addition of 30 % (v/v) ethylene glycol. They were then looped 
again and flash frozen in a stream of gaseous nitrogen at 100 ºK and mounted onto the 
detector. Several crystals were saved and data was collected using a synchrotron at the I04 
beamline of the Diamond light source, Oxford. Two initial test images were taken 90º apart 
with 1º oscillation to ensure crystal centering and to obtain a collection strategy using the 
auto-indexing and collection strategy components of Mosflm [146]. A fluorescence scan at 
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the mercury LIII edge was conducted to select X-ray energies at which to collect data in a 
MAD experiment (figure 6.9c).  The scan suggested the absence of mercury in the crystal as 
there was very little excitation, however two wavelengths were selected corresponding to 6 
eV above the hypothetical peak at 12290 eV, and the hypothetical inflection at 12281 eV for 
a mercury derivative and used to collect full datasets. For both wavelengths 180 images were 
collected with 0.5º oscillation per image at a crystal to detector distance of 363 mm using an 
ADSC Q315r detector. Data extending to approximately 2.9 Å were collected for both X-ray 
energies (figure 6.10).  
6.5.4 K3C-H340C mutant EMTS co-crystallisation data collection 
Crystals were selected for data collection based on their size and overall definition from the 
initial robot trials. Crystals were looped and placed into a cryoprotectant solution consisting 
of the well solution with the addition of 30 % (v/v) ethylene glycol. They were then looped 
again and flash frozen in a stream of gaseous nitrogen at 100 ºK and mounted onto the 
detector. Several crystals were saved and data was collected using a synchrotron at the I04 
beamline of the Diamond light source, Oxford. Two initial test images were taken 90º apart 
with 1º oscillation to ensure crystal centering and to obtain a collection strategy using the 
auto-indexing and collection strategy components of Mosflm [146]. A fluorescence scan at 
the mercury LIII edge was conducted to select X-ray energies at which to collect data in a 
MAD experiment (figure 6.9d). Three energies were selected based on the fluorescence 
absorbance spectrum profile. The peak (maximised f’’) and inflection point (minimised f’) 
were selected as 12291 eV and 12281 eV respectively, and high energy remote (maximised 
∆f’ from inflection) was selected as 12400 eV. For each wavelength 360 images were 
collected with 0.5º oscillation per image at a crystal to detector distance of 280 mm using an 
ADSC Q315r detector. Data extending to approximately 2.9 Å were collected for each X-ray 
energy (figure 6.10). 
6.5.5 Mutant data processing 
The mutant X-ray diffraction datasets were auto-processed at Diamond through the xia2 
system using the 3dii mode [147]. Data were indexed and integrated by XDS and scaled by 
XSCALE [148]. The K3C mutant datasets indexed to a primitive orthorhombic space group, 
most likely P212121 based on systematic absences, with the unit cell parameters a = 63.2 Å, b 
= 99.0 Å, c = 109.2 Å, roughly corresponding to the native dataset (table 6.4). The K3C 
datasets contained data to approximately 2.1 Å however it was incomplete beyond 
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approximately 2.5 Å (figure 6.11) producing poor statistics for the overall data. The S128C 
datasets indexed to a primitive orthorhombic space group, most likely P212121 based on 
systematic absences, with the unit cell parameters a = 63.5 Å, b = 99.0 Å, c = 108.5 Å, 
indicating that the crystals were isomorphous with the native dataset (table 6.5). The A357C 
datasets indexed to a primitive orthorhombic space group, with the unit cell parameters a = 
63.6 Å, b = 99.4 Å, c = 107.9 Å. For this mutant, the programme Pointless [153] suggested 
the pattern of the space group was most likely to have a 2-fold axis rather than a 2-fold screw 
along a. Analysis of the raw data showed that this was based on the presence of a 12 σ 
reflection for the 5 0 0, however the intensity of the reflection is still much weaker than the 
vast majority of the even ordered reflections along the a-axis. Whether the assignment is 
correct, or an artefact arising from poor data is unclear, though the overall similarity between 
the unit cell dimensions and the pattern of reflections elsewhere would support the view that 
the crystal form is the same as for the native data. Therefore the data was treated as belonging 
to the same space group as the native, K3C and S128C datasets.  The K3C-H340C datasets 
indexed to the space group P21, with the unit cell parameters a = 46.6 Å, b = 46.1 Å, c = 98.5 
Å, β = 96.1°, showing a unique space group among the datasets (table 6.7). Matthews 
coefficients were approximately the same for the K3C, S128C and A357C datasets due to the 
similarity in unit cell parameters. The Matthews coefficient was calculated using Mattprob 
[149] for the K3C-H340C datasets and showed the asymmetric unit was predicted to contain 
one or two protein molecules, with one being overwhelmingly the most likely, giving a 
Matthews coefficients of 2.91 and a solvent content of 58 % (Table 6.8).  
 
 
Figure 6.11 Data collection statistics against resolution for the BPSL1958 K3C data. The graph shows Rmerge
and completeness for the peak dataset. The graph suggests the data is complete and of a good quality to 2.5 Å. 
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Low energy 
remote 
Inflection Peak 
High energy 
remote 
Space group Orthorhombic P Orthorhombic P Orthorhombic P Orthorhombic P 
Unit cell parameters     
a (Å) 63.3 63.2 63.2 63.3 
b (Å) 99.0 98.9 98.8 99.0 
c (Å) 109.4 109.2 109.3 109.3 
Energy (eV) 12260 12284 12287 12295 
Resolution range (Å) 73.40 – 2.07 73.28 – 2.07 73.31 – 2.07 73.36 – 2.07 
Unique reflections 31603 (328) 31522 (334) 31614 (352) 31608 (329) 
Rmerge 0.038 (0.233) 0.043 (0.249) 0.043 (0.183) 0.043 (0.222) 
Rpim 0.012 (0.176) 0.012 (0.137) 0.012 (0.135) 0.014 (0.167) 
Completeness (%) 74.4 (10.8) 74.5 (11.1) 74.8 (11.7) 74.4 (10.8) 
Anomalous completeness (%) 72.5 (4.3) 72.7 (4.6) 72.9 (5.3) 72.6 (4.5) 
Multiplicity 11.1 (2.4) 11.1 (2.5) 11.1 (2.6) 11.2 (2.5) 
Anomalous multiplicity 5.9 (2.0) 5.9 (2.0) 5.9 (2.0) 5.9 (2.0) 
Mean (I)/σ(I) 39.7 (3.4) 40.2 (4.4) 39.5 (4.5) 35.5 (3.3) 
 
Table 6.4 Data collection statistics for the BPSL1958 K3C crystal. Numbers in parentheses indicate values for 
the highest resolution shell. 
    
 Inflection Peak 
High energy 
remote 
Space group Orthorhombic P Orthorhombic P Orthorhombic P 
Unit cell parameters    
a (Å) 63.5 63.5 63.6 
b (Å) 99.3 98.9 99.2 
c (Å) 108.0 108.5 108.2 
Energy (eV) 12289 12294 12500 
Resolution range (Å) 41.15 – 1.99 45.01 – 2.15 41.19 – 1.81 
Unique reflections 46473 (3253) 37128 (2722) 57674 (2705) 
Rmerge 0.092 (0.386) 0.124 (0.598) 0.048 (0.427) 
Rpim 0.049 (0.313) 0.089 (0.432) 0.039 (0.318) 
Completeness (%) 98.0 (94.4) 98.3 (98.5) 92.2 (60.5) 
Anomalous completeness (%) 91.3 (87.3) 92.0 (92.3) 82.0 (46.6) 
Multiplicity 3.3 (3.1) 3.3 (3.3) 3.1 (2.5) 
Anomalous multiplicity 1.8 (1.6) 1.8 (1.8) 1.7 (1.4) 
Mean (I)/σ(I) 11.0 (2.3) 7.5 (2.2) 12.1 (2.1) 
 
Table 6.5 Data collection statistics for the BPSL1958 S128C crystal. Numbers in parentheses indicate values for 
the highest resolution shell. 
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Inflection Peak 
Space group Orthorhombic P Orthorhombic P 
Unit cell parameters   
a (Å) 99.4 99.4 
b (Å) 107.9 107.9 
c (Å) 63.7 63.6 
Energy (eV) 12281 12290 
Resolution range (Å) 45.16 – 2.94 45.14 – 2.92 
Unique reflections 14787 (1027) 15064 (1041) 
Rmerge 0.139 (0.750) 0.184 (0.815) 
Rpim 0.097 (0.440) 0.097 (0.465) 
Completeness (%) 97.9 (94.2) 97.8 (93.2) 
Anomalous completeness (%) 89.7 (79.3) 89.2 (78.5) 
Multiplicity 3.3 (3.1) 3.3 (3.1) 
Anomalous multiplicity 1.9 (1.8) 1.9 (1.8) 
Mean (I)/σ(I) 6.3 (1.9) 6.3 (1.8) 
 
Table 6.6 Data collection statistics for the BPSL1958 A357C crystal. Numbers in parentheses indicate values 
for the highest resolution shell. 
    
 Inflection Peak 
High energy 
remote 
Space group P21 P21 P21 
Unit cell parameters    
a (Å) 46.5 46.6 46.6 
b (Å) 46.1 46.1 46.2 
c (Å) 98.2 98.5 98.5 
β (º) 95.9 96.1 96.2 
Energy (eV) 12281 12291 12400 
Resolution range (Å) 48.86 – 2.82 97.92 – 2.92 48.99 – 2.67 
Unique reflections 10151 (753) 9259 (666) 12043 (9.8) 
Rmerge 0.261 (0.682) 0.301 (0.717) 0.340 (0.868) 
Rpim 0.190 (0.475) 0.130 (0.305) 0.177 (0.448) 
Completeness (%) 99.2 (99.9) 99.9 (99.8) 99.5 (99.8) 
Anomalous completeness (%) 90.9 (92.3) 99.7 (99.8) 92.8 (92.8) 
Multiplicity 3.6 (3.7) 7.3 (7.5) 3.6 (3.7) 
Anomalous multiplicity 1.9 (1.9) 3.8 (3.9) 1.9 (1.9) 
Mean (I)/σ(I) 4.7 (1.8) 6.5 (2.6) 5.0(1.9) 
 
Table 6.7 Data collection statistics for the BPSL1958 K3C -H340C crystal. Numbers in parentheses indicate 
values for the highest resolution shell.  
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Molecules in 
the AU 
Probability 
(based on 
resolution) 
Probability 
(all proteins 
in the pdb) 
Vm (Å3 / Da) Solvent 
content (%) 
Molecular 
weight (Da) 
1 0.9925 0.9918 2.91 57.78 36110 
2 0.0075 0.0082 1.46 15.56 72220 
 
Table 6.8 Matthews coefficient calculations and probabilities for crystals of BPSL1958 K3C-H340C. The 
results show a possibility of one or two protein molecules inhabiting the asymmetric unit. 
 
 
6.6 Experimental phasing for BPSL1958 
Initial phasing was attempted with the programmes of the SHELX package [154] using the 
HKL2MAP graphical user interface for SHELXC and SHELXD [155]. SHELXC was first 
used to judge the presence and quality of any anomalous signal within the datasets from all 
the crystals. This suggested that the only datasets with any anomalous signal came from the 
BPSL1958 K3C crystal from the initial crystal trial, and this contained significant anomalous 
signal to 4.5 Å and usable signal to 3.2 Å (figure 6.12).  SHELXD was used to calculate the 
heavy atom substructure in all possible primitive orthorhombic space groups using all data to 
3.5 Å. The best solution was identified with a correlation coefficient of 51.13 and a Patterson 
figure of merit of 26.29. A total of six potential heavy atom sites were found, two very strong 
sites, two weaker sites and two very weak sites (figure 6.13). Preliminary protein phasing, 
density modification and initial model building were conducted using SHELXE-beta with 
auto-tracing. Five rounds of twenty cycles of phase calculation and density modification, 
including NCS averaging, followed by auto-tracing were carried out for both the original and 
the inverted hands of the mercury substructure. A solvent content of 48 % was used 
corresponding to two molecules in the asymmetric unit. The solutions for the two 
substructure hands gave values of 0.439 and 0.639, and 0.445 and 0.649, for the contrast and 
connectivity of the original and inverted hands respectively, preventing the assignment of a 
hand to the substructure based on these figures of merit.  SHELXE produced models for the 
original and inverted hands consisting of 104 and 108 residues respectively, with correlation 
coefficients for partial structure against the data of 11.24 % and 7.29 %. The models for the 
two hands, if correct, only corresponded to a small fraction of the expected protein in the 
asymmetric unit and were unconvincing when viewed alongside the electron density maps. 
Furthermore inspection of the maps for the two hands provided no insight into the correct 
substructure hand, or provided a base for further model building, as both were equally 
uninterpretable (figure 6.14). 
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(a) d’’/sigma against resolution BPSL1958 K3C datasets 
 
(b) d’’/sigma against resolution BPSL1958 S128C datasets 
 
(c) d’’/sigma against resolution BPSL1958 A357C datasets 
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(d) d’’/sigma against resolution BPSL1958 K3C-H340C datasets 
 
 
Figure 6.12 Results from SHELX C showing anomalous signal from the four BPSL1958 mutants datasets. The 
four graphs show d’’/sigma plotted against resolution for each dataset. A value of 1.2  or above indicates the 
presence of good anomalous signal and it can therefore clearly be seen the only datasets that include useful 
anomalous data are the K3C mutant datasets. 
 
 
 
 
Figure 6.13 Results from SHELX D for BPSL1958 K3C MAD experiment showing the best solution. Peaks are 
predicted to have occupancies of 0.99, 0.97, 0.71, 0.67, 0.36 and 0.35 and clearly exist as sets of two sites. 
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(a) Original substructure hand  
 
(b) Inverted substructure hand  
 
 
Figure 6.14 Sample region of electron density for the original hand and inverted hand solutions for the  
BPSL1958 K3C mercury MAD phasing experiment. Both maps are contoured at 1 sigma and show the same 
cross section of density. a The initial electron density map output from SHELX E for the original substructure 
hand. b The initial electron density map output from SHELX E for the inverted substructure hand. 
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6.7 The space group of BPSL1958 crystals 
Analysis of the self-Patterson functions for the native, K3C, S128C and A357C mutant 
datasets all of which had been assigned to P212121 suggested they all possessed essentially the 
same non-crystallographic translational symmetry corresponding to a translation of ½ along 
the c axis of the unit cell (table 6.9). For the K3C and A357C mutants this was aligned with 
the other unit cell axes but for the native and S128C mutants it was slightly offset along the a 
axis. Therefore if the correct space group is P212121 the asymmetric unit contains two 
molecules of the protein related to each other by a translation of ½ along the longest unit cell 
axis.  
 
(a) BPSL1958 native dataset 
Peak  Height RMS-1 Fractional coordinates Orthogonal coordinates 
Origin 135.57 0.0000 0.0000 0.0000 0.00 0.00 0.00 
Translation 41.42 0.0220 0.0000 0.5000 1.40 0.00 54.08 
(b) BPSL1958 K3C peak dataset 
Peak  Height RMS-1 Fractional coordinates Orthogonal coordinates 
Origin 133.81  0.0000 0.0000 0.0000 0.00 0.00 0.00 
Translation 53.67 0.0000 0.0000 0.5000 0.00 0.00 54.58 
(c) BPSL1958 S128C peak dataset 
Peak  Height RMS-1 Fractional coordinates Orthogonal coordinates 
Origin 134.81 0.0000 0.0000 0.0000 0.00 0.00 0.00 
Translation 41.36 0.0238 0.0000 0.5000 1.52 0.00 54.08 
(d) BPSL1958 A357C peak dataset 
Peak  Height RMS-1 Fractional coordinates Orthogonal coordinates 
Origin 106.16 0.0000   0.0000   0.0000   0.00 0.00 0.00 
Translation 51.42 0.0000   0.0000   0.5000   0.00 0.00 53.92    
 
Table 6.9 Self Patterson analysis of the native and three single mutant datasets for crystals of BPSL1958. The 
analyses were conducted using a resolution cut off of 3 Å for each dataset and a grid spacing equivalent to 1 Å 
along each axis. All datasets suggest the presence of a translation half way along the longest unit cell axis giving 
rise to peaks equating to 31, 40, 31 and 48 % of the origin peak, for the native, K3C, S128C and A357C datasets 
respectively. 
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Figure 6.15 Heavy atom sites for the BPSL1958 K3C MAD solution. The image is viewed with the a-axis 
vertical and the b-axis horizontal to the page clearly showing a non-crystallographic two-fold axis between the 
sites located at ¼ a and 0 b coincident with the c-axis of the unit cell. The numbers represent the relative 
occupancies of the sites, and the pairs of sites with similar occupancies are those related by the axis. 
 
 
Polar angles Orthogonal translation Fractional translation 
Omega Phi Kappa a b c a b c 
179.95 43.93 179.82 31.48 197.87 0.10 0.4981 2.0001 0.0001 
 
Table 6.10 The non-crystallographic symmetry axis between heavy atom sites for the BPSL1958 K3C MAD 
solution. The axis was located using Profess conducted with a maximum search distance of 40 Å. As the omega 
angle is effectively 180°, the rotation around phi is redundant and the resulting rotation is around an axis located 
coincident with the c-axis of the unit cell. The value of effectively 180° for the kappa angle represents a two-
fold rotation around this axis. The translational relationship can be approximated to a translation of ½, 2 and 0 
along the axes a, b and c respectively. The a-axis translation could equally be defined as 0, ¼ or ¾ as the space 
group symmetry operators combine with the NCS axis. The b-axis value of 2 could be more simply defined as 0. 
This confirms the positioning of the axis of rotation, ¼ along a, and coincident with the b and c unit cell axes 
found by initial inspection of the heavy atom sites. 
a 
b 
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On inspection, the heavy atom sites found in the MAD phasing experiment using the K3C 
mutant datasets appeared to possess a two-fold non-crystallographic symmetry element 
coincident with the two-fold screw axis along the c-axis of the unit cell (figure 6.15). The 
programme Profess from the CCP4 suite [156] was used to determine the exact relationship, 
confirming the presence and location of the non-crystallographic rotation axis (table 6.10). 
This NCS symmetry element further explains the relationship between two copies of the 
protein found in the asymmetric unit and the space group of the crystals. As the pseudo 
symmetry axis is coincident with the crystallographic axis, the asymmetric unit can be 
considered to consist of two molecules related by a pseudo 2-fold symmetry axis around a 
crystallographic 21 screw axis, or alternatively if the true space group is P21212, two 
molecules related by a translation of ½ along a crystallographic 2-fold axis. The BPSL1958 
K3C-H340C double mutant crystallised in a different space group to the others which was 
monoclinic as opposed to orthorhombic containing a single copy of the molecule. 
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7.0 Studies on the protein BPSS0211 
This section describes the purification, crystallisation and structure solution of the target 
BPSS0211 by selenium MAD experiments. The section also includes a discussion of the 
structure of the protein. 
7.1 Protein purification for BPSS0211 
7.1.1 Native protein purification 
Approximately 3 g of cell paste was resuspended in 30 ml 50 mM TRIS pH 8.0 and disrupted 
by sonication. Cell debris and insoluble proteins were removed by centrifugation at 70,000 g 
for 15 minutes and the supernatant was loaded onto a DEAE-Sepharose fast flow column 
equilibrated with 50 mM TRIS pH 8.0. A 200 ml gradient from 0 to 500 mM NaCl was then 
applied to the column and 8 ml fractions were collected. Fractions were analysed by SDS-
PAGE and BPSS0211 was found to not interact with the column coming through in the initial 
flow-through. The DEAE flow-through was taken and subjected to an ammonium sulphate 
cut. An equal volume of 4 M ammonium sulphate was added to bring the concentration of 
ammonium sulphate to 2 M and the solution was incubated on ice for 10 minutes. 
Precipitated protein was collected by centrifugation at 70,000 g for 10 minutes before 
resuspension in 20 ml 1.5 M ammonium sulphate, incubation on ice for 10 minutes and 
centrifugation at 70,000 g for 10 minutes. The supernatant was taken and proteins were 
precipitated by bringing the overall concentration of ammonium sulphate to 2 M followed by 
incubation on ice for 10 minutes. The sample was centrifuged at 70,000 g for 10 minutes and 
the pellet was resuspended in 1 ml 50 mM TRIS pH 8.0 before being loaded on a 1.6 x 60 cm 
Superose 6 gel filtration column equilibrated in 50 mM TRIS pH 8.0 and 500 mM NaCl and 
eluted using the same buffer collecting 2 ml fractions (figure 7.1). Peak fractions containing 
the protein were pooled and concentrated using a Vivaspin concentrator with a 5 kDa MWCO 
to 8 mg ml-1 protein. The buffer was exchanged for 10 mM TRIS pH 8.0 using a Zeba spin 
desalting column (Thermo scientific) for use in crystallisation trials and the purification was 
analysed by PAGE (figure 7.2). The overall yield of protein was high with 23 mg being 
obtained which was estimated by SDS-PAGE to be over 95 % pure. 
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BPSS0211 Superose 6 purification step 
Figure 7.1 Chromatogram trace for the gel filtration purification step of BPSS0211. 2 ml fractions were 
collected throughout and the green highlighted region indicates fractions taken as pure protein. 
 
 
Figure 7.2 SDS-PAGE gel showing the purification of BPSS0211. The molecular weight of BPSS0211 is 6.8
kDa and the highlighted bands indicate the protein in fractions taken for subsequent purification steps or as pure 
protein.  
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7.1.2 Seleno-methionine protein purification 
Protein containing seleno-L-methionine was purified using the same techniques as for native 
protein. Approximately 4 g of cell paste was used resulting in a yield of 12 mg protein at 8 
mg ml-1 for use in crystallisation trials. 
7.1.3 Purification analysis 
The success of the somewhat simplistic purification protocol arises from the initial high level 
of overexpression, the protein’s inability to interact with DEAE and the protein’s relatively 
small size allowing it to be significantly separated from other proteins by gel filtration. The 
elution profile for BPSS0211 from the gel filtration column shows a shouldered double peak 
suggesting differing oligomeric states roughly corresponding to molecular weights of 11 kDa 
and 23 kDa, which themselves are best explained by a dimeric and tetrameric form of the 
protein, although this remains to be confirmed (figure 7.1). 
7.2 Protein crystallisation for BPSS0211 
7.2.1 Native protein crystallisation 
Four initial 96 condition robot screens, the JCSG+, PACT, Pegs and Classics suites, were 
conducted using purified native protein. 200 nl of protein was mixed with 200 nl of well 
solution and the trays were incubated at 17 ºC. Several initial hits were obtained, producing a 
variety of crystal forms across different conditions (figure 7.3), PACT B2 – B5 containing 
100 mM MIB buffer varying from pH 5 to 8 over the four conditions and 25 % (w/v) PEG 
1500 produced a long rod crystal form, JCSG B6 containing 100 mM phosphate-citrate buffer 
pH 4.2, 40 % (v/v) ethanol and 5 % (w/v) PEG 1000 produced a cubic form and JCSG E6 
containing 100 mM imidazole pH 8.0, 200 mM zinc acetate and 20 % (w/v) PEG 3000 
produced a multifaceted crystal form. These conditions were selected for hanging drop 
optimisation trials, PACT B2 – B5 were optimised by varying the PEG concentration (15 – 30 
% (w/v)) and pH (5.0 – 8.0), JCSG B6 by altering PEG concentration (0 – 20 % (w/v)), 
ethanol concentration (20 – 50 % (v/v)) and pH (4 – 6) and JCSG E6 by varying PEG 
concentration (5 – 30 % (w/v)) and pH (7.5 – 8.5). The optimisations for PACT B2 – B5 and 
JCSG B6 did not produce any larger crystals of better quality than the robot screen while 
attempts to optimise around the JCSG E6 condition led to the production of large, well 
defined crystals.  
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7.2.2 Seleno-methionine protein crystallisation 
Seleno-methionine crystals were produced by screening around the optimised JCSG E6 
condition varying PEG concentration (5 – 15 % (w/v)) and were found to be best in the same 
condition as for native. 
 
 
 
  
PACT B3 – Robot screen  
100 mM MIB pH 6 
25 % (w/v) PEG 1500 
Drop size 200 nl protein + 200 nl well solution 
JCSG B6 – Robot screen  
100 mM Phosphate-citrate pH 4.2 
40 % (v/v) Ethanol 
5 % (w/v) PEG 1000 
Drop size 200 nl protein + 200 nl well solution 
 
 
 
 
 JCSG E6 – Robot screen  
100 mM imidazole pH 8 
200 mM zinc acetate 
20 % (w/v) PEG 3000 
Drop size 500 nl protein + 200 nl well solution 
 
 
Figure 7.3 Photographs of BPSS0211 native crystals. The crystals in the three different conditions exhibit 
different crystal forms. 
100 µm 
100 µm 
100 µm 
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7.3 BPSS0211 Native data 
7.3.1 Native data collection 
Native crystals were selected for data collection based on their size and overall definition 
from the optimisation trials. These were from the optimised JCSG E6 condition, 100 mM 
imidazole pH 8.0, 200 mM zinc acetate and 12 % (w/v) PEG 3,000. Crystals were looped and 
placed into a cryoprotectant solution consisting of the well solution with the addition of 30 % 
(v/v) ethylene glycol. They were then looped again and flash frozen in a stream of gaseous 
nitrogen at 100 ºK and mounted onto the detector. Initial diffraction analysis was conducted 
in order to determine the diffraction quality of several crystals using an in-house Rigaku 
MM007 rotating anode generator and a MAR 345 research image plate. Two images were 
collected 90º apart with 1º oscillation. A number of crystals that diffracted beyond 3 Å on the 
home source were saved and taken to a synchrotron at the I03 beamline of the Diamond light 
source, Oxford. Two initial test images were taken 90º apart with 1º oscillation to ensure 
crystal centering and to obtain a collection strategy using the auto-indexing and collection 
strategy components of Mosflm [146]. For the data set 100 images were collected with 1º 
oscillation per image using X-rays of 12678 eV at a crystal to detector distance of 256 mm 
using an ADSC Q315r detector. Data extending to 2.2 Å were collected (figure 7.4). 
 
  
Native dataset Seleno-methionine peak dataset 
 
Figure 7.4 Diffraction images of native and seleno-methionine crystals of BPSS0211. 
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7.3.2 Native data processing 
The datasets were auto-processed at Diamond through the xia2 system using the 3dii mode 
[147]. Data were indexed and integrated by XDS and scaled by XSCALE [148]. Data 
indexed to space group P6222 or P6422, with the unit cell parameters a = b = 69.3 Å, c = 84.1 
Å, (table 7.1). Matthews coefficients calculated using Mattprob [149] showed the asymmetric 
unit was predicted to contain one, two or three protein molecules giving Matthews 
coefficients of 4.29, 2.15 or 1.43 respectively, with two molecules being the most probable 
(table 7.2). 
 
 
Native 
protein 
crystal 
Seleno-methionine protein crystal 
peak inflection high energy 
remote 
Space group P 62 2 2 P 62 2 2 P 62 2 2 P 62 2 2 
Unit cell parameters     
a (Å) 69.3 69.2 69.3 69.4 
b (Å) 39.3 69.2 69.3 69.4 
c (Å) 84.1 83.9 84.1 84.2 
Energy (eV) 12678 12661 12655 13450 
Resolution range (Å) 59.99 – 2.17 59.91 – 3.02 60.04 – 3.08 60.07 – 3.13 
Unique reflections 6751 (480)  2605 (178)  2485 (182)  2380 (166)  
Rmerge 0.073 (0.682)  0.147 (1.072)  0.151 (0.814)  0.147 (0.723)  
Rpim 0.025 (0.215)  0.045 (0.303)  0.046 (0.235)  0.044 (0.207)  
Completeness (%) 99.7 (99.5)  99.7 (99.4)  99.8 (100.0)  99.7 (100.0)  
Anomalous completeness (%) 99.7 (99.0)  99.7 (99.3)  99.8 (100.0)  99.8 (100.0)  
Multiplicity 11.1 (11.7)  12.9 (14.1)  12.9 (13.5)  12.9 (13.8)  
Anomalous multiplicity 6.2 (6.3)  7.5 (7.6)  7.5 (7.7)  7.5 (7.6)  
Mean (I)/σ(I) 18.9 (3.8)  16.3 (3.1)  15.5 (4.0)  16.7 (4.3)  
 
Table 7.1  Data collection statistics for native and seleno-methionine BPSS0211 crystals. Numbers in  
parentheses indicate values for the highest resolution shell. 
 
Molecules in 
the AU 
Probability 
(based on 
resolution) 
Probability 
(based on all 
proteins) 
Vm (Å3 / Da) Solvent 
content (%) 
Molecular 
weight (Da) 
1 0.0033 0.0572 4.29 71.33 6794 
2 0.9936 0.9367 2.15 42.66 13588 
3 0.0023 0.0060 1.43 13.99 20382 
 
Table 7.2 Matthews coefficient calculations and probabilities for BPSS0211. The results show a possibility of 
one, two or three protein molecules inhabiting the asymmetric unit. 
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7.4 BPSS0211 Seleno-methionine protein data 
7.4.1 Seleno-methionine data collection 
Seleno-methionine crystals were selected from the same condition as for native crystals and 
looped and mounted using the same methodology. A number of crystals were saved and data 
was collected from a single crystal using a synchrotron at the I03 beamline of the Diamond 
light source, Oxford. A fluorescence scan at the selenium K edge was conducted to confirm 
Selenium incorporation and select X-ray energies at which to collect data in a MAD 
experiment (figure 7.5 a). Three energies were selected for data collection based on the 
fluorescence absorbance spectrum. The peak (maximised f’’) and inflection point (minimised 
f’) were selected as 12661 eV and 12655 eV respectively using CHOOCH [157] (figure 7.5 
b) and the high energy remote (maximised ∆f’ from inflection) was selected as 13450 eV to 
provide a similar beam size and flux. Two initial test images were taken 90º apart with 1º 
oscillation to ensure crystal centering and to obtain a collection strategy using the auto-
indexing and collection strategy components of Mosflm [146]. For each wavelength 120 
images were collected with 1º oscillation per image at a crystal to detector distance of 375.3 
mm using an ADSC Q315r detector. Data extending to 3.1 Å were collected for each X-ray 
energy (figure 7.4). 
7.4.2 Seleno-methionine data processing 
The X-ray diffraction datasets were auto-processed at Diamond through the xia2 system 
using the 3dii mode [147]. Data were indexed and integrated by XDS and scaled by XSCALE 
[148]. Data indexed to the same space group as for native data with similar unit cell 
parameters (table 7.1).  
7.5 Experimental phasing for BPSS0211 
Initial phasing was conducted with the programmes of the SHELX package [154] using the 
HKL2MAP graphical user interface for SHELXC and SHELXD [155]. The native protein 
crystal dataset along with the seleno-methionine protein crystal peak, inflection and high 
energy remote datasets were inputted into SHELXC. The seleno-methionine datasets 
contained anomalous signal beyond 4.5 Å, and surprisingly the native dataset was also found 
to contain significant anomalous signal to beyond 3.0 Å (figure 7.6). The anomalous signal in 
the native data was found to arise from the incorporation of metal ions in the crystal structure. 
SHELXD was used to calculate the heavy atom substructure using all data to 3.5 Å. The best 
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Figure 7.5 Selenium K-edge fluorescence scan and CHOOCH plot for BPSS0211 seleno-methionine crystals. a
The fluorescence spectrum at the Selenium K-edge confirmed the incorporation of Selenium into the protein 
crystals and showed maximal fluorescence at 12661 eV, 3 eV above the theoretical value of 12658 eV. b Three 
energies were chosen for the MAD experiment based on the CHOOCH plot, the peak to obtain maximum f’’, 
the inflection point to obtain minimum f’, and the high energy remote to maximise ∆f’. The energies used were 
12661 eV for the peak, 12655 eV for the inflection and 13450 eV for the high energy remote. 
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(b) CHOOCH plot of f'' and f' against energy (eV)
f'' f'
solution was identified with a correlation coefficient of 44.65 and a Patterson  figure of merit 
of 16.60 in space group P6222. A total of three potential heavy atom sites were found with 
one on the 2-fold axis and therefore lying on a special position (figure 7.7). Preliminary 
protein phasing, density modification and initial model building were conducted using 
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(a) d’’/sigma against resolution 
 
 
(b) Self-anomalous correlation coefficient against resolution 
 
 
Figure 7.6 Results from SHELX C showing anomalous signal from the four BPSS0211 datasets. a Graph of 
d’’/sigma plotted against resolution. A value of 1.2 or above indicates of good anomalous signal. b Graph of 
self-anomalous correlation coefficient plotted against resolution. A value of 30 % or above indicates good 
anomalous signal. 
SHELXE-beta with auto-tracing. Five rounds of twenty cycles of phase calculation and 
density modification followed by auto-tracing were carried out for both the inverted and the 
original hands of the selenium substructure. A solvent content of 71, 43 and 14 % were used 
corresponding to one, two or three molecules in the asymmetric unit. The best solution gave 
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Figure 7.7 Results from SHELX D for BPSS0211 MAD experiment showing the best solution. Peaks are 
predicted to have occupancies of 1.00, 0.32 (on a special position so halved to 0.16) and 0.28. 
values of 1.220 and 0.831 for the contrast and connectivity and a model consisting of 51 
residues in two alpha helices was built with a correlation coefficient for partial structure 
against native data of 48.87 %. These results (table 7.3) coupled with an inspection of the 
resultant electron density maps (figure 7.8 a) proved the original hand with a solvent content 
of 71 % was the correct solution. 
 
Hand Original Inverted 
Predicted molecules in the ASU 1 2 3 1 2 3 
Solvent content 0.71 0.43 0.14 0.71 0.43 0.14 
Contrast 1.220 1.074 1.684 0.609 0.419 0.201 
Connectivity 0.831 0.803 0.736 0.737 0.700 0.658 
Pseudo-free correlation coefficient 76.14 73.99 58.15 45.15 51.54 47.45 
Residues built 51 53 51 23 - - 
Correlation coefficient for structure 48.87 48.92 46.98 8.97 - - 
Mean figure of merit for structure 0.730 0.717 0.548 0.43 - - 
 
Table 7.3 Results from SHELX E for BPSS0211 MAD experiment. The programme was run for different 
solvent contents based on the presence of one, two or three protein molecules in the asymmetric unit for the 
original and the inverted hand. SHELX E failed to trace anything for the inverted hand solutions with two or 
three molecules in the asymmetric unit. The best solution is for one molecule in the asymmetric unit with the 
original hand giving a significantly better result.  
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(a) SHELXE (b) Final 
 
 
 
Figure 7.8 Sample region of electron density for BPSS0211. Both maps use data to 2.2 Å, are contoured at 1.5 
sigma and show the same region of density around residues Tyr-12, Gln-34 and Leu-38 from the final model. a 
The initial electron density map output from SHELX E. b The electron density map for the final model. 
 
7.6 Model Building and refinement for BPSS0211 
A structure containing side chains was constructed using AutoBuild, part of the PHENIX 
suite of programs [158]. The initial poly alanine chain produced by SHELXE was used as a 
starting model along with the native data and the primary sequence of the protein. The 
resulting model consisted of 51 residues, with side chains, arranged in 2 alpha helical 
fragments with 32 water molecules. The model had an R-factor of 0.2949 (Rfree 0.3126) and a 
correlation coefficient of 0.68. Further refinement was conducted using iterative cycles of 
model building, refinement and evaluation using Coot [159] and REFMAC5 [152]. For the 
final model all water molecules were removed and a select few were included using strict 
criteria to avoid over fitting the density. Water molecules were only placed in positions where 
there was a sigma level of 2.0 or above giving a molecule with a b-factor of less than 60 Å2 
and sensibly positioned in relation to hydrogen bonding to the protein or other ligands. The 
final model consists of 51 residues in a single chain, 2 metal ions, 1 imidazole, 1 acetate ion 
and 26 water molecules (figure 7.9). The model has an R-factor of 0.2485 (Rfree 0.2996) and 
agrees well with the electron density (figure 7.8 b). 
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Figure 7.9 Cartoon representation of the overall fold for the  final structure of BPSS0211.  The protein  is 
coloured as a chainbow from blue to red, the imidazole and acetate molecules are shown as sticks , red spheres 
represent water molecules and the grey spheres represent metal ions. 
N 
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Resolution (Å) 2.17 
Number of reflections 6408 
Protein molecules per asymmetric unit  1 
Number of atoms 422 
Number of residues 51 
Number of waters 26 
Number of ions 2 
Ramachandran favoured (%) 95.9 
Ramachandran outliers (%) 0.0 
RMS bond length deviation (Å) 0.014 
RMS bond angle deviation (º) 1.572 
Average main chain B-factors (Å2) 36.9 
Average side chain B-factors (Å2) 48.5 
Average waters B-factors (Å2) 49.0 
Average buffer component B-factors (Å2) 40.2 
R-factor (%) 0.249 
Rfree (%) 0.299 
Molprobity score 1.45 (99th percentile) 
 
Table 7.4 Final refinement and validation statistics for BPSS0211. 
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(a) Side chain parameters 
 
(b) Main chain parameters 
 
Figure 7.10 Main chain and side chain properties for the final BPSS0211 model. The figure was generated 
using PROCHECK [157] and shows all residues have properties better than or within the expected range for the 
resolution of the data. 
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Figure 7.11 Ramachandran plot and statistics for the final BPSS0211 model. The figure was generated using 
Molprobity [158] and shows all residues have acceptable values for their phi and psi angles with 95.9 % falling 
within favoured regions. 
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7.7 The model of BPSS0211  
The model has been restrained to standard bond lengths and angles, and the root mean square 
deviation (RMSD) of bond lengths and angles in the final structure is 0.014 Å and 1.572º, 
respectively. The structure was validated using PROCHECK [160] and the Molprobity server 
[161] which showed the overall structure was of good quality (table 7.4). All main chain and 
side chain parameters were better than or within the expected range for the resolution of the 
data (figure 7.10) and all residues fell within allowed regions of the Ramachandran plot 
(figure 7.11). 
7.7.1 Alternate residue conformation in the BPSS0211 structure 
A single residue in the structure, Glu-55, has been modelled as having alternative 
conformations with 50 % occupancy in both forms as this best fits the electron density (figure 
7.12). 
 
Figure 7.12 The alternate conformations of Glu-55 in the BPSS0211 structure. The map is contoured to 1.5 
sigma and despite the residue not being entirely contained within the electron density the dual conformation best 
explains the density. 
 
7.7.2 Metal ions in the BPSS0211 structure 
The final model contains two metal ions, which due to the presence of 200 mM Zn2+ in the 
crystallisation solution were assumed to be zinc although no analysis was done to confirm 
this assumption. One of the zinc ions (Zn 2 site) is thought to be potentially biologically 
significant as it forms interactions present on a dimer interface and is co-ordinated by Glu-53 
and a symmetry related mate (figure 7.13 a) (section 7.9.2), with the other (Zn 1 site) forming 
a crystal contact, co-ordinated by His-17, Asp-22 and a single acetate and imidazole molecule 
from the buffer components (figure 7.13 b). 
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 (a) Zn 2 site (b) Zn 1 site 
  
 
Figure 7.13 Metal ions and their co-ordinating ligands in the BPSS0211 structure. The regions shown include 
the metal ions (grey spheres), buffer components (white carbon atom structures) and a number of residues from 
symmetry related monomers of BPSS0211 (represented by the blue, pink, yellow, green and cyan carbon atoms 
in structures). a The Zn 2 site lies on a 2-fold axis and is co-ordinated by Glu-53 residues provided from two 
symmetry related molecules. b The Zn 1 site is co-ordinated by residues His-17 and Asp-22 from two symmetry 
related models, along with an acetate and imidazole molecule from the buffer components.  
Zn
2+
 Zn
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Glu-53 
Glu-53 
His-17 Asp-22 
 
7.7.3 Unmodelled density in BPSS0211 structure 
The first and last residues for which there is unambiguous density are Thr-10 and Glu-60, 
respectively. For both termini there are regions of unmodelled density (figure 7.14 a and b) 
possibly representing further residues unable to be built due to disorder in the crystal.  
 
(a) N-terminal (b) C-terminal 
 
 
  
Figure 7.14 Electron density maps showing regions of unmodelled density for the BPSS0211 termini. Both 
maps are contoured to 0.5 sigma. a Unmodelled density at the N-terminal showing the possibility other residues 
may be present but disordered. b Unmodelled density at the C-terminal showing the possibility other residues 
may be present but disordered.  
Thr-10 
Glu-60 
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The final structure contains a number of other regions where interpretation of the density is 
ambiguous. One of these lies close to a Zn2+ site metal ion (figure 7.15). Attempts to explain 
the broad electron density feature, which had a peak height in the difference map equivalent 
to a well ordered water molecule, with either water molecules or buffer components were 
unsatisfactory. Disregarding geometry, the density could be explained with the addition of 
three water molecules, with one lying on the 2-fold symmetry axis having half occupancy. 
For data of the resolution and quality obtained it is impossible to interpret this area 
unambiguously but the most likely explanation is that it represents a mixed population of 
water molecules and buffer components. 
 
(a) Fobs map (b) Fobs - Fcalc map 
  
 
Figure 7.15 Unmodelled density around the zinc 2 metal ion in the BPSS0211 structure. The region shown 
includes the metal ion (grey sphere), two water molecules (red spheres) and a number of residues from two 
symmetry related monomers of BPSS0211 (represented by blue and pink carbon atoms in two structures). a The 
Fobs map for the density contoured at 0.5 sigma. The extra density above the metal ion clearly represents 
additional unmodelled molecules co-ordinating the remain ing sites of the metal ion. b The Fobs - Fcalc map for 
the density contoured at 5 sigma. The presence of a peak at this level overwhelmingly demonstrates the need for 
additional components in the model.  
Zn
2+
 
Glu-53 Glu-53 
 
7.8 BPSS0211 represents a novel structure 
The structure of BPSS0211 was submitted to the Dali server [162] for comparison to known 
structures in the PDB (table 7.5). The resulting hits had poor Z-scores and levels of sequence 
identity, and alignments to the known structures were unconvincing. The relatively low 
RMSD scores observed for the top hits can be explained by the relatively small size of the 
structure (51 residues) and the helical nature of the protein, limiting the available possible 
conformations the structure could adopt to those allowed for helix packing and therefore 
observed in other proteins, negating this as a means of assigning functional significance. 
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1 3oaa-O 5.2 2.3 51 284 10 ATP Synthase alpha subunit (Escherichia coli)  
 
 
2 3oaa-W 5.2 2.3 51 284 10 ATP Synthase alpha subunit (Escherichia coli)  
 
 
3 2wpd-G 5.1 2.2 51 269 6 Mitochondrial ATP Synthase alpha subunit (Saccharomyces cerevisiae) 
 
 
 
4 1vf6-B 5.1 3.2 51 60 12 PALS1-Associated tight junction protein (Homo 
sapiens) 
 
 
 
5 4b2q-G 5.1 2.2 51 269 6 Mitochondrial ATP Synthase alpha subunit (Saccharomyces cerevisiae) 
 
 
 
6 4b2q-g 5.1 2.2 51 269 6 Mitochondrial ATP Synthase alpha subunit (Saccharomyces cerevisiae) 
 
 
 
7 1kmi-Z 5.0 1.8 51 177 20 CHEY – Chemotaxis protein (Escherichia coli)  
 
 
8 4adz-A 5.0 3.6 51 90 4 CSOR – Copper sensitive operon repressor (Sterptomyces lividans) 
 
 
 
9 2w6g-G 5.0 2.5 48 140 2 Mitochondrial heart isoform ATP Synthase 
alpha subunit (Bos taurus) 
 
 
 
10 4adz-B 5.0 3.7 51 90 4 CSOR – Copper sensitive operon repressor (Sterptomyces lividans) 
 
 
Table 7.5 Dali server results for the model of BPSS0211. The top ten hits are listed alongside their related Z-
scores, RMSD scores, alignment statistics and a brief description of each protein. The combination of relatively 
low Z-scores and poor alignments suggest that BPSS0211 is not homologous to any structure currently in the 
PDB. 
 
 
7.9 Analysis of the quaternary structure of BPSS0211 
Analysis of the crystal packing shows that the subunits form plausible dimers and tetramers. 
If these are biologically relevant they might confirm the apparent oligomeric states predicted 
from the gel filtration profile (figure 7.1). Based on the characteristics of the different 
monomer-monomer interfaces the quaternary structure can best be described as a dimer of 
dimers. Subunits A (green) and B (blue) form one dimer and the other two subunits C 
(yellow) and D (pink) form the other dimer which in turn interact to form the tetramer (figure 
7.16). The assemblies and interfaces between monomers were explored using the PISA 
webserver [163] with a model containing only the protein chain and the zinc ion present on 
the 2-fold symmetry axis. 
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Figure 7.16 Cartoon representation of the quaternary structure of BPSS0211. The two dimers are formed 
between monomers, A (blue) and B (green), and C (yellow) and D (pink), while the tetramer is formed between 
the two dimers and contains one metal ion (grey spheres) per dimer at the interface.  
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The relevant interfaces can be described using the tetramer PQR axes nomenclature, with the 
Q axis relating the monomers comprising an individual dimer (A to B), and the P and R axes 
relating the monomer interactions that form the tetrameric protein (A to C and A to D, 
respectively) (figure 7.16).  
7.9.1 Monomer-monomer interface forming dimeric BPSS0211 
The dimer interface between the two monomers (figure 7.17 a), Q-axis, has a buried surface 
area of 1450 Å2 from each subunit (rounded to the nearest 50 Å2) involving 32 residues 
providing van der Waals interactions (table 7.6 a) (figure 7.18) and six hydrogen bonds (table 
7.6 d) including two salt bridges (table 7.6 e) (figure 7.19) (table 7.6). Analysis using PISA 
suggested that the extensive level of interaction, involving 49 % of solvent accessible 
surfaces, between the monomers demonstrates this is a biologically relevant dimer potentially 
representing the native state of the protein. Furthermore, calculating the likelihood the 
interactions are crystal contacts, based on the properties of other crystals in the PDB [164], 
gave a probability of 4.9 x 10-5 that the interaction is insignificant  strongly suggesting the 
dimer interface is biologically relevant. 
7.9.2 Monomer-monomer interfaces forming tetrameric BPSS0211 
The tetramer interface between the two dimers (figure 7.17 b) is divided into two sets of 
interactions between a monomer of one dimer and the two monomers of the other dimer 
around the P and R axes. Together the interactions occur over an area of 400 Å2 for each 
subunit involving 9 residues providing van der Waals interactions (tables 7.6 b and c) and two 
possible hydrogen bonds (although these are long) (table 7.6 f) (figure 7.20). The tetramer 
interactions also include two metal ions, assumed to be zinc, on the 2-fold unit cell axis. Each 
zinc ion is co-ordinated by the OE2 oxygen of Glu-53 from one member of each dimer across 
the R-axis (either A and D or B and C) (figure 7.21), with the other two co-ordination sites 
unoccupied due to problems interpreting the density (section 7.7.3). Analysis using PISA, 
calculated a total buried surface area, accounting for 77 % of solvent accessible surfaces (28 
% of which equates to the tetramer interface), suggesting that the level of interaction between 
the dimers suggests this is a biologically relevant tetramer. Calculating the likelihood the 
interactions are crystal contacts [164]  gave a probability of 1.9 x 10-2 that the interaction is 
insignificant suggesting the interface is biologically relevant, although the level of 
significance is substantially less than for the dimer interface. 
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(a) Dimeric BPSS0211 
 
 
 
 
(b) Tetrameric BPSS0211 
                
 
Figure 7.17 Space-filling models of the quaternary structures of BPSS0211. a Dimeric BPSS0211. b
Tertrameric BPSS0211. Each figure has two images taken 90º apart, for a this is about the R-axis and b about 
the Q-axis. 
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Figure 7.18 Residues involved in van der Waals interactions on the monomer-monomer interface forming 
dimeric BPSS0211. Residues displayed are those that were predicted to be more than 30 % surface buried. 
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Figure 7.19 Residues involved in polar interactions on the monomer-monomer interface forming dimeric 
BPSS0211. Hydrogen bonds are shown in yellow and the salt bridges are shown in orange. 
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Figure 7.20 Residues involved in the monomer-monomer interfaces forming tetrameric BPSS0211. Residues 
displayed are those that were predicted to be more than 30 % surface buried including those forming a potential 
hydrogen bond, Gln-36 and Glu-53, which is shown in yellow. The interactions involving the two zinc ions 
(grey spheres) are also shown with co-ordination bonds shown in red. 
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Figure 7.21 Co-ordination  of a zinc ion on the tetramer interface of BPSS0211. As indicated in  the text, co-
ordination of the zinc ion also involves unmodelled molecules from the solvent. The hydrogen bonds between 
Gln-36 and Glu-53 are shown in yellow and the zinc co-ordination bonds are shown in red. 
Glu-53 
Glu-53 
Gln-36 
Gln-36 
Zn
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(a) Surface accessibility of residues on the Q-axis (dimer) interface  
Residue Accessible surface 
area (Å2) 
Buried surface area 
(Å2) Surface buried (%) 
Thr-10 152 76 50 
Pro-11 91 56 62 
Tyr-12 74 2 2 
Gly-13 14 5 32 
Val-14 125 0 0 
Ala-15 35 0 0 
Ile-16 54 54 100 
His-17 135 30 22 
Gln-18 109 0 0 
Ala-19 3 0 10 
Ile-20 105 76 73 
Ala-21 89 0 0 
Asp-22 103 0 0 
Gly-23 52 10 20 
Asp-24 67 0 0 
Leu-25 107 58 54 
Ala-26 78 0 0 
Gln-27 73 0 0 
Met-28 60 60 100 
Lys-29 97 28 29 
Ser-30 48 0 0 
Leu-31 9 2 21 
Arg-32 125 60 48 
Thr-33 84 0 0 
Gln-34 74 0 0 
Ala-35 24 24 100 
Gln-36 105 29 27 
Ala-37 61 0 0 
Leu-38 69 43 62 
Leu-39 130 80 61 
Ala-40 79 0 0 
Gln-41 92 40 44 
Gln-42 65 47 72 
Gly-43 50 0 0 
Asn-44 91 15 17 
Leu-45 107 107 100 
Ala-46 57 14 25 
Thr-47 82 0 0 
Ala-48 53 45 85 
Leu-49 84 74 88 
Glu-50 110 0 0 
Leu-51 135 49 36 
Leu-52 96 95 100 
Glu-53 98 25 25 
Val-54 81 0 0 
Glu-55a+b 86 42 49 
Ile-56 90 83 92 
Ala-57 66 0 0 
Lys-58 144 0 0 
Leu-59 144 63 44 
Glu-60 178 38 22 
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(b) Surface accessibility of residues on the P-axis (tetramer) interface 
Residue Accessible surface 
area (Å2) 
Buried surface area 
(Å2) Surface buried (%) 
Thr-10 152 0 0 
Pro-11 91 0 0 
Tyr-12 74 0 0 
Gly-13 14 0 0 
Val-14 125 0 0 
Ala-15 35 0 0 
Ile-16 54 0 0 
His-17 135 0 0 
Gln-18 109 0 0 
Ala-19 3 0 0 
Ile-20 105 0 0 
Ala-21 89 0 0 
Asp-22 103 0 0 
Gly-23 52 0 0 
Asp-24 67 0 0 
Leu-25 107 0 0 
Ala-26 78 0 0 
Gln-27 73 0 0 
Met-28 60 0 0 
Lys-29 97 0 0 
Ser-30 48 0 0 
Leu-31 9 0 0 
Arg-32 125 0 0 
Thr-33 84 0 0 
Gln-34 74 0 0 
Ala-35 24 0 0 
Gln-36 105 58 55 
Ala-37 61 0 0 
Leu-38 69 0 0 
Leu-39 130 26 20 
Ala-40 79 56 71 
Gln-41 92 0 0 
Gln-42 65 13 20 
Gly-43 50 46 92 
Asn-44 91 0 0 
Leu-45 107 0 0 
Ala-46 57 35 62 
Thr-47 82 22 26 
Ala-48 53 0 0 
Leu-49 84 0 0 
Glu-50 110 45 41 
Leu-51 135 0 0 
Leu-52 96 0 0 
Glu-53 98 15 15 
Val-54 81 0 0 
Glu-55a+b 86 0 0 
Ile-56 90 0 0 
Ala-57 66 0 0 
Lys-58 144 0 0 
Leu-59 144 0 0 
Glu-60 178 0 0 
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(c) Surface accessibility of residues on the R-axis (tetramer) interface 
Residue Accessible surface 
area (Å2) 
Buried surface area 
(Å2) Surface buried (%) 
Thr-10 152 0 0 
Pro-11 91 0 0 
Tyr-12 74 0 0 
Gly-13 14 0 0 
Val-14 125 0 0 
Ala-15 35 0 0 
Ile-16 54 0 0 
His-17 135 0 0 
Gln-18 109 0 0 
Ala-19 3 0 0 
Ile-20 105 0 0 
Ala-21 89 0 0 
Asp-22 103 0 0 
Gly-23 52 0 0 
Asp-24 67 0 0 
Leu-25 107 0 0 
Ala-26 78 0 0 
Gln-27 73 0 0 
Met-28 60 0 0 
Lys-29 97 0 0 
Ser-30 48 0 0 
Leu-31 9 0 0 
Arg-32 125 0 0 
Thr-33 84 0 0 
Gln-34 74 0 0 
Ala-35 24 0 0 
Gln-36 105 0 0 
Ala-37 61 0 0 
Leu-38 69 0 0 
Leu-39 130 23 18 
Ala-40 79 0 0 
Gln-41 92 0 0 
Gln-42 65 0 0 
Gly-43 50 0 0 
Asn-44 91 0 0 
Leu-45 107 0 0 
Ala-46 57 0 0 
Thr-47 82 0 0 
Ala-48 53 0 0 
Leu-49 84 0 0 
Glu-50 110 0 0 
Leu-51 135 0 0 
Leu-52 96 0 0 
Glu-53 98 36 37 
Val-54 81 0 0 
Glu-55a+b 86 0 0 
Ile-56 90 0 0 
Ala-57 66 0 0 
Lys-58 144 0 0 
Leu-59 144 0 0 
Glu-60 178 0 0 
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(d) Unique hydrogen bonds across the Q-axis 
Residue in monomer 1 Residue in monomer 2 Bond distance (Å) 
Thr-10 [OG1] Gln-41 [OE3] 2.54 
Lys29 [NZ] Glu-60 [OE2] 2.89 
Gln-36 [NE2] Glu-53 [OE2] 3.16 
 
(e) Unique salt bridges across the Q-axis 
Residue in monomer 1 Residue in monomer 2 Bond distance (Å) 
Lys-29 [NZ] Glu-60 [OE2] 2.89 
 
(f) Unique hydrogen bonds across the P-axis 
Residue in monomer 1 Residue in monomer 2 Bond distance (Å) 
Gln-36 [NE2] Glu-53 [OE1] 3.85 
 
(g) Overall statistics 
Interface axis Q P R 
Symmetry operator -x+y+1,y,-z+1 -x+1,-y,z x-y,x-y,z-1/3 
Interface area (Å2) 1429.0 315.8 59.2 
Number of interfacing residues from each monomer 32 9 2 
Number of hydrogen bonds from each monomer 6 2 0 
Number of salt bridges from each monomer 2 0 0 
 
 
Table 7.6 Dimer interfaces of BPSS0211 around the P, Q and R axes. 
 
7.10 Residue conservation across BPSS0211, BPSS0212, BPSS0213 and 
homologs from other species 
A Blast search [165] was conducted using the BPSS0211 protein sequence to identify all 
related proteins. The results fall into two sets of two categories. The first is the length of the 
construct, whether like BPSS0211 the domain exists in isolation or like BPSS0212 and 
BPSS0213 it is part of a larger construct. The pattern of conservation between the two forms 
is largely similar within organisms (data not shown). The second characteristic is defined by 
the species the protein derived from, those from members of the pseudomallei group have 
sequence identities of over 80 % and those from other Burkholderia species and more 
distantly related organisms have identities between 62 and 36 %. Residues that were 
conserved in over 90 % of the aligned sequences were identified using Clustal Omega [166] 
(figure 7.22) and mapped onto the protein structure. None of the conserved residues lie on the 
P or R axes tetramer interfaces but are located either on the Q-axis dimer interface or at the 
interface of helices I and II in the monomer (figures 7.23 and 7.24). 
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 lcl|11807       1 --MSQAQGHPVTPYGVAIHQAIADGDLAQMKSLRTQAQALLAQQGNLATALELLEVEIAKLERRK 
gi|77358834    42 ANMSQAQGHPVTPYGVAIHQAIADGDLAQMKSLRTQAQALLAQQGNLATALELLEVEIAKLERRK 
gi|53721246     1 --MSQAQGHPVTPYGVAIHQAIADGDLAQMKSLRTQAQALLAQQGNLATALELLEVEIAKLERRK 
gi|167579012    1 --MNQAHGHPITPYGVAIHQAIADGDLAQMKSLRTQAQALLGQQGNLATALELLEVEIAKLERRK 
gi|83717204    67 ENMNQAHGHPITPYGVAIHQAIADGDLAQMKSLRTQAQALLGQQGNLATALELLEVEIAKLERRK 
gi|167838629    1 --MSQAHGHPVTPYGVAIHQAIADGDLAQMKSLRTQAQALLGQQGNLATALELLEIEIARLERSK 
gi|167572048    1 --MNQASGHPITPYGVAIHQAIAGGDLAQMKTLRAQAQALLSQQGNLSTALELLEVEIARLEQKK 
gi|167564853    1 --MNQASGHPITPYGVAIHQAIAGGDLAQMKTLRAQAQALLSQQGNLSTALELLEIEIARLEQKK 
gi|299066744    1 -MNQESHQAAIPPYGVAIHDAIIDGDLRTMKALLSRAEAVLGEQGDLRTAVELLRLEIAKAERG- 
gi|17546444     1 -MNQESRQAVIPPYGVAIHDAIIDGDLRTMKALLSRAEAVLDEQGDLRTAVELLRLEIAKAERG- 
gi|83749044     1 -MSKEYRPTIIPPYGVAIHDAIIGGDLTKMKTLLSQAETVLGEQGDLRTAVELLRLEIAKAERG- 
gi|300703984    1 -MSKESRPTIIPPYGVAIHDAIIGGDLKKMKTLLSQAETVLGEQGDLRTAVELLRLEIAKAERG- 
gi|206588781    8 NTEILTLPTIIPPYGVAIHDAIIGGDLKKMKTLLSQAETVLGEQGDLRTAVELLRLEIAKAERG- 
gi|386333428   35 AMSKESRPTIIPPYGVAIHDAIIGGDLKKMKTLLSQAETVLGEQGDLRTAVELLRLEIAKAERG- 
gi|171319249    1 --MNRETGHVIPPYGVAIHQAISEGDVSKMKALLSQAEEVLKQHGDLAAAVGKLKQEIVRRERA- 
gi|172064839    1 --MNRETGHVIPPYGVAIHQAISEGDVSKMKALLSQAEEVLKQHEDLAAAVGKLKQEIARRERA- 
gi|344169539   17 AMNKESRQAVIPPYGVAIHDAIVGGDLKKMKALLSHAETVLDEQGDLRTAVELLRLEIAKAERA- 
gi|170701387    1 --MNRETGHVIPPYGVAIHQAISEGDVSKMKALLGQAEEVLKQHEDLAAAVGKLKQEIARRERA- 
gi|397892014    1 --MSSSSLHPVTPYGVAIQEAIALGNLPQMKSLLKQRDSSQKESKELSSAYEQLAQEVARLERR- 
gi|399010595    1 --MSSSSLHPVTPYGVAIQEAISLGNLPQMKSLLKQRDTSQKESKDLSSAYEQLAQEVARLERR- 
gi|320108754    1 -------MTDVRPYGVAIQQAVASGDLQKMKSTLLTAEKHVADYGDVSSALEVLKIEIAKLEAHK 
gi|374293820    1 --MSEAPLRSIKPYGVAISDAIVSGDLAKMKEVAAAAEQHLAEHGDVASILHLLKVEIAKAEAGS 
gi|320108753    1 -MSETGSHHPIPLYAVSIHNAAASGDLAAMKKTVTDAEEHLKTYGNVGAAVEALKVEIAKLESDT 
gi|389684822    1 --MSSSSQHVIPPYGVAIQKAISLGNLPQMKSLLKQRDKSQKESKDLSSAYEQLAQEVARLERR- 
gi|398858635    1 --MSNSTRHSMPPYGVAIQSAIKTGDLPQMKTLLKQRDASTPENKELTTAYEQLAKEVARLEKH- 
gi|389877167    9 LYAAPPQPHPIPLYAATLHAAVARNDVDELDSLICQAEAYLDKYGDLPSLIEQLKTEIAKLER-- 
gi|399010596  152 QAY----PPIHPLYAAPIHGAIASGDLAQMKTLASQAQEQLEQLPQLRNALDAAKDEIGKLERR- 
gi|70729524     1 --MSNASQHVIPPYGVAIQSAISEGKLPEMKALLAKRDPARNEPKDLHNAYEQLAQEVARLERR- 
gi|398842843    1 --MSSSTRHSMPPYGVAIQSAIKAGSLPEMKTLLKQRDASTPENKELSTAYEQLAKEVARLEKH- 
gi|398904661  134 ----EHPHHPVPLYAVAVQQAQTSGDLAQLKAVVSQGEQQLAHSGALRNALDQLNVEIKRLEAR- 
gi|398904659    1 --MSSSTRHSMPPYGVAIQSAIKAGSLPEMKTLLKQRDASTPENKELTTAYEQLAKEVARLEKH- 
gi|398858637  134 ----EHPHHAVPLYAVAVQQAQASGDLAQLKAVVSQGEQQLAHSGALRNALDQLNVEIARLEAR- 
gi|399001393  134 ----EHPHHAVPLYAVAVQQAQTSGDLAQLKSVVSQGEQQLANSGALRSALEQLKAEIARLEAR- 
gi|374293821    1 ----MSTPPIRMLYGGAMTEAIASGDLSKMKEVASAAETHLNENGDVASMLEILKIEIAKAEAKG 
gi|170701389  133 ---FEPRHPVTPLYGVGLQQARQSGDLGRMKALARQAEQQLADAGRIEEALAGLNAEIARLEAAR 
gi|399001391    1 --MSNSTSHSMPPYGVAIQGAIKAGNLPQMKTLLKQRDASKPENKELNAAYEQLAKEVARLEKH- 
gi|172064837  133 ---FEPRHPVTPLYGVGLQQARQSGDLGRMKALARQAEQQLADAGRIEEALAGLNAEIARLEAAR 
gi|171319251  133 ---FEPRHPVTPLYGVGLQQARQSGDLGRMKALARQAEQQLADAGRIEAALAGLTAEIARLEAGR 
gi|399088056    1 -------MAIIILYGQAITDGIAKGDLAELQRLQAQAEAHLAEYGDVPTLLTTLKVEIAKLEGGA 
gi|398842841  134 ----EHPHHAVPLYAVAVQQAQTSGDLAQLKAVVSQGEQQLAHSGALRNALDQLNVEIARLEAR- 
gi|398977256    1 ---MTGSNHNIPPYGVAIQSAITGGDLQQMKTLLKQRDSTKPEAKELQTAYEKLAKEVTRLEKP- 
gi|83716493   148 GASSRTAYGPVPLYGVTIQYAAVSGDLAHMKTLATYARQQLESRDDIAAALSALKAEIAKLESRQ 
gi|77458582    50 GLDMTGSNHNIPPYGVAIQSAITGGDLQQMKTLLKQRDSTKPEAKELQTAYEKLAKEVSRLEKP- 
gi|399088058    1 -------MTPIPLYAAAITQAVSGGDLDQLRKLQSLAEEHVREHGDISTLLSLLKVEIAKLT--- 
gi|167838631  135 ---DPPHEHVVPMYGVGLQEARASGDLSRMKAIAQQAEQQLADHDAIAAELETLEAEIARLEARR 
gi|70729523   152 HPL----PPISALYGAPIHGAIASGDLAQMKSLHKVATQQLEQLPLIRTALVAAKAEISQQERR- 
gi|399088055    1 --------MAMVLYGSAITDGIAKGDLTELQRLQAQAEAHVTEYGDIPTLLTALKVEIAKLEGGA 
gi|399088057    1 --------MSIKPYGVAVTDAIASGELARLKEAQAAAEAHLAEYGDIPTLLALLKVEIAKLGG-- 
gi|167572050  135 ---EPSHEHVVPLYGVGLQEARASGDLSRMKALVRQAEQQLADHDAIAAELSKLEAEIARLEPRR 
gi|167564855  135 ---EPLHEHVVPLYGVGLQEARASGDLSRMKALVRQAEQQLADHDAIAAELSKLEAEIARLEPRR 
gi|53721247   148 GQSSMSAIGSAAMYGVAIQSAAASGDLAHMRTLSAYARQQLESRDEIAAALSELKAEIAKLESRQ 
gi|403521574  170 GQSSMSAIGSAAMYGVAIQSAAASGDLAHMRTLSAYARQQLESRDEIAAALSELKAEIAKLESRQ 
gi|251766819  170 GQSSMSAIGSAAMYGVAIQSAAASGDLAHMRTLSAYARQQLESRDEIAAALSELKAEIAKLESRQ 
gi|126444886  135 ---DPPSEHVMPMYGVGLQEARASGDLSRMKALARQAEQQLADHDVIAAELQKLEAEIARLEARR 
gi|53716187   135 ---DPPSEHVMPMYGVGLQEARASGDLSRMKALAQQAEQQLADHDVIAAELQKLEAEIARLEARR 
gi|53721248   135 ---DPPSEHVMPMYGVGLQEARASGDLSRMKALAQQAEQQLADHDVIAAELQKLEAEIARLEARR 
gi|167905195  135 ---DPPSEHVMPMYGVGLQEARASGDLSRMKALAQQAEQQLADHDVIAAELQKLEAEIARLEARR 
gi|300703986  135 ---YQQHVHPMPMYAVSLQQAKASGDLGQMKALASLAEKQLADAPQIKAELDKLHTEIAKLEGRA 
gi|83749042   135 ---YQQHIHPMPMYAVSLQQAKASGDLGQMKALASLAEKQLADAPQIKAELDKLHTEIAKLEGRA 
gi|398971251  134 -----PTPHPQPLYAVAVQQAQTGGNLAQLKTVVQQAEQQVAHEGALRSALEHLKAEIARLETR- 
gi|397891292  155 LPY----PPITPLYAAPIHGAIASGDLAQMKSLASLAQQQLEQLPQLRSALDAAKDEIGRLERR- 
gi|70729522   139 SQAGPAAEVRHPLYAVALQQAQASGDLARLKALVAQGEQQLANADNLTQAVQQLQAEISRLEQR- 
gi|77458580   133 ----PPEHHVQPLYAVAVQTAQASGDLAQLKVAVQQGEQQLAHEGALRSALEQLNAEIARLEAR- 
gi|126447397  148 GQSSMSAIGSAAMYGVAIQSVAASGDLAHMRTLSAYARQQLESRDEIAAALSELKAEIAKLESRQ 
gi|389685184  155 LPY----PPITPLYAAPIHGAIASGDLTQMKSLASLAQQQLDQLPQLRSALDAAKDEIGRLERR- 
gi|17546446   135 ---H---QPVMPMYAVSLQQAKASGDLGQMKALASLAEKQLADAPQIKAELDKLHTEIAKLEGRA 
gi|299066746  135 ---Y---QPIMPMYAVSLQQAKASGDLGQMKTLASLAEKQLADAPQIKAELDKLHTEIAKLEGRA 
gi|374293819    1 -MSDSTVAPFRPMYMATMTDAIAGGDLATMKQVAAEAEQHLATYGDVPGLLQLLKVEIAKAEANS 
gi|300691418  144 PESLNALTIGRVLYGVAIQRATASGDLAHMKTLAAYAQQQLDSHEEIASAHAALHAEIRKLEGRQ 
gi|167572049  150 LEAARSAYGPMPMYAATIQYAAVSGDLAHMKTLASYARQQLESRDDIAAALKTLKAEIAKLESRQ 
gi|167564854  150 LEAARSAYGPMPMYAATIQYAAVSGDLAHMKTLASYARQQLESRDDIAAALKTLKAEIAKLESRQ 
gi|167838630  148 GGSPRTAYGPVPLYGVTIQYAAASGDLAHMKTLATYARQQLDSHDDIAAALAALKTEIARLESRQ 
gi|170701388  144 VEP---HGGPRPLYGAPIQQAAASGDLAHMKTVAAAAKHQLESRDEIAAALAALKTEIARLEAGN 
gi|171319250  144 VEP---HGGPRPLYGAPIQQAAASGDLAHMKTVAAAAKHQLESRDEIAAALAALKTEIARLEAGN 
gi|172064838  144 VEP---HGGPRPLYGAPIQQAAASGDLAHMKTVAAAARHQLESRDEIAAALAALKTEIARLEAGN 
consensus     181              *.  .  .   . .  .. .             .      .  *... .                            
. 
 
 
 
Figure 7.22 Residues conserved in over 90 % of BPSS0211 homologs. The alignment has been produced using 
Clustal Omega [162] and BOXSHADE [135] and the consensus is shown. Residues that are completely 
conserved are shaded black and shown as (*) in the consensus, more than 95 % are also shaded black but shown 
as (.), more than 90 % are shaded grey and shown as (.) in the consensus, with the remaining residues left blank. 
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Figure 7.23 Conserved residues in BPSS0211 are located on the dimer interface or at the interface of helices I 
and II in the monomer. 
 
            
Figure 7.24 The unique residues conserved in a dimer of BPSS0211. The two stereo images are taken 90º apart 
and show the residues positioned at the dimer interface or the interface of helices I and II in the monomer. 
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7.11 BPSS0211 represents an oligomerisation domain 
The quaternary structure of BPSS0211 suggests that it represents an oligomerisation domain 
that can exist on its own (BPSS0211) or as part of a larger construct (BPSS0212 and 
BPSS0213). The pattern of residue conservation between BPSS0211, BPSS0212 and 
BPSS0213, within Burkholderia pseudomallei and homologs from other species, show those 
involved in dimer formation, but not tetramer formation are heavily conserved. Coupled with 
the quaternary structure, this suggests that BPSS0211 represents an oligomerisation platform 
which mediates assembly of a complex, whose stoichiometry between combinations of 
BPSS0211, BPSS0212 and BPSS0213, remains to be determined. 
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8.0 Studies on the protein BPSS0212 
This section covers the purification, crystallisation, data collection and attempts to solve the 
structure of the target BPSS0212. 
8.1 Protein purification for BPSS0212 
8.1.1 Native protein purification 
Approximately 3 g of cell paste was resuspended in 30 ml 50 mM TRIS pH 8.0 and disrupted 
by sonication. Cell debris and insoluble protein was removed by centrifugation at 70,000 g 
for 15 minutes and the supernatant was loaded onto a DEAE-Sepharose fast flow column 
equilabrated with 50 mM TRIS pH 8.0. A 200 ml gradient from 0 to 500 mM NaCl was then 
applied to the column and 8 ml fractions were collected (figure 8.1 a). Fractions were 
analysed by SDS-PAGE (figure 8.2) and those containing BPSS0212 were combined. The 
sample was diluted two-fold before loading onto a ResourceQ column equilibrated with 50 
mM TRIS pH 6.3. A 120 ml gradient was applied to the column and 2.5 ml fractions were 
collected (figure 8.1 b). Peak fractions were combined and concentrated to 1.5 ml using a 
Vivaspin concentrator with a 10 kDa MWCO. This was then loaded onto a 1.6 x 60 cm 
Superose 6 gel filtration column equilibrated in 50 mM TRIS pH 8.0 and 500 mM NaCl and 
eulted using the same buffer collecting 2 ml fractions (figure 8.1 c). Peak fractions were 
combined, the buffer was exchanged for 10 mM TRIS pH 8.0 and the protein was 
concentrated to 5 mg ml-1 for use in crystallisation trials using the same Vivaspin 
concentrator.  The overall yield of protein was 7 mg which was estimated by SDS-PAGE to 
be over 90 % pure (figure 8.2) 
 
 
 
Figure 8.1 Chromatogram traces for the purification of BPSS0212. a DEAE purification step showing column 
loading and elution. 8 ml fractions were collected starting at the beginning of the gradient at 36 ml. b ResourceQ
purification step showing column loading and elution. 2 ml fractions were collected starting at the beginning of 
the gradient at 39 ml. c Gel filtration purification step showing elution with 2 ml fractions collected throughout. 
For all traces, green highlighted regions indicate volumes taken for subsequent purification steps or as pure 
protein. 
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(a) BPSS0212 DEAE purification step
 
(b) BPSS0212 ResourceQ purification step 
  
(c) BPSS0212 Superose 6 purification step 
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Figure 8.2 SDS-PAGE gel showing the purification of BPSS0212. The molecular weight of BPSS0212 is 22.5 
kDa and the red highlighted bands indicate the protein in fractions taken for subsequent purification steps or as 
pure protein. The blue highlighted bands indicate degradation products of BPSS0212.  
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8.1.2 Seleno-methionine protein purification 
Protein containing seleno-L-methionine was purified using the same techniques as for native 
protein. Approximately 3 g of cell paste was used resulting in a yield of 5 mg protein at 5 mg 
ml-1 for use in crystallisation trials. 
8.1.3 Purification analysis 
The elution profile for BPSS0212 from the gel filtration column shows a broad peak roughly 
corresponding to approximately 35 kDa, a molecular weight best explained by a dimeric form 
of the protein (figure 8.1 c). SDS-PAGE analysis of the purification shows the sample for 
crystallisation studies was over 90 % pure but suffering severely from degradation even 
during the timescale of the purification process (figure 8.2). A sample kept at 4 ºC for two 
weeks following purification was sent for mass spectrometry (Simon Thorpe, University of 
Sheffield) to identify the degradation products (figure 8.3). The results showed several 
fragments of different molecular weights although none corresponded perfectly with any 
particular fragment of the protein. 
 
 
 
Figure 8.3 Mass spectrometry results for a sample of purified BPSS0212. 
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8.2 Protein crystallisation for BPSS0212 
8.2.1 Native protein crystallisation 
Seven initial 96 condition robot screens, the Ammonium sulphate, Classics, JCSG+, MPDs, 
PACT, PEGs and pH clear suites, were conducted using purified BPSS0212 at 5 mg ml-1 in 
10 mM TRIS pH 8.0 and 100 mM NaCl. The screens were conducted using 200 nl of protein 
mixed with 200 nl of well solution and the trays were incubated at 17 ºC. Over fifty hits were 
obtained in many different conditions producing mainly needle clusters or rod shaped 
crystals. Some of these conditions were selected for optimisation trials however all attempts 
to optimise any of the initial hits were unsuccessful with either no crystals or delicate thin 
needle clusters developing that were unsuitable for data collection. 
8.2.2 Seleno-methionine protein crystallisation 
Four initial 96 condition robot screens, the Classics, JCSG+, PACT and Pegs, were conducted 
using purified seleno-methionine BPSS0212 at 5 mg ml-1 in 10 mM TRIS pH 8.0 and 100 
mM NaCl. The screens were conducted using 200 nl of protein mixed with 200 nl of well 
solution and the trays were incubated at 17 ºC. Similar hits were obtained to the native 
protein, appearing in many different conditions and similarly to the native protein these 
crystals defied optimisation trials. 
 
 
  
Native – Pegs D12 – robot screen 
100 mM TRIS pH 8.5 
15 % (w/v) PEG 20,000 
Drop size 200 nl protein + 200 nl well solution 
 
Se-met – Pegs D12 – robot screen 
100 mM TRIS pH 8.5 
15 % (w/v) PEG 20,000 
Drop size 200 nl protein + 200 nl well solution 
 
Figure 8.4 Photographs of BPSS0212 native and seleno-methionine protein crystals. 
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8.3 BPSS0212 native data  
8.3.1 Native data collection 
Native crystals were selected for data collection from conditions in the robot trials which 
produced the largest best defined crystals. They were looped and placed into a cryoprotectant 
solution consisting of the well solution with the addition of 30 % (v/v) ethylene glycol. They 
were then looped again and flash frozen in a stream of gaseous nitrogen at 100 ºK and 
mounted onto the detector. Initial diffraction analysis was conducted in order to determine the 
diffraction quality of the crystals using an in-house Rigaku MM007 rotating anode generator 
and a MAR 345 research image plate. Two images were collected 90º apart with 1º 
oscillation. Crystals from conditions Pegs D12 produced reasonable diffraction images with 
data extending beyond 3.5 Å. These crystals were saved and taken to the I02 beamline of the 
Diamond light source, Oxford. Two initial test images were taken 90º apart with 1º oscillation 
to ensure crystal centering and to obtain a collection strategy using the auto-indexing and 
collection strategy components of Mosflm [146]. For the dataset 210 images were collected 
with 0.5º oscillation per image at a crystal to detector distance of 378 mm using an ADSC 
Q315r detector. Data extending to 2.5 Å were collected (figure 8.5). 
 
 
  
Native dataset Seleno-methionine peak dataset 
 
Figure 8.5 Diffraction images of native and seleno-methionine crystals of BPSS0212. 
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8.3.2 Native data processing 
The X-ray diffraction datasets were auto-processed at Diamond through the xia2 system 
using the 3dii mode [147]. Data were indexed and integrated by XDS and scaled by XSCALE 
[148]. Initially the space group was thought to be P422 as described by Mosflm [146] 
following data collection using the home source and collection of the first two images, 
however once a complete dataset had been collected the data indexed to a primitive 
orthorhombic space group, most likely P21212 based on the pattern of systematic absences, 
with the unit cell parameters a = 40.5, b = 97.7 Å, c = 40.0 Å, (table 8.1). As the crystal 
contents were unknown, Matthews coefficients were calculated using Mattprob [149] for a 
molecular weight of 16 kDa, decided by analysis of the fragments identified by mass 
spectrometry (figure 8.3), suggesting a single molecule in the asymmetric unit. The real 
contents of the crystals remain unknown and the predicted contents were treated with caution 
(table 8.2).  
 
 
Dataset 
Native 
protein 
crystal 
Seleno-methionine protein crystal 
peak inflection 
high energy 
remote 
Space group Orthorhombic P Orthorhombic P Orthorhombic P Orthorhombic P 
Unit cell parameters     
a (Å) 40.47 40.22 40.26 40.22 
b (Å) 97.74 97.52 97.60 97.55 
c (Å) 38.95 38.80 38.82 38.81 
α (º) 90.00 90.00 90.00 90.00 
β (º) 90.00 90.00 90.00 90.00 
γ (º) 90.00 90.00 90.00 90.00 
Energy (eV) 12658 12655 12657 13450 
Resolution range (Å) 40.47 – 2.30 31.03 – 2.50 27.95 (2.44) 40.22 – 2.54 
Unique reflections 26781 (1154) 35269 (1369) 72911 (2477) 34417 (1394) 
Rmerge 0.073 (0.431) 0.097 (0.505) 0.099 (0.731) 0.116 (0.614) 
Rpim 0.048 (0.323) 0.059 (0.324) 0.032 (0.304) 0.054 (0.376) 
Completeness (%) 96.3 (75.2) 98.3 (85.9) 96.9 (80.0) 99.2 (90.6) 
Anomalous completeness (%) 91.5 (66.5) 97.9 (83.6) 96.5 (78.6) 99.0 (90.4) 
Multiplicity 3.8 (3.0) 6.3 (4.0) 12.4 (7.4) 6.4 (4.2) 
Anomalous multiplicity 2.1 (1.6) 3.4 (2.0) 6.9 (3.9) 3.5 (2.1) 
Mean (I)/σ(I) 10.8 (2.1) 15.1 (2.2) 22.2 (2.5) 12.4 (2.0) 
 
Table 8.1 Data collection statistics for native and seleno-methionine BPSS0212 crystals. Numbers in 
parentheses indicate values for the highest resolution shell. 
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Molecules in 
the AU 
Probability 
(based data 
resolution) 
Probability 
(all proteins 
in the pdb) 
Vm (Å3 / Da) Solvent 
content (%) 
Molecular 
weight (Da) 
1 1.0000 1.0000 2.47 50.26 16000 
      
Table 8.2 Matthews coefficient calculations and probabilities for native crystals of BPSS0212. The results show 
a possibility of a single protein molecule inhabiting the asymmetric unit . 
 
8.4 Phasing by molecular replacement for BPSS0212 
The structure of BPSS0211 solved as part of this structural genomics project (section 7) was 
used to create a search model. The model was cut back to a poly alanine chain using 
chainsaw [150] before use for an automated search for two copies of the molecule in Phaser 
[151] with the native data set. The data were input and Phaser was run in P21212 and all 
alternative related space groups. Unfortunately the best result was of a poor quality with low 
Z-scores of 3.6 and 4.4 for the rotation and translation searches respectively. The resulting 
refined model was also unconvincing, with an R-factor of 0.61, after refinement with 
REFMAC5 [152], suggesting a solution had not been found. 
8.5 BPSS0212 Seleno-methionine data  
8.5.1 Seleno-methionine data collection 
Seleno-methionine crystals were selected from the same robot screen condition as for native 
crystals as the crystal contents and form could be assumed to be similar. A number of crystals 
were mounted using the same methodology as for native crystals and saved. Data was 
collected from a single crystal using a synchrotron at the I24 microfocus beamline of the 
Diamond light source, Oxford. A fluorescence scan at the Selenium K edge was conducted to 
confirm Selenium incorporation and select X-ray energies to collect data for in a MAD 
experiment (figure 8.6 a). Three energies were selected for data collection based on the 
fluorescence absorbance spectrum. The peak (maximised f’’) and inflection point (minimised 
f’) were selected as 12657 eV and 12655 eV respectively using CHOOCH [157] (figure 8.6 
b) and the high energy remote (maximised ∆f’ from inflection) was selected as 13450 eV. 
Two initial test images were taken 90º apart with 1º oscillation to ensure crystal centering and 
to obtain a collection strategy using the auto-indexing and collection strategy components of 
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Mosflm [146]. For the peak dataset 720 images were collected and for the inflection and 
remote datasets 360 images were collected with 0.2º oscillation per image at a crystal to 
detector distance of 422 mm using an ADSC Q315r detector. Data extending to 2.4 Å were 
collected for each X-ray energy (figure 8.5). 
 
 
 
 
Figure 8.6 Selenium K-edge fluorescence scan and CHOOCH plot for BPSS0212 seleno-methionine crystals. a
The fluorescence spectrum at the Selenium K-edge confirmed the incorporation of Selenium into the protein 
crystals and showed maximal fluorescence at 12657 eV, 1 eV below the theoretical value of 12658 eV. b Three 
energies were chosen for the MAD experiment based on the CHOOCH plot, the peak to obtain maximum f’’, 
the inflection point to obtain minimum f’ and the high energy remote to maximise ∆f’. The three energies used 
were 12657 eV for the peak, 12655 eV for the inflection and 13450 eV for the high energy remote. 
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8.5.2 Seleno-methionine data processing 
The X-ray diffraction datasets were auto-processed at Diamond through the xia2 system 
using the 3dii mode [147]. Data were indexed and integrated by XDS and scaled by XSCALE 
[148]. Data indexed to the same space group as for native data with similar unit cell 
parameters (table 8.1).  
8.6 Experimental phasing for BPSS0212 
Initial phasing was conducted with the programmes of the SHELX package [154] using the 
HKL2MAP graphical user interface for SHELXC and SHELXD [155]. The native protein 
crystal dataset along with the seleno-methionine protein crystal peak, inflection and high 
energy remote datasets were inputted into SHELXC. The seleno-methionine datasets 
contained significant anomalous signal beyond 3.5 Å (figure 8.7). SHELXD was used to 
calculate the heavy atom substructure using all data to 3.5 Å searching for different numbers 
of sites in all primitive orthorhombic space groups. The best solution was identified with a 
correlation coefficient of 53.60 and a Patterson figure of merit of 25.30 searching for 7 
Selenium sites in space group P21212. A total of 4 good potential heavy atom sites were found 
(figure 8.8). Preliminary protein phasing, density modification and initial model building 
were conducted using SHELXE-beta with auto-tracing. Five rounds of twenty cycles of phase 
calculation and density modification followed by auto-tracing were carried out for both the 
inverted and the original hands of the Selenium substructure using a predicted solvent content 
of 50 %. The solutions for the two sub-structure hands gave values of 0.419 and 0.467, and 
0.686 and 0.693, for the contrast and connectivity of the original and inverted hands 
respectively, preventing the assignment of a hand to the substructure based on these figures 
of merit.  SHELXE produced models for the original and inverted hands consisting of 15 and 
24 residues respectively, with correlation coefficients for partial structure against the data of 
2.60 % and 5.98 %. Inspection of the electron density maps for the two hands provided no 
further insight into the correct substructure hand, and coupled with the models it was 
unconvincing an interpretable solution had been reached (figure 8.9). 
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d’’/sigma plotted against resolution 
 
Figure 8.7 Results from SHELX C showing anomalous signal from the four BPSS0212 datasets. Graph of 
d’’/sigma plotted against resolution, a value of 1.2 or above indicates good anomalous signal. 
 
 
Site occupancy plotted against peak number 
 
Figure 8.8 Results from SHELX D for BPSS0212 MAD experiment showing the best solution. Peaks are 
predicted to have occupancies of 0.99, 0.59, 0.54 and 0.51 before a drop to 0.20 and below.  
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(a) Original substructure hand  
 
(b) Inverted substructure hand  
 
Figure 8.9 Sample region of electron density for the original hand and inverted hand solutions for the 
BPSS0212 selenium MAD phasing experiment. Both maps are contoured at 1.5 sigma and show the same cross 
section of density covering the entire unit cell. a The initial electron density map output from SHELX E for the 
original substructure hand. b The initial electron density map output from SHELX E for the inverted 
substructure hand. 
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9.0 Studies on the protein BPSS0213 
This section covers the purification, crystallisation and preliminary data collection for the 
target BPSS0213. 
9.1 Purification of BPSS0213 
Approximately 3 g of cell paste was resuspended in 30 ml 50 mM TRIS pH 9.0 and disrupted 
by sonication. Cell debris and insoluble protein was removed by centrifugation at 70,000 g 
for 15 minutes and the supernatant was loaded onto a DEAE-Sepharose fast flow column 
equilabrated with 50 mM TRIS pH 9.0. A 200 ml gradient from 0 to 500 mM NaCl was 
applied to the column and 8 ml fractions were collected (figure 9.1 a). Fractions were 
analysed by SDS-PAGE (figure 9.2) and the peak fractions containing BPSS0213 were 
concentrated to 1.5 ml using a Vivaspin concentrator with a 10 kDa MWCO. This was then 
loaded onto a 1.6 x 60 cm Superose 6 gel filtration column equilibrated in 50 mM TRIS pH 
8.0 and 500 mM NaCl and eluted using the same buffer collecting 2 ml fractions (figure 9.1 
b). Fractions were analysed by SDS-PAGE (figure 9.2) and those containing BPSS0213 were 
combined. The buffer was exchanged for 100 mM NaCl and 10 mM TRIS pH 8.0 and the 
protein was concentrated to 6 mg ml-1 for use in crystallisation trials using a Vivaspin 
concentrator with a 10 kDa MWCO. 
9.1.1 Protein sample analysis for BPSS0213 
The elution profile for BPSS0213 from the gel filtration column shows a single peak roughly 
corresponding to a dimeric form of the protein (figure 9.1 b). SDS-PAGE analysis of the 
purification shows the sample for crystallisation studies was over 90 % pure but suffering 
from degradation even during the timescale of the purification process (figure 9.2). 
9.2 Crystallisation of BPSS0213 
Four initial 96 condition robot screens, the JCSG+, PACT, Pegs and Classics suites, were 
conducted using purified BPSS0213 at 6 mg ml-1 in 10 mM TRIS pH 8.0 and 100 mM NaCl. 
The screens were conducted using 200 nl of protein mixed with 200 nl of well solution and 
the trays were incubated at 17 ºC. Two hits were found in the JCSG+ robot crystal screen 
after four months. Tiny crystals were found in condition JCSG D6, 200 mM Magnesium 
chloride, 100 mM TRIS pH 8.5 and 20 % (w/v) PEG 8,000. A single crystal was found in 
JCSG D7, 200 mM Lithium sulphate, 100 mM TRIS pH 8.5 and 40 % (v/v) PEG 400. 
Optimisation 
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(a) BPSS0213 DEAE purification step 
 
 
(b) BPSS0213 Superose 6 purification step 
 
Figure 9.1 Chromatogram traces for the purification of BPSS0213. a DEAE purification step showing column 
loading and elution. 8 ml fractions were collected starting at the beginning of the gradient at 40 ml. b Gel 
filtration purification step showing elution with 2 ml fractions collected throughout. For both traces, green
highlighted regions indicate volumes taken for subsequent purification steps or as pure protein. 
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Figure 9.2 SDS-PAGE gels showing the purification of BPSS0213. The molecular weight of BPSS0213 is 21.7 
kDa and the highlighted bands indicate the protein in fractions taken for subsequent purification steps or as pure 
protein. The blue highlighted bands indicate degradation products of BPSS0213. 
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trials were conducted for JCSG D6 by altering the PEG concentration (10 – 30 % (w/v)), 
protein concentration (3 – 10 mg ml-1) and pH (8.0 – 9.0) but resulted in no further crystals 
growing. A further robot screen around this initial condition using the 96 well Optisalts 
screen also resulted in no crystals forming. Attempts to optimise JCSG D7 by altering the 
PEG concentration (25 – 55 % (w/v)), protein concentration (3 – 10 mg ml-1) and pH (8.0 – 
9.5) using 2 µl protein solution and 2 µl well solution hanging drop trials produced drops 
containing crystals alongside possible quasi crystals and fungal growth (figure 9.3) while the 
initial hit later turned out to be a salt crystal. 
 
 
JCSG D7 – Hanging drop  
200 mM Lithium sulphate 
100 mM TRIS pH 8.5 
40 % (w/v) PEG 400 
Drop size 2 µl protein + 2 µl well solution 
 
Figure 9.3 Photograph of BPSS0213 crystals. 
 
9.3 Data collection for BPSS0213 
A number of crystals were looped by dragging a tennis racket loop through the crystallisation 
drop before being flash frozen in a stream of gaseous nitrogen at 100 ºK and mounted onto 
the detector. Diffraction analysis was conducted using an in-house Rigaku MM007 rotating 
anode generator and a MAR 345 research image plate. A single image was taken using an 
exposure time of 900 s and a crystal to detector distance of 200 mm (figure 9.4). The image 
contained some low resolution reflections not associated with ice rings suggesting that there 
were ordered protein crystals present in the crystallisation drop. Attempts to optimise the 
crystallisation conditions have not yet been conducted. 
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Figure 9.4 Diffraction image for a number of crystals of BPSS0213. Ice rings are found at 3.897, 3.669, 3.441, 
2.671 and 2.249 Å, the presence of diffraction at lower resolutions indicate the presence of protein crystals.  
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Chapter three 
Introduction to, and results from, an on-going project to elucidate the 
structure and mechanism of proteins in the thioredoxin system from 
Burkholderia pseudomallei 
 
 
 
 
Section 10 The thioredoxin system is essential and represents a potential drug 
target for bacterial diseases 
 
Section 11 Studies on the protein BPSL1497 
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10.0 The thioredoxin system is essential and represents a potential 
drug target for bacterial diseases 
Intracellular proteins exist in a very reducing environment and cysteine residues are 
maintained in the sulphydryl (-SH) form with disulphide bridges (-S-S-) existing very rarely. 
There are two systems responsible for the maintenance of protein thiol states, the glutathione 
and thioredoxin systems. The thioredoxin system in Burkholderia pseudomallei comprises 
two proteins, thioredoxin (BPSL1497) and thioredoxin reductase (BPSL2605).  
10.1 Thioredoxin 
Thioredoxins are a highly conserved class of small (10 – 12 kDa) peptides, present in all 
organisms. They all share the same characteristic tertiary structure containing a 
dithiol:disulphide active site with the motif CXXC (usually CGPC). Thioredoxin has several 
essential roles within the prokaryotic cell alongside its role as a protein disulphide 
oxidoreductase [167]. Thioredoxin also works as a high capacity electron donor to a number 
of important redox enzymes including ribonucleotide reductase and thioredoxin peroxidase. 
The protein has a further role in controlling the transcription of some genes by reducing key 
cysteine residues in a number of transcription factors. A BLAST search [165] for the 
thioredoxin protein sequence from Burkholderia pseudomallei demonstrates that it is clearly 
homologous to the protein from Escherichia coli sharing 65 % of residue identities (figure 
10.1 a).  
10.2 Thioredoxin reductase 
Thioredoxin reductase represents the second component of the thioredoxin system. It is a 
flavoprotein responsible for the NADPH dependent reduction of thioredoxin to regenerate its 
biologically active disulphide bond. Two forms of thioredoxin reductase are known and have 
evolved separately: prokaryotes, archea and the majority of plants have a low molecular 
weight (approximately 35 kDa) thioredoxin reductase while higher eukaryotes have a high 
molecular weight (approximately 55 kDa) variety that contains a seleno-cysteine residue and 
operates by a different mechanism. The difference between the two forms of thioredoxin 
reductase, and the essential nature of the system, marks the protein as a potential drug target 
in fighting bacterial infections. The mechanism of low molecular weight thioredoxin 
reductase has been extensively studied [168-176]. The thioredoxin reductase transfers 
reducing equivalents from NADPH to its bound flavin, which reduces an internal disulphide 
bond, which can then reduce the disulphide bond of thioredoxin (figure 10.2). A BLAST 
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search [165] for the thioredoxin reductase protein sequence from Burkholderia pseudomallei 
demonstrates that it is clearly homologous to the protein from Escherichia coli sharing 68 % 
of residue identities (figure 10.1 b). [177] 
(a) Thioredoxin (BPSL1497) 
Score = 154 bits (390), Expect = 6e-49, Method: Compositional matrix adjust.  
Identities = 69/107 (64%), Positives = 89/107 (83%), Gaps = 0/107 (0%) 
 
BP     2  SEQIKHISDASFEQDVVKSDKPVLLDFWAEWCGPCKMIAPILDEVAKDYGDKLQIAKINV 61 
          S++I H++D SF+ DV+K+D  +L+DFWAEWCGPCKMIAPILDE+A +Y  KL +AK+N+ 
EC     1  SDKIIHLTDDSFDTDVLKADGAILVDFWAEWCGPCKMIAPILDEIADEYQGKLTVAKLNI 60 
 
BP    62  DENQATPAKFGVRGIPTLILFKNGAVAAQKVGALSKSQLTAFLDSHL 108 
          D+N  T  K+G+RGIPTL+LFKNG VAA KVGALSK QL  FLD++L 
EC    61  DQNPGTAPKYGIRGIPTLLLFKNGEVAATKVGALSKGQLKEFLDANL 107 
 
(b) Thioredoxin reductase (BPSL2605) 
Score = 447 bits (1150), Expect = 2e-157, Method: Compositional matrix adjust. 
Identities = 215/319 (67%), Positives = 257/319 (81%), Gaps = 1/319 (0%) 
 
BP     3  TPKHAKVLILGSGPAGYTAAVYAARANLSPLLITGIAQGGQLMTTTDVENWPADADGVQG 62 
          T KH+K+LILGSGPAGYTAAVYAARANL P+LITG+ +GGQL TTT+VENWP D + + G 
EC     2  TTKHSKLLILGSGPAGYTAAVYAARANLQPVLITGMEKGGQLTTTTEVENWPGDPNDLTG 61 
 
BP    63  PELMQRFLAHAQRFNTEIVFDHIHTAKLHEKPIRLIGDSGEYTCDSLIIATGASAQYLGL 122 
          P LM+R   HA +F TEI+FDHI+   L  +P RL GD+GEYTCD+LIIATGASA+YLGL 
EC    62  PLLMERMHEHATKFETEIIFDHINKVDLQNRPFRLNGDNGEYTCDALIIATGASARYLGL 121 
 
BP   123  QSEEAFMGRGVSACATCDGFFYRGQNVAVVGGGNTAVEEALYLTGIAKKVTVIHRRDKFR 182 
           SEEAF GRGVSACATCDGFFYR Q VAV+GGGNTAVEEALYL+ IA +V +IHRRD FR 
EC   122  PSEEAFKGRGVSACATCDGFFYRNQKVAVIGGGNTAVEEALYLSNIASEVHLIHRRDGFR 181 
 
BP   183  AEPILVDRLLEKEKEGAVEIKWDHVLDEVTGDDSGVSGVRIKHV-TTGATEDVAVQGLFI 241 
          AE IL+ RL++K + G + +  +  L+EVTGD  GV+GVR++    +   E + V GLF+ 
EC   182  AEKILIKRLMDKVENGNIILHTNRTLEEVTGDQMGVTGVRLRDTQNSDNIESLDVAGLFV 241 
 
BP   242  AIGHKPNTDIFKGQLEMKDGYIITNSGLSGNATGTSVPGVFAAGDVQDHIYRQAITSAGT 301 
          AIGH PNT IF+GQLE+++GYI   SG+ GNAT TS+PGVFAAGDV DHIYRQAITSAGT 
EC   242  AIGHSPNTAIFEGQLELENGYIKVQSGIHGNATQTSIPGVFAAGDVMDHIYRQAITSAGT 301 
 
BP   302  GCMAALDAQRYLESLHDHK 320 
          GCMAALDA+RYL+ L D K 
EC   302  GCMAALDAERYLDGLADAK 320 
 
Figure 10.1 BLAST search results for BPSL1497 and BPSL2605. The two sequences designated BP are from 
Burkholderia pseudomallei and those designated EC are from Escherichia coli. 
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Figure 10.2 Schematic representation of the catalytic cycle of thioredoxin reductase. There are two different 
conformations of the enzyme represented by the straight and bent forms. The cycle can be thought of to begin in 
the FO conformation with the enzyme in a 2 electron reduced state with an oxidised flavin and reduced cysteine 
residues. The enzyme then alters conformation to the FR state, allowing interaction with NADPH and the 
reduction of the flavin moeity to produce a four electron reduced form of the enzyme. In this conformation the 
enzyme is also able to interact with thioredoxin (Trx), replacing the disulphide in Trx with two sulphdryl groups 
by oxidising its own cysteine residues to form a disulphide. The enzyme then rearranges into its original 
conformation allowing the reduction of the disulphide by the flavin. Figure adapted from “Crystal structure of 
reduced thioredoxin reductase from Escherichia coli: Structural flexibility in the isoalloxazine ring of the flavin 
adenine dinucleotide cofactor” [173] 
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10.3 Thioredoxin reductase has two distinct conformations  
As part of the mechanism employed by this enzyme, a large conformational change has to 
occur. The two conformers of the protein are referred to as the flavin oxidising (FO) and 
flavin reducing (FR) forms. 
10.3.1 The FO conformation of thioredoxin reductase 
The first structure solved for a low molecular weight thioredoxin reductase was from 
Escherichia coli [178]. The structure contained a dimer of two identical subunits, each 
consisting of two distinct domains. One domain contains the active site cysteine residues and 
a NADPH binding site and is therefore termed the NADPH binding domain. The other 
domain, designated the FAD binding domain, contains the non-covalently bound flavin 
moiety. In the structure the isoalloxazine ring of the FAD is closely associated with the active 
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site cysteines, allowing the transfer of reducing equivalents from the FAD to the active site 
disulphide. However the NADPH binding site is distant from the flavin and the active site 
cysteine residues are buried and therefore inaccessible to the enzymes thioredoxin substrate. 
It was proposed that the protein must undergo a conformational change as part of its 
mechanism to allow the transfer of reducing equivalents along the chain from NADPH, to 
FAD, to the internal disulphide and finally to thioredoxin. As the solved conformation 
allowed the transfer of reducing equivalents from the FAD to the active site disulphide it was 
classified as the flavin oxidising (FO) form of the protein.  
10.3.2 The FR conformation of thioredoxin reductase 
The two domains of the enzyme share structural homology to the corresponding domains of 
other members of the pyridine nucleotide disulphide oxidoreductase flavoprotein family, such 
as glutathione reductase. However in glutathione reductase the organisation of the domains is 
drastically different, with an extra interface domain involved in dimerisation. The active site 
cysteine residues are also located on different domains, and a conformational change is not 
required as part of the enzymes mechanism [179]. A model of an alternative, flavin reducing 
(FR), conformation of thioredoxin reductase was proposed based on the structure of 
glutathione reductase [178]. In the model the two domains were rotated with respect to each 
other, allowing the FAD and NADPH molecules to interact and exposing the active site 
cysteine residues to the solvent. The proposed domain rotation appeared to be plausible as the 
two domains made relatively few contacts with other regions of the dimeric enzyme and that 
no barriers to the change existed that couldn’t be resolved by the adjustment of sidechains 
[178]. The requirement for a conformational change was supported by other studies involving 
measuring the kinetic, spectroscopic and redox properties of various mutated forms of the 
enzyme, cross-linked domains preventing conformational switching and complexes created 
by cross-linking thioredoxin reductase with thioredoxin [180-184]. A 3.0 Å structure relating 
to the FR conformation has since been solved for the protein from Escherichia coli [185]. 
Mutant variants of thioredoxin and thioredoxin reductase with one remaining active site 
cysteine each were used to form a stable covalent complex. The disulphide cross-link 
prevents the two proteins dissociating with thioredoxin acting as a “doorstop”, locking 
thioredoxin reductase into the FR conformation [181]. The structure supported the predicted 
model with the two domains rotated 67º with respect to each other. The active site cysteine 
residues are clearly available for interaction with thioredoxin and the structure was solved in 
the presence of AADP+, which is found in the NADPH binding site with its pyridine ring 
151 
 
stacked against the isoalloxazine ring of the FAD. The FR conformation is therefore able to 
pass reducing equivalents between NADPH and FAD, and the active site cysteine residues 
and its substrate.  
 
(a) Thioredoxin reductase in the FO conformation 
 (b) Thioredoxin reductase locked in the FR conformation by thioredoxin 
 
Figure 10.3 The two conformations of thioredoxin reductase from Escherichia coli. 
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10.4 Project aim 
A crystal structure of the oxidized FO conformation of thioredoxin reductase from 
Burkholderia pseudomallei had previously been determined to 1.45 Å within the Sheffield 
crystallography group (Martin Bush, Thesis 2009). The aim of this project was to solve a high 
resolution structure of thioredoxin from Burkholderia pseudomallei to lead into work 
determining the FR conformation of thioredoxin reductase at high resolution in the future. A 
high resolution of this complex, representing an intermediate of the catalytic mechanism, 
would resolve some of the remaining ambiguities in the proposed mechanism of thioredoxin 
reductase. This work will lead to a better understanding of the system in Burkholderia 
pseudomallei and, due to the high levels of conservation, across all prokaryotic organisms. 
This information could then be used to inform the design of inhibitors to thioredoxin 
reductase providing novel antibacterial compounds. 
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11.0 Studies on thioredoxin from Burkholderia pseudomallei 
This section describes the cloning, overexpression, purification, crystallisation, data 
collection, processing and resulting structure for thioredoxin from Burkholderia pseudomallei 
(BPSL1497) solved by molecular replacement. 
11.1 Cloning of BPSL1497 
BPSL1497 was amplified from Burkholderia pseudomallei strain D286 genomic DNA by 
PCR using BioMix Red (Bioline) and specific primers (Eurofins) (table 11.1). PCR products 
were purified using agarose gel electrophoresis and a QIAquick® Gel Extraction Kit 
(Qiagen) by standard protocols. The purified PCR product was ligated into a pETBlue-1 
vector using an AccepTor vector kit (Novagen) and used to transform Novablue competent 
cells (Novagen) which were plated on LB-agar with the addition of 100 µg ml-1 carbenicillin 
70 µg ml-1 X-gal and 80 µM IPTG for selection and blue-white screening of colonies. Gene 
presence and orientation was confirmed by colony PCR on white colonies (figure 11.1) 
before plasmids were recovered by miniprep and sequenced (Geneservice) to ensure the gene 
sequence was correct. 
 
                      
                    
 
Figure 11.1 Agarose gels showing 
the results of colony PCR for 
BPSL1497 cloning using different 
primers. Bpsl1497F and 
Bpsl1497R correspond to the start 
and end of the gene, pETBlueUP 
and pETBlueDOWN correspond 
to regions on the plasmid. The 
expected band size using 
pETBlueUP and Bpsl1497R was 
422 base pairs while Bpsl1497F 
and pETBlueDOWN should 
produce a band at 405 base pairs if 
the gene has inserted correctly. 
Colonies 3 and 5 produce the 
correct sized bands for both 
reactions. 
pETBlueUP and  
Bpsl1497R 
Bpsl1497F and 
pETBlueDOWN 
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Oligoname Sequence 
bpsl1497 F 5’-ATGAGCGAACAGATCAAACACATCA-3’ 
bpsl1497 R 5’-GCATCCGGTTTTAGAGAGATGGCTGT-3’ 
 
Table 11.1 Primers used for the PCR amplification of BPSL1497 from genomic DNA.  
 
 
11.2 Protein overexpression and purification for BPSL1497 
11.2.1 Overexpression 
Plasmids containing correctly sequenced genes were used to transform Tuner (DE3) pLacI 
competent cells (Novagen) for overexpression. A small-scale over expression trial was 
performed for BPSL1497 to find post induction conditions that would produce soluble 
protein. The best post induction condition was found to be 1 mM IPTG at 37 ºC for 20 hours. 
11.2.2 Purification 
Approximately 4 g of cell paste was resuspended in 40 ml 50 mM TRIS pH 9.0 and disrupted 
by sonication. Cell debris and insoluble protein was removed by centrifugation at 70,000 g 
for 15 minutes and the supernatant loaded onto a DEAE-Sepharose fast flow column 
equilibrated with 50 mM TRIS pH 9.0. A 200 ml gradient from 0 to 300 mM NaCl was then 
applied to the column and 8 ml fractions were collected (figure 11.2a). Fractions were 
analysed by SDS-PAGE (figure 11.3) and fractions containing BPSL1497 were pooled and 
concentrated to 1.5 ml using a Vivaspin concentrator with a 5 kDa MWCO. This was then 
loaded onto a 1.6 x 60 cm Superose 6 gel filtration column equilibrated in 50 mM TRIS pH 
8.0 and 500 mM NaCl and eulted using the same buffer collecting 2 ml fractions (figure 
11.2b). Peak fractions containing BPSL1497 were combined. The buffer was exchanged for 
10 mM TRIS pH 8.0 using a Vivaspin concentrator with a 5 kDa MWCO and the protein was 
concentrated to 10 mg ml-1 for use in crystallisation trials using the same Vivaspin 
concentrator. The overall yield of protein was 12 mg and was estimated by SDS-PAGE to be 
over 95 % pure (figure 11.3). 
11.2.3 Purification analysis 
The elution profile for BPSL1497 from the gel filtration column shows a single large peak 
roughly corresponding to a monomeric form of the protein (figure 12.2b). 
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(a) BPSL1497 DEAE-sepharose purification step 
 
 
(b) BPSL1497 Superose 6 purification step 
 
 
Figure 11.2 Chromatogram traces for the purification of BPSL1497. a DEAE purification step showing column 
loading and elution. 8 ml fractions were collected starting at the beginning of the gradient at 32 ml. b Gel 
filtration purification step showing elution with 2 ml fractions collected after the void volume of 44 ml. For all 
traces, green highlighted regions indicate volumes taken for subsequent purification steps or as pure protein. 
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Figure 11.3 SDS-PAGE gel showing the purification of BPSL1497. The molecular weight of BPSL1497 is 11.8
kDa and the highlighted bands indicate the protein in fractions taken for subsequent purification steps or as pure 
protein.  
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11.3 Protein crystallisation for BPSL1497 
Two initial 96 condition robot screens, the JCSG+ and PACT suites, were conducted using 
purified BPSL1497 at 10 mg ml-1. 200 nl of protein was mixed with 200 nl of well solution 
using a matrix hydra II plus one (Thermo Scientific) robot and the trays were incubated at 17 
ºC. Several hits were found in the screens with varying morphologies from needle clusters to 
well defined cubic crystals in JCSG+ condition C7, 100 mM sodium acetate pH 4.5, 200 mM 
zinc acetate and 10 % (w/v) PEG 3,000 (figure 11.4). Attempts to optimise the crystals by 
altering the PEG concentration (5 – 20 % (w/v)) using 5 µl protein solution and 5 µl well 
solution found optimum conditions were 100 mM sodium acetate pH 4.5, 200 mM zinc 
acetate and 7 % (w/v) PEG 3,000. This condition produced several large crystals for data 
collection.  
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PACT A10 – Robot screen  
200 mM Magnesium chloride 
100 mM Sodium acetate pH 5.0 
20 % (w/v) PEG 6000 
PACT C1 – Robot screen  
100 mM PCB buffer pH 4.0 
25 % (w/v) PEG 1500 
  
PACT C2 – Robot screen  
100 mM PCB buffer pH 5.0 
25 % (w/v) PEG 1500 
JCSG+ C6 – Robot screen  
100 mM Phosphate-citrate pH 4.2 
40 % (w/v) PEG 300 
 
 
 
 JCSG+ C7 – Robot screen  
200 mM Zinc acetate 
100 mM Sodium acetate pH 4.5 
10 % (w/v) PEG 3000 
 
 
Figure 11.4 Photographs of BPSL1497 crystals. 
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11.4 BPSL1497 initial data 
11.4.1 Initial data collection 
Crystals were selected for data collection based on their size and quality from the 
optimisation trials. Crystals were looped and placed into a variety of cryoprotectant solutions 
made using the well solution with the addition of differing concentrations of ethylene glycol 
(15 – 30 % (v/v)), PEG 400, (10 – 30 % (v/v)), glycerol (10 – 30 % (v/v)) or MPD (15 – 30 
% (v/v)). Once crystals were placed into any of the cryoprotectant solutions they began to 
show signs of distress with the crystals visibly cracking. They were then looped again and 
flash frozen in a stream of gaseous nitrogen at 100 ºK and mounted onto the detector. Initial 
diffraction analysis was conducted in order to determine the diffraction quality of several 
crystals using an in-house Rigaku MM007 rotating anode generator and a MAR 345 research 
image plate. Two images were collected 90º apart with 1º oscillation and a crystal to detector 
distance of 250 mm for a variety of crystals and cryoprotectants. The diffraction from these 
crystals was very poor with obvious multiple lattices and smeared diffraction spots. A new set 
of crystals were looped and flash frozen without the addition of any cryoprotectant. The 
diffraction from these crystals was of exceptional quality and due to the strength of 
diffraction the presence of ice rings was not a problem. A number of crystals that diffracted 
beyond 2 Å on the home source were saved and taken to a synchrotron at the I03 beamline of 
the Diamond light source, Oxford. Three initial test images were taken 45º apart with 1º 
oscillation to ensure crystal centering and to obtain a collection strategy using the auto-
indexing and collection strategy components of Mosflm [146]. For the initial data set 900 
images were collected with 0.1º oscillation per image using X-rays of 15000 eV at a crystal to 
detector distance of 351.7 mm using an ADSC Q315r detector. Data extending to 1.3 Å were 
collected (figure 11.5). 
11.4.2 Initial data processing 
The X-ray diffraction datasets were auto-processed at Diamond through the xia2 system 
using the 3dii mode [147]. Data were indexed and integrated by XDS and scaled by XSCALE 
[148]. The data indexed to space group P41212 or P43212, with the unit cell parameters a = b = 
34.3 Å, c = 191.5 Å, (table 11.2). Although the dataset contained data to 1.3 Å, it was 
incomplete beyond 1.45 Å (figure 11.6). The asymmetric unit was predicted to contain one 
protein molecule with a Vm of 2.38 based on the probabilities of Matthews coefficients 
calculated using Mattprob [149] (table 11.3). 
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Figure 11.5 Diffraction image for BPSL1497 initial data collection.  
 
 
 
 
Dataset Initial crystal 
Space group P43212 
Unit cell parameters  
a (Å) 34.3 
b (Å) 34.3 
c (Å) 190.7 
Energy (eV) 15000 
Resolution range (Å) 34.31 – 1.28 
Unique reflections 29794 (1691) 
Rmerge 0.054 (0.306) 
Rpim 0.026 (0.249) 
Completeness (%) 96.6 (77.5) 
Multiplicity 5.7 (2.4) 
Mean (I)/σ(I) 16.5 (2.4) 
 
Table 11.2 Data collection statistics for initial protein crystal. 
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Figure 11.6 Data collect ion statistics against resolution for the BPSL1497 init ial data. The graph shows Rmerge
and completeness for the dataset. The graph suggests the BPSL1497 in itia l data is incomplete but of good 
quality to the edge. 
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Table 11.3 Matthews coefficient calculations and probabilities for BPSL1497. The results show there is one 
protein molecule inhabiting the asymmetric unit.  
 
11.5 Phasing by molecular replacement 
The Phyre 2 server [141] was used to create a suitable search model for molecular 
replacement using an Escherichia coli thioredoxin structure (PDB 3DXB) [186]. The search 
model was cut back to a poly alanine chain using chainsaw [150] before use for an automated 
search in Phaser [151]. The 1.5 Å dataset was input and Phaser was run in P41212 and all the 
possible related space groups, searching for one molecule in the asymmetric unit. The best 
result was found using space group P43212, the enantimorph of the original designation, 
which produced Z-scores of 7.1 and 15.1 for the rotation and translation functions 
respectively and  an R-factor of 0.565 following refinement with REFMAC5 [152]. The 
resulting model and electron density were examined to confirm the result was unbiased by the 
search model with the presence of density relating to side chains visible (figure 11.10 a). 
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11.6 Model building and refinement 
The starting model was then input into the Buccaneer pipeline along with the primary 
sequence of BPSL1497 to generate a model containing side chains. The pipeline consists of 
Buccaneer fast build [187] which produced a model with an R-factor of 0.514 (Rfree 0.533) 
followed by 10 cycles of refinement using REFMAC5 [152] leading to a reduction in R-
factor to 0.411 (Rfree 0.449). Further refinement was conducted using iterative cycles of 
model building, refinement and evaluation using Coot [159] and REFMAC5 [152]. The 
process was repeated until a model for the initial data consisting of 105 residues, 201 water 
molecules and 3 zinc ions. The model had an R-factor of 0.1624 (Rfree 0.1918) and agreed 
well with the electron density (figure 11.10 b). 
11.7 High resolution data 
11.7.1 High resolution data collection 
The crystals of BPSL1497 were clearly capable of diffracting beyond the limits of the data 
collected. The presence of a long cell dimension, of approximately 192 Å along the c-axis, 
made collecting high resolution data difficult due to the proximity of the reflections to each 
other in the diffraction images. This is a particular problem for the low resolution data as the 
intensity of the reflections causes them to bleed into each other making assigning intensities 
for individual reflections problematic. In order to obtain higher resolution data, crystals that 
could diffract to high resolution with particularly low mosaicity were selected by analysis on 
the home source in Sheffield. These crystals were saved and taken to the I04 beamline of the 
Diamond light source, Oxford. Two initial test images were taken 90º apart with 1º oscillation 
to ensure crystal centering and to obtain a collection strategy using the auto-indexing and 
collection strategy components of Mosflm [146]. The beam used was slit down to the 
smallest possible size, 20 µm by 20 µm, to separate the reflections further. Two datasets were 
collected from the same crystal to best enable all data to be collected. The first set was 
collected using a low transmission and a relatively long detector distance of 289 mm in order 
to obtain a complete set of good quality low resolution data. The second dataset used a high 
transmission and relatively close detector distance of 127 mm, to maximise the measurable 
diffraction at high angles. For the two data sets 180 images were collected with 0.5º 
oscillation per image using X-rays of 12658 eV using an ADSC Q315r detector (figure 11.7).  
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Low resolution dataset High resolution dataset 
 
Figure 11.7 Diffraction images for BPSL1497 high resolution data collection.  
 
 
 
 
Dataset Low resolution High resolution Merged 
Space group P43212 P43212 P43212 
Unit cell parameters    
a (Å) 34.5 34.4 34.4 
b (Å) 34.5 34.4 34.4 
c (Å) 193.0 192.7 192.8 
Energy (eV) 12658 12658 - 
Resolution range (Å) 64.35 – 1.70 32.12 – 1.07 38.55 – 1.07 
Unique reflections 13049 (705) 51425 (3413) 52072 (6933) 
Rmerge 0.077 (0.384) 0.089 (0.419) 0.110 (0.386) 
Rpim 0.037 (0.256) 0.043 (0.280) 0.036 (0.227) 
Completeness (%) 93.9 (70.3) 97.9 (90.4) 98.9 (92.7) 
Multiplicity 5.5 (2.5) 5.9 (2.9) 7.2 (3.4) 
Mean (I)/σ(I) 12.5 (2.1) 10.5 (2.3) 10.5 (2.5) 
 
Table 11.4 Data collection statistics for higher resolution merged data. 
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(a) Data collection statistics against resolution for low resolution dataset 
 
 
(b) Data collection statistics against resolution for high resolution dataset 
 
 
(c) Data collection statistics against resolution for merged dataset 
 
 
Figure 11.8 Data statistics against resolution against resolution for the BPSL1497 merged high resolution 
dataset and its constituent parts. The graphs show Rmerge and completeness for each dataset. The low resolution 
data is complete to 1.95 Å, while the h igh resolution data is complete between 2.05 and 1.07 Å. The two  
datasets once merged and scaled together produce a dataset with good statistics to 1.10 Å. 
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11.7.2 High resolution data processing 
The X-ray diffraction datasets were auto-processed at Diamond through the xia2 system 
using the 3dii mode [147]. Data were indexed and integrated by XDS and scaled by XSCALE 
[148]. Both datasets indexed to space group P41212 or P43212, with the unit cell parameters a 
= b = 34.5 Å, c = 193.0 Å, for the low resolution data and a = b = 34.4 Å, c = 192.7 Å, for the 
high resolution data (table 11.4). The two datasets were then merged and scaled together 
using sortmtz and scala [188] from the CCP4 suite of programmes [156]. Data from 38.57 to 
2.00 Å from the low resolution dataset and 2.50 to 1.07 Å from the high resolution dataset 
were used and the resulting merged dataset had reasonable statistics (table 11.4) (figure 11.8). 
11.8 Building the final model 
The refined model from the 1.45 Å data was input into REFMAC5 [152] alongside the new 
1.07 Å resolution merged data to allow phasing by direct refinement producing a model with 
an R-factor of 0.3333 (Rfree 0.3446). Further refinement was conducted using iterative cycles 
of model building, refinement and evaluation using Coot [159] and REFMAC5 [152]. The 
final model (figure 11.9) consists of 105 residues, 4 zinc ions and 179 water molecules. The 
model had an R-factor of 0.187 (Rfree 0.205) and agreed well with the electron density (figure 
11.10 c). 
 
Figure 11.9 Cartoon representation of the overall fold of BPSL1497 showing the active site disulphide bond. 
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Resolution (Å) 1.07 
Number of reflections 49294 
Protein molecules per asymmetric unit 1 
Number of atoms 1024 
Number of residues 105 
Number of waters 179 
Number of ions 4 
Ramachandran favoured (%) 98.1 
Ramachandran outliers (%) 0.0 
RMS bond length deviation (Å) 0.008 
RMS bond angle deviation (º) 1.253 
Average main chain B-factors (Å2) 9.0 
Average side chain B-factors (Å2) 13.9 
Average waters B-factors (Å2) 24.5 
Average buffer component B-factors (Å2) 11.8 
R-factor (%) 0.187 
Rfree (%) 0.205 
Molprobity score 1.2 (91st percentile) 
 
Table 11.5 Final refinement statistics for BPSL1497. 
 
(a) Phaser (b) Final model for the 1.45 Å  data 
  
  
(c) Final model for the  1.07 Å data  
Figure 11.10 Sample reg ion of electron density for 
BPSL1497. Maps are contoured at 2 sigma and show 
the same region of density around residues Glu-72, 
Val-73 and Arg-74, from the final h igh resolution 
model. a The initial electron density map output from 
Phaser. b The electron density map for the final 1.5 Å  
model. c  The electron density map for the final 1.07 Å  
model. 
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(a) Side chain parameters 
(b) Main chain parameters 
Figure 11.11 Main chain and side chain properties for the final BPSL1497 model. The figure was generated 
using PROCHECK [157] and shows all residues have properties within the expected range for the resolution of 
the data. 
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General 
 
Glycine 
  
 
Proline 
 
 
Pre-proline 
  
 
Figure 11.12 Ramachandran plot and statistics for the final BPSL1497 model. The figure was generated using 
Molprobity [158] and shows all residues have acceptable values for their phi and psi angles with 98.1 % falling 
within favoured regions. 
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11.9 The model of BPSL1497 
The model has been restrained to standard bond lengths and angles and the root mean square 
deviation (RMSD) of bond lengths and bond angles in the final structure for the high 
resolution data is 0.008 Å and 1.253º respectively. The structure was validated using 
PROCHECK [160], and the Molprobity server [161] which showed the overall structure was 
of good quality. All main chain and side chain parameters are better than or within the 
expected range for the resolution of the data (figure 11.11) and all residues fell within 
allowed regions of the Ramachandran plot (figure 11.12). 
11.9.1 Metal ions in the BPSL1497 structure 
The final model contains four metal ions, which due to the presence of 200 mM Zn2+ in the 
crystallisation solution were assumed to be zinc although no analysis was done to confirm 
this assumption. Three of the four ions are found mediating crystal contacts between 
symmetry related molecules, with one of these falling on a 2-fold symmetry axis with half 
occupancy. 
11.10 BPSL1497 is similar to thioredoxin structures from other species 
As expected the overall structure of thioredoxin from Burkholderia pseudomallei is very 
similar to that from other species (figure 11.13 a). The RMSD when compared to thioredoxin 
from Escherichia coli [189] (PDB 2TRX) is 0.6 and there are only minor differences between 
the two structures. The active site architecture is also conserved (figure 11.3 b), as is the 
positioning of a number of key structural residues (data not shown) identified by sequence 
homology and functional studies [190]. 
11.10.1 Interface residues of thioredoxin and thioredoxin reductase in Burkholderia 
pseudomallei are conserved 
In the Escherichia coli thioredoxin to thioredoxin reductase complex structure, the two 
proteins make seven hydrogen bonds with each other (table 11.6). The residues involved in 
these interactions are generally conserved in the Burkholderia pseudomallei proteins with 
two exceptions. In thioredoxin Tyr-70 is replaced by Phe-71 and in thioredoxin reductase 
Ala-237 is replaced by Gln-237 in the Escherichia coli and Burkholderia pseudomallei 
proteins respectively, however as these hydrogen bonds involve the carbonyl oxygens of the 
residues, these differences should not affect the formation of the hydrogen bonds. The 
positions of the residues involved in these interactions are conserved between the Escherichia 
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(a) Overall fold 
 
 
(b) Active site 
Figure 11.13 The structure of BPSL1497 is similar to other thioredoxin structures. In both images the 
Burkholderia pseudomallei structure is shown in blue and the Escherichia coli structure in green. a The overall 
fold of the molecules. b The active site architecture. 
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Thioredoxin residue Thioredoxin reductase residue Bond length (Å) 
Trp-31 [NE1] Cys-138 [CO] 3.1 
Arg-73 [NH] Gly-129 [CO] 3.2 
Arg-73 [NE] Arg-130 [CO] 3.0 
Arg-73 [NH1] Arg-130 [CO] 2.9 
Arg-73 [NH1] Ala-237 [CO] 2.7 
Ile-75 [NH] Asp-139 [OD1] 2.8 
Tyr-70 [CO] Arg-130 [NH2] 2.6 
 
Table 11.6 Hydrogen bonds between thioredoxin and thioredoxin reductase in the Escherichia coli complex 
structure. 
 
(a) Trp-31 (b) Tyr-70 
  
 
(c) Arg-73 
 
(d) Ile-75 
  
 
Figure 11.14 Conservation of residues forming hydrogen bonds between thioredoxin and thioredoxin reductase.  
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coli and Burkholderia pseudomallei thioredoxin structures (figure 11.13) and thioredoxin 
reductase structures (Martin Bush, Thesis 2009), suggesting the interactions between the two 
proteins in each system are very similar. This suggests the system is ideal for further studies 
to determine a high resolution structure of the thioredoxin reductase to thioredoxin mutant 
proteins covalent complex. 
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Chapter four 
Discussion of results obtained as part of this thesis 
 
 
 
 
Section 12 Summary, conclusions and future work 
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12.0 Summary, conclusions and future work 
The work in this thesis is mainly concerned with a small-scale structural genomics project for 
targets from Burkholderia pseudomallei. An overview of the successes of the programme, 
together with highlights from the work on each of the selected targets, including an analysis 
of the structure determined for BPSS0211 are discussed in this section. A structure was also 
solved for thioredoxin from Burkholderia pseudomallei as part of an on-going project to 
resolve the remaining ambiguities in the thioredoxin reductase catalytic mechanism. 
12.1 Overview of the structural genomics project 
Nine targets were initially selected for study based on their perceived role as potential 
pathogenicity determinants of the human bacterial pathogen, Burkholderia pseudomallei. The 
assignments were based on a target’s possession of at least one of two criteria. The first was 
their expression in the pathogenic Burkholderia pseudomallei but not the closely related, non-
pathogenic Burkholderia thailandensis. The second required their expression be controlled as 
part of a stress response, which controls other known virulence factors. Once selected, the 
genes were cloned into expression vectors and overexpression trials were conducted. 
Conditions that allowed the soluble overexpression of five of the targets were found and large 
scale growths were carried out to obtain material from which to purify the target proteins. 
Each of the expressed proteins were purified and crystallised to varying degrees of success 
and a single structure was solved for the target BPSS0211 (table 12.1). An abundance of 
information has been amassed for the targets studied, however this project has been cut short 
by time constraints and there is a plethora of additional work to be considered, both structural 
and functional, that would be worthwhile conducting to extend this study.  
12.2 The insoluble targets: BPSL3012, BPSS0214, BPSS1588 and 
BPSS2055 
Sequence analysis of BPSS1588 identified an N-terminal signal sequence, directing the 
protein for secretion from the cell. The protein was also predicted, following secondary 
structure assignment and threading analysis, to possess a collagen binding domain. The four 
genes were cloned into expression plasmids, with the resulting sequences for BPSL3012 and 
BPSS1588 having no differences when compared to the K96243 genome sequence while 
BPSS0214 had three residue changes, L81Q, E174D and F388S, and BPSS2055 had a single 
change D322G. Overexpression trials yielded conditions for all four targets where the protein 
could be produced in the insoluble cellular fraction. However, the inability to produce soluble 
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Target Cloned Expressed Purified Crystallised Structure 
solved 
BPSL0599 Yes Yes Yes Yes No 
BPSL1958 Yes Yes Yes Yes No 
BPSL3012 Yes No    
BPSS0211 Yes Yes Yes Yes Yes 
BPSS0212 Yes Yes Yes Yes No 
BPSS0213 Yes Yes Yes Yes No 
BPSS0214 Yes No    
BPSS1588 Yes No    
BPSS2055 Yes No    
 
Table 12.1 Summary of results for the structural genomics project.  
protein for the four targets, BPSL3012, BPSS0214, BPSS1588 and BPSS2055 means 
regrettably further studies on these proteins would be difficult to conduct. The insolubility of 
the two targets that possess residue changes from the K96243 strain, BPSS0214 and 
BPSS2055, may be resultant from incorrect folding caused by mutations created by PCR 
error. The insolubility of BPSS1588 could be related to the reducing environment of the cell. 
As the protein contains multiple cysteine residues and usually exists outside of the cellular 
environment the formation of disulphide bonds might be required for correct folding. 
Alternative constructs and expression systems could be considered to produce soluble protein 
for all four targets however this would effectively require the process to be entirely restarted. 
Another option would be to attempt refolding experiments on overexpressed insoluble 
protein. This would involve a large scale growth under conditions that provide abundant 
amounts of insoluble protein, followed by cell lysis, protein denaturation and screening 
conditions to subject the proteins to for refolding. Commercial screens are available for this 
purpose, such as the Pierce® Protein Refolding Kit (Thermo Scientific). If solubilisation was 
successful, further studies could then be conducted on these targets. 
12.3 BPSL0599 
The gene was cloned into an expression plasmid and the resulting DNA sequence was 
identical to that found in the K96243 genome sequence. Overexpression of BPSL0599 
resulted in two distinct molecules, one being the full length protein and the other a stable 
fragment consisting of the 103 N-terminal residues. Separation of these two proteins during 
purification was problematic and three samples were used in initial crystallisation trials. 
These were a mixed sample and two samples containing predominantly the full length, or the 
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N-terminal fragment. Conditions producing crystals from the samples consisting the two 
partially separated species were identified; however the crystals are currently unsuitable for 
X-ray analysis. Following testing, optimisation screens around conditions containing protein 
crystals could be conducted, or if the crystals are salt, further screening could be done. 
Problems in crystal optimisation might arise from the two forms of the protein that are 
produced during overexpression that are not completely separated during purification. As the 
fragments are inherently similar it is likely that the crystals might be mixtures which could be 
alleviated by producing a new construct corresponding to the stable fragment which could 
then be expressed in isolation allowing the purification of a homogeneous sample for further 
crystal trials.  
12.4 BPSL1958 
BPSL1958 contains a highly repetitive sequence of a 52 amino acids repeated six and three 
quarter times with the repetitive nature also apparent at the DNA level. This suggests the gene 
was created in a recent duplication event and there has not been enough time for the sequence 
of the individual repeats to drift. Analysis of the secondary structure and threading results 
strongly suggest this protein forms a beta propeller structure with each of the repeats forming 
an individual blade. The gene was cloned into an expression plasmid with a single sequence 
difference, S312A, compared to the K96243 genome sequence. Due to the lack of any 
methionine, cysteine or tyrosine residues in the primary sequence and the absence of a 
suitable homology model in the PDB, it was necessary to produce a number of mutants to 
allow phasing experiments to be conducted. Cysteine mutations (K3C, S128C, A357C, K3C-
D244C, K3C-H340C) were created to allow covalent mercury binding in co-crystallisation 
experiments and a triple methionine mutant (K3C-I44M-I252M-I356M) was produced to 
allow the production and crystallisation of seleno-methionine protein. The native protein and 
all mutant forms of the protein were overexpressed and purified by a two-step procedure, 
involving anion exchange chromatography followed by gel filtration. The protein eluted from 
the gel filtration column anomalously with a predicted molecular weight much lower than 
expected, likely due to the protein interacting with the matrix of the beads. Crystallisation 
trials using the native protein found a single condition capable of producing crystals, 
following optimisation a crystal was selected and a dataset was collected. Cysteine mutant 
forms of the protein were all placed into co-crystallisation trials with the mercurial compound 
EMTS. Hits were found for all mutants and crystal optimisation was attempted. This was 
successful only for the K3C and S128C mutant forms with little improvement seen for the 
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other mutants. MAD data were collected from crystals of the K3C, S128C, A357C and K3C-
H340C mutants, though the only crystals which produced any anomalous signal were 
obtained by a co-crystallisation experiment between the K3C mutant and EMTS. This data 
was used to calculate a set of initial phases for the structure although the resulting map was 
uninterpretable. Crystals containing the seleno-methionine K3C-I44M-I252M-I356M 
quadruple mutant protein were produced by seeding experiments, although the diffraction 
properties of these crystals and the incorporation of seleno-methionine into the protein are yet 
to be determined. The next step towards structure resolution for BPSL1958 would be further 
seeding trials for the seleno-methionine K3C-I44M-I64M-I356M mutant protein. Once useful 
crystals have been produced, diffraction data could be collected for this target in order to 
obtain a further set of initial estimates for the protein phases through Selenium MAD data 
collection and processing. These phases could then be combined with the phases calculated 
from the mercury MAD K3C mutant data. Failing optimisation of seleno-methionine mutant 
crystals, it would be necessary to create further mutants and subject these to purification and 
co-crystallisation trials. If this created an interpretable electron density map a model could be 
constructed through iterative rounds of model building and refinement. 
12.5 BPSS0211, BPSS0212 and BPSS0213 
The three genes are contained within the four gene BPSS0211-BPSS0214 operon where all 
four genes in the operon are annotated as having no known function. BPSS0212 and 
BPSS0213 are homologs of each other and are annotated as containing two domains of 
unknown function, the N-terminal DUF1842 and C-terminal DUF1843 which is homologous 
to the full length BPSS0211. 
12.5.1 BPSS0211 
The gene was cloned into an expression plasmid with the same sequence as found in the 
K96243 genome sequence. Native and seleno-methionine proteins were overexpressed and 
purified by a three-step procedure, involving anion exchange chromatography and an 
ammonium sulphate cut followed by gel filtration. The protein eluted from the gel filtration 
column as a shouldered peak possibly corresponding to two oligomeric states of the protein 
with predicted molecular weights corresponding to a dimeric and tetrameric form of the 
protein. Initial crystallisation screens were conducted resulting in several hits, one of which 
was optimised to produce the crystals used for data collection. Data was collected from both 
native and seleno-methionine protein crystals from the same crystallisation condition 
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allowing calculation of a set of initial phase estimates by MAD techniques. A 2.17 Å 
structure with good overall statistics was built with a single protein molecule in the 
asymmetric unit consisting of 51 residues arranged into two alpha helices along with some 
buffer components including a potentially biologically relevant Zinc ion. Analysis of the 
crystal packing suggested the protein arranged as a tetramer best described as a dimer of 
dimers. Analysis of the interfaces between subunits suggested that both dimers and tetramers 
were stable and the tetramer was the most probable quaternary structure. Questions remain 
regarding the structure of BPSS0211, ultimately higher resolution data may resolve some of 
the ambiguities in the model, particularly surrounding the potentially biologically relevant 
zinc ion. It would also be informative to determine whether residues 1-9 and 61-63 are absent 
or disordered in the crystal. A mass spectrometry analysis conducted on crystals of the protein 
would answer this question. Finally conformation of the oligomeric state of BPSS0211 in 
solution could be achieved by sedimentation centrifugation and native gel electrophoresis. 
This could be conducted in the presence and absence of Zinc and a number of other divalent 
metal cations to determine if their presence has an effect on the proteins quaternary structure. 
12.5.2 BPSS0212 
The gene was cloned into an expression plasmid with a single residue difference, Q187R, 
when compared to the K96243 genome sequence. Native and seleno-methionine proteins 
were overexpressed and purified by a three-step procedure, involving two forms of anion 
exchange chromatography followed by gel filtration. The protein eluted from the gel filtration 
column with a predicted molecular weight corresponding to a dimeric protein. Throughout 
the purification process, the protein was observed to be suffering from degradation which 
continued after purified. Crystallisation trials resulted in the production of a number of poor 
quality crystals that defied optimisation. Data was collected from both native and seleno-
methionine protein crystals grown from the same condition allowing calculation of a set of 
initial phase estimates by MAD techniques. The quality of the initial phases was low and the 
resulting electron density map was impossible to interpret. Due to the degradation of the 
protein it is unclear what the contents of the crystal are, and it is likely the degradation has 
hampered the growth of high quality crystals. In order to produce better quality crystals 
needed to determine the structure it will be necessary for the crystal contents to be accurately 
identified by mass spectrometry or protein sequencing. The crystallised fragment could then 
be cloned and expressed allowing for its purification without other contaminating fragments. 
Alternatively it may be possible to produce a stable full length protein or to stabilise the 
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fragment of the protein that crystallises, long enough for optimisation trials to be conducted. 
The use of protease inhibitors throughout the purification process and present in the 
crystallisation condition might achieve this, preventing the breakdown of the protein. Once 
useful crystals have been produced, better quality diffraction data could be collected allowing 
a superior set of initial phases to be calculated. If this created an interpretable electron density 
map, a model could then be constructed through iterative rounds of model building and 
refinement. 
12.5.3 BPSL0213 
The gene was cloned into an expression plasmid with the same sequence as found in the 
K96243 genome sequence. The protein was overexpressed and purified by a two-step 
procedure, involving anion exchange chromatography followed by gel filtration. The protein 
eluted from the gel filtration column with a predicted molecular weight corresponding to a 
dimeric protein. Throughout the purification process, the protein was observed to be suffering 
from degradation which continued after purified, although this was at a much slower rate than 
for the related BPSS0212 protein. Crystallisation trials were conducted and a single condition 
has been identified that produces low quality protein crystals. The next steps towards 
structure resolution for BPSS0213 would be crystal optimisation trials. Once useful crystals 
have been produced, diffraction data could be collected for this target. The next step would be 
obtaining a set of initial phases, through Selenium MAD experiments. Once initial phase 
estimates have been produced a model could be constructed through iterative rounds of 
model building and refinement. 
12.5.4 Understanding the role of BPSS0211 as part of the BPSS0211-BPSS0214 operon 
The inferred function of BPSS0211 from the solved structure as an oligomerisation domain 
asks a number of questions regarding the nature of the operon it exists within. An analysis of 
the conservation of residues between BPSS0211 and the homologous regions of BPSS0212 
and BPSS0213, and with homologs of the three proteins from other bacterial species was 
conducted. The conserved residues were mapped onto the BPSS0211 structure and their 
positions in the tertiary and quaternary structure were analysed. Conserved residues appear 
on one of two interfaces, either between the two helices of the monomeric structure or as part 
of the interface that forms the dimeric structure. This suggests the possibility of heterodimers 
forming between the different proteins in the operon. Determining the nature of any possible 
assembly of homo dimers and tetramers of the individual proteins and hetero dimers and 
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tetramers of the three proteins could provide an insight into the biological role of BPSS0211 
within the cell. Further understanding could then be derived from ascribing a function to the 
other domain, DUF1842, found in BPSS0212 and BPSS0213, possibly by determining the 
structure of either protein. 
12.6 The structural genomic approach to structure determination 
The Protein Structure Initiative (PSI) funded by the American National institute of health 
(NIH) represents the largest structural genomics project embarked upon. The project began in 
2000 with an initial pilot phase (PSI-I) focused on the demonstration of feasibility and 
development of methodology. This was then applied in the second phase (PSI-II) to targets on 
a large scale commencing in 2005. The ultimate goal of the project is to make three 
dimensional structural information an integral part of all biological research and to provide 
this information through experimentally determined structures or homology modelling for 
any target based on its primary sequence. To this end the programme aims to provide 
structural coverage for all families of proteins and therefore one selection criteria is for 
unique targets not represented in the PDB. For selection purposes these were defined as 
proteins with less than 30% identity to proteins for which structures had already been 
determined. Other criteria include targets of potential therapeutic interest and those required 
to give greater coverage of biological pathways. 
 
One benefit of structural genomics is the generation of economies of scale in structure 
determination, reducing the cost of each individual structure solved. The estimated cost of 
solving a unique protein structure in an average structural biology group is predicted to be 
between $250,000 and $300,000 while the cost of solving a similar structure as part of the 
pilot phase of the PSI was $138,000 [191]. This figure has subsequently reduced as the 
project has continued and therefore in terms of structures solved structural genomics clearly 
represents a cost effective solution to structure determination.  
 
The overall success rate to structure of below 3 % for individual targets selected and studied 
as part of phases I and II of the PSI is very low (table 12.2), although as the projects continue 
this is set to rise. It is unclear in large scale projects how many targets are dropped 
prematurely when the individual project runs into difficulties; whereas in a smaller, more 
focused approach, such as the one described here, more time and effort can be applied to a 
specific target which ultimately may result in a much higher success rate. 
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PSI centre Selected Cloned Expressed Purified Crystallised NMR Structure in PDB 
ATCG3D 7 7 7 7 6 0 6 
CESG 1425 1083 932 254 71 15 40 
CHTSB 129 124 29 10 0 0 5 
GPCR 3 3 0 0 0 0 0 
ISFI 428 330 244 210 175 0 129 
JCSG 26357 25448 15667 15665 2607 0 962 
MCSG 7763 6559 4759 2169 485 0 389 
MPP 516 231 212 33 0 0 0 
NESG 11219 4269 4064 1437 144 155 279 
NYCOMPS 532 362 90 43 0 0 0 
NYSGRC 9895 2391 2091 537 68 0 52 
NYSGXRC 3309 2749 2373 1183 333 0 228 
TMPC 97 73 53 18 0 0 0 
Combined 72422 49804 34882 23205 3889 170 2090 
       
Success from previous 
stage (%)  68.8 70.0 66.5 0.2 51.5 
Success from target 
selection (%)  68.8 48.2 32.0 5.6 2.9 
 
Table 12.2 Statistics for phase I and II of the Protein Structure Initiative. 
 
12.6.1 Appraisal of the study described in this thesis 
The approach adopted in the study can be considered a small scale, highly targeted structural 
genomics program. The need for new treatments for the disease melioidosis, coupled with the 
large proportion of genes of unknown function within the bacterium’s genome, demonstrates 
the need for studies into the biology of Burkholderia pseudomallei, particularly around 
systems involved in the organisms pathogenicity. The ultimate aims of this project were to 
identify potential pathogenicity determinants, elucidate their structures with the intention of 
ascribing a function based on structural analysis and subsequent informed functional studies, 
in order to develop the understanding of the unknown aspects of the biology of Burkholderia 
pseudomallei. Improvements could be made to the target selection strategy, and the criteria 
for selection could be broadened. A potential expansion of the project could be to consider 
targets whose expression is controlled by other alternative sigma factors known to control the 
expression of virulence factors, such as RpoE. Selected targets could be examined in terms of 
the predicted success for their crystallisation, and difficult targets discarded or their 
sequences further analysed and modified in order to improve the likelihood of crystals being 
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obtained. A number of programs exist to determine these characteristics including the 
XtalPred server [192]. This program makes predictions based on the predicted biochemical 
and biophysical nature of a protein’s primary sequence, such as length, pI and disordered 
regions [193]. The current success rate to structure of 11 % for the study described here is not 
particularly high, although better than for the large-scale PSI; however several of the targets 
are getting close to having structures determined and if given more time, the project would 
yield more structures and begin to shed light on the functions of the targets involved. The 
current lack of structural information for the remaining targets prevented the assignment of 
even putative functions to be tested. The only structure solved as part of this study represents 
a domain conserved between three out of four members of an operon. While it is predicted 
that the solved target, BPSS0211, plays a role in the oligomerisation of the operon 
components, it is unclear what role the BPSS0211-BPSS0214 plays in the organism and 
therefore what, if any, role it plays in pathogenicity. As such the aim of the project to further 
the understanding of the biology of Burkholderia pseudomallei, with the ultimate aim of 
developing new treatments, can be broadly viewed as a failure to date. Overall the project, if 
continued, could yield a wealth of information about the selected targets and represents a 
viable approach to furthering the understanding of an organism’s biology that could easily be 
extended within Burkholderia pseudomallei or applied to other pathogenic bacteria. 
12.7 Thioredoxin system project 
The thioredoxin gene BPSL1497 was cloned into an expression plasmid which was used to 
overexpress the protein. This was then purified by a two-step procedure, involving anion 
exchange chromatography followed by gel filtration. Crystallisation screens identified a 
number of conditions under which the protein would crystallise in different crystal forms. 
One of these was optimised leading to the production of large crystals used for data 
collection. The crystals were of an exceptional quality diffracting to very high resolution and 
a number of datasets were collected. Initial protein phase estimates were calculated by 
molecular replacement and the structure was determined to 1.07 Å resolution. The model had 
reasonable statistics which could likely be improved through further refinement. The overall 
fold of the protein was found, as expected, to correlate well with previously solved 
thioredoxin structures from other species and the architecture of the active site and other 
important residues were also conserved.  
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12.7.1 Towards a structure of the FR conformation of thioredoxin reductase 
The ultimate aim of this project is to determine a high resolution structure for a covalent 
complex between thioredoxin (BPSL1497) and the FR conformation of thioredoxin reductase 
(BPSL2605). Currently the only determined structure corresponding to this comes from 
Escherichia coli and the resolution only extends to 3.0 Å. At this resolution there are details 
that cannot be resolved, leaving unanswered questions about the mechanism of bacterial 
thioredoxin reductase enzymes. A similar technique to that used to produce a structure 
relating to the FR conformation of Escherichia coli thioredoxin reductase [181] could be 
applied to the homologous protein from Burkholderia pseudomallei. The Escherichia coli 
structure was solved by locking thioredoxin reductase into the FR conformation by forming a 
complex with thioredoxin before crystallisation. This was achieved by mutating one of the 
two active site cysteine residues in each protein, and forming a disulphide cross-link between 
the remaining cysteine residues. The thiol reagent 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB) 
was used to “activate” the thioredoxin mutant by producing a mixed disulphide between the 
remaining active site cysteine and thionitrobenzoic acid. The “activated” thioredoxin mutant 
protein was then mixed with the thioredoxin reductase mutant protein producing the 
disulphide linked complex. The complex remains stable as the mutated cysteine residues are 
no longer able to attack the disulphide bond as would occur if the native proteins were used. 
The active site cysteine residues in thioredoxin and thioredoxin reductase from Escherichia 
coli are residues 32 and 35, and 135 and 138 respectively, and correspond to residues 33 and 
36, and 136 and 139 of the Burkholderia pseudomallei proteins. For the Escherichia coli 
structure, the covalent complex was formed by linking cysteine-32 of thioredoxin to cysteine-
138 of thioredoxin reductase as this is probably the physiologically relevant intermolecular 
disulphide [183]. Therefore the two desired mutant forms are BPSL1497 C36S and 
BPSL2605 C136S. 
12.7.2 Obtaining ultra-high resolution data 
Some of the BPSL1497 crystals tested diffracted to beyond 0.8 Å and it may therefore be 
possible to obtain ultra-high resolution data for this protein in the future. Ultra-high 
resolution data is useful in crystallography as it allows accurate experimental calculation of 
the geometry of proteins, which can then be used to improve all structure determination 
experiments. The problem with obtaining this data from the crystals of BPSL1497 is the 
presence of a long unit cell axis causing difficulty in separating the reflections on this axis. 
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One solution to collecting ultra-high resolution data from such a crystal would be to use a 
larger detector, allowing the collection of high angle reflections while maintaining reflection 
separation in the diffraction images. Higher resolution data might also be achieved by a 
number of data collection techniques using the available apparatus at the Diamond 
synchrotron light source. Testing a large number of crystals to find the least mosaic would 
reduce the spread of individual reflections in the images. Another technique requires the 
careful mounting of crystals to ensure they are rotated around the long unit cell axis during 
data collection. Using a smaller X-ray beam, such as the I24 microfocus beamline at 
Diamond which can be reduced to 5 µm by 5 µm and increasing the wavelength of the X-ray 
beam may also further separate the reflections. 
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13.0 Cloning to purified protein 
The section includes a discussion of the theory behind techniques used in this thesis. It also 
describes in detail the laboratory techniques used to clone, overexpress and purify target 
proteins from Burkholderia pseudomallei.  
13.1 Recombinant DNA technology and protein production 
X-ray crystallography structural studies require large quantities of soluble, correctly folded, 
relatively pure protein. Proteins can be obtained from a native source although it is often 
unfeasible, due to low levels of expression, difficulty in obtaining enough initial material, and 
in this case the pathogenicity of the original organism. Recombinant DNA technologies are 
therefore routinely employed to produce large amounts of a target protein. The technique 
involves extraction of the DNA from the organism being studied followed by amplification of 
the gene of interest by use of PCR. The gene is then inserted into an expression plasmid and 
transformed into a host that can be manipulated into producing large amounts of the protein 
of interest. 
13.1.1 Polymerase chain reaction 
In a standard PCR several components are required, including a heat stable DNA polymerase 
enzyme, the four deoxynucleoside triphosphates (dNTPs), a DNA template containing the 
region that is to be amplified and DNA primers complementary to the ends of the region of 
template DNA that is to be amplified, all in a suitable buffer for the reaction to take place. 
The PCR progresses through several cycles of amplification. Each cycle consists of three 
phases achieved by altering the temperature of the reaction. The first phase, denaturation, 
consists of boiling the reaction in order to disrupt hydrogen bonds between DNA bases 
resulting in the production of single strands of DNA with no internal secondary structure. 
This is followed by the annealing phase where the temperature is dropped to below the 
melting point of the DNA primers allowing them to bind to their complementary sections on 
the template DNA. During the final elongation phase, at the polymerase’s optimal 
temperature, the polymerase binds to the DNA and progresses along the strand producing a 
new copy of the desired region. The high GC content of Burkholderia pseudomallei’s genome 
[49] can cause problems with strand separation and primers annealing to the genome. This is 
due to the increased temperatures required for strand separation and the increased frequency 
of primers annealing to mismatching DNA sections. The use of DMSO as a PCR additive 
chemically disrupts the hydrogen bonding between base pairs, facilitating DNA strand 
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separation and PCR efficiency, and allows the use of lower temperatures in the reaction. A 
lower annealing temperature can in some circumstances result in an improved amplification 
with either a larger yield of the desired DNA or a reduction in the number of contaminants 
also produced during the PCR reaction caused by primers annealing to incorrect regions of 
the template DNA [145].  
13.1.2 pET vectors 
The pET expression system (Novagen) is a range of expression vectors and hosts for the 
tightly controlled production of large quantities of a target protein. The plasmids used in this 
project, pET21a (figure 13.1) and pETBlue-1 (figure 13.2), possess a cloning region 
containing a T7 promoter sequence followed by a Lac operator sequence, ribosome binding 
site and a T7 terminator sequence. In conjunction with a suitable expression host they can be 
used to produce large quantities of a target protein (figure 13.3).  
13.1.3 Cloning with pET21a 
The plasmid pET21a (figure 13.1) contains multiple restriction enzyme sites in its cloning 
region for the insertion of the target gene by traditional restriction cloning. The restriction 
sites used in this project are NdeI, BamHI and EcoRI. Following restriction digestion of both 
the plasmid and the amplified gene fragment the insert can be ligated into the vector using T4 
DNA ligase. The resulting plasmid can then be transformed into a bacterial strain lacking the 
T7 polymerase gene to prevent any background expression which could be problematic at 
this stage. The plasmid, pET21a, also contains a copy of the LacI gene to ensure sufficient 
repressor protein is produced for the operator sequences in the genome and the plasmid once 
it is transferred into an expression strain. 
13.1.4 Cloning with pETBlue-1 
The plasmid pETBlue-1 (figure 13.2) allows insertion of the target gene through a blunt end 
cloning into an EcoRV restriction site present in a copy of the α-peptide fragment of the LacZ 
gene. The resulting plasmid can then be transformed into a bacterial strain lacking the T7 
polymerase gene to prevent any background expression and with a copy of the ω-peptide 
gene of LacZ in its genome. Colonies containing a plasmid with an insertion can be chosen 
by blue/white screening on agar containing IPTG and X-gal. The LacZ gene fragments 
together code for β-galactosidase which is able to break down X-gal producing a blue 
pigment. If the LacZ α-peptide gene is intact (no insertion) it is expressed and able to 
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(a) Plasmid map of pET21a 
 
 
(b) Sequence of the cloning region of pET21a vector 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
BglII                  T7 Promoter          lac operator           XbaI 
 -----------------------------------------------                                                                                                                  -------------------------------------------------------------------------------------------------------------------------------------                                  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------                                -----------------------------------------------                                                                                                                                                                                                 
agatctcgatcccgcgaaattaatacgactcactataggggaattgtgagcggataacaattcccctctagaaataattttgtttaactttaag
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
 
 
 rbs        NdeI  NheI                             BamHI        SacI        HindIII         XhoI
-----------------------------------------------                                          ----------------------------------------------  ----------------------------------------------                                                                                                                                                                                                                         -----------------------------------------------                                                 ----------------------------------------------                                                          -----------------------------------------------                                                                         --------------------------------
aaggagatatacatatggctagcatgactggtggacagcaaatgggtcgcggatccgaattcgagctccgtcgacaagcttgcggccgcactcg
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                .                                             .                                                  .                                                             .                                               -----------------------------------------------                                             .            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                -----------------------------------------------                                                         ------------------------------------------------                                                                                                                                                                               
                                                         EcoRI         SalI         NotI 
 
---------------                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
agcaccaccaccaccaccactgagatccggctgctaacaaagcccgaaaggaagctgagttggctgctgccaccgctgagcaataactagcata
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                     T7 Terminator      . 
                                                                                                                ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
accccttggggcctctaaacgggtcttgaggggttttttg 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
 
 
Figure 13.1 The pET21a plasmid. a The plasmid contains the cloning region (black arrow), two origins of 
replication from F1 phage and pBR322 and two genes; LacI, the coding sequence for the lactose operator 
protein and Ap, the coding sequence for β-lactamase providing ampicillin resistance. b Sequence of the cloning 
region of pET21a vector. The region contains a T7 promoter sequence followed by a lac operator sequence, 
ribosome binding site and multiple cloning sites.  
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(a) Plasmid map of pETBlue-1 
 
 
(b) Sequence of the cloning region of pETBlue-1 vector 
 
   T7 Promoter   .      lac operator    .      XbaI 
-----------------------------------------------------------------------------------------------------------------------------------------                               -----------------------------------------------------------------------------------------------------------------------------------------------------------------------                                 ------------------------------------------------- 
taatacgactcactataggggaattgtgagcggataacaattcccctctagacttacaatttccattcgccattcaggctgcgcaactgttggg
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
                                                                        lacZ gene 
      
 
aagggcgatcggtacgggcctcttcgctattacgccagcttgcgaacggtgggtgcgctgcaaggcgattaagttgggtaacgccaggattctc
 
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 
                                   BglII        NheI                           rbs       EcoRV 
                                                                                                                                                                                                                                                                                -----------------------------------------------                                                 -----------------------------------------------                                                                                                                                                                                                  ---------------------------------------------                                         ------------------------------------------------   ------
ccagtcacgacgttgtaaaacgacggccagcgagagatcttgattggctagcagaataattttgtttaactttaagaaggagatatagatatcg
 
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 
EcoRI    AvaI 
----------------------------------------                         ---------------------------------------------- 
aattcctgcccgggcgttgtaatcatagtcataatcaatactcctgactgcgttagcaatttaactgtgataaactaccgcattaaagctattc
 
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                            lacZ gene 
 
 
gatgataagctgtcaaacatgataattcttgaagacgaaagggc 
 
----------------------------------------------------------------------------------------------------------------------------------------------------------------                                                                                ----------------------------------------- 
    lacZ gene                  rbs 
 
Figure 13.2 The pETBlue-1 plasmid. a The plasmid contains the cloning region inside a copy of the lacZ gene 
(black arrow), two origins of replication from F1 phage and pBR322 and the coding sequence for β-lactamase 
providing ampicillin resistance. b. The cloning region contains a T7 promoter sequence followed by a lac 
operator sequence, ribosome binding site and EcoRV restriction site for blunt end cloning. 
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Figure 13.3 Regulating protein expression in the pET expression system. Expression hosts are all DE3 lysogen 
strains possessing a copy of T7 prophage DNA which contains the T7 polymerase gene downstream to a lac 
promoter site and lac operator binding site. They also contain a copy of the LacI gene which encodes for the lac 
repressor protein. Under normal conditions the absence of lactose allows the lac repressor to bind the lac 
operator sequence preventing expression of the T7 polymerase. When IPTG (a non-hydrolysable lactose analog) 
is added it binds to the lac repressor preventing it binding the operator sequence and allowing the transcription 
of the T7 polymerase gene. Target genes are inserted into pET vectors downstream to a T7 promoter and lac 
operator site. Once translated the T7 polymerase is able to transcribe a target gene inside a pET vector leading to 
its expression. The plasmid pET21a contains an additional copy of the lac repressor gene to ensure there is no 
basal expression without the addition of IPTG, pETBlue-1 does not contain a copy of the gene and must 
therefore be used with strains that contain an additional copy of the gene encoded on a plasmid such as pLacI 
strains. 
combine with the ω-peptide of LacZ produced by expression from the genome resulting in a 
functional copy β-galactosidase and a blue colony. White colonies contain plasmids with an 
insertion preventing the expression of the α-peptide and therefore β-galactosidase activity. 
The plasmid, pETBlue-1 does not contain a copy of the LacI gene and therefore must be used 
in conjunction with expression strains that have a copy of this gene for protein expression 
such as the pLacI strains that contain a plasmid with the gene maintained by a 
chloramphenicol resistance marker. 
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13.1.5 pET expression hosts 
Expression hosts in the pET expression system are all DE3 strains containing a copy of T7 
RNA polymerase gene and the lacI gene within their chromosomal DNA. Expression of the 
polymerase is under lacUV5 control and is induced by the addition of IPTG to a bacterial 
culture. Once the polymerase is expressed it can transcribe the plasmid DNA into mRNA 
which can then be translated, leading to production of large amounts of the target protein 
(figure 13.3). 
13.2 Cloning into pET21a and pETBlue-1 plasmids 
13.2.1 Primer design 
Primers were designed for target genes using the genome sequence of the B. pseudomallei 
K96243 strain, as strain D286 which was used for PCR amplification has not been sequenced. 
All primers were checked to ensure both primers of each pair had a similar melting point. It 
was also checked that no problems would arise from self-complementarity or secondary 
structure formation using oligocalc [194] and in silico PCR was performed to ensure only one 
section of genomic DNA would be amplified [195]. Primers for pET21a were all between 28 
and 29 nucleotides in length and contained a 6 to 8 nucleotide sequence upstream of the 
restriction site to allow the restriction enzymes to cleave the PCR product efficiently. 
Forward primers were designed to contain an NdeI (CATATG) restriction site followed by 14 
to 17 nucleotides of genomic DNA starting with the second amino acid encoding codon of the 
gene (NdeI restriction site contains a start codon). Reverse primers contained either a BamHI 
(GGATCC) or EcoRI (GAATTC) restriction site, depending on the presence of either site in 
the gene sequence which was checked using NEBCutter [196], followed by 14 to 17 
nucleotides of genomic DNA from downstream of the gene. Forward primers for pETBlue-1 
cloning were designed to incorporate genomic DNA starting from the start codon of the gene 
while reverse primers contained genomic DNA from downstream of the gene. 
13.2.2 Polymerase chain reaction amplification 
Target genes were amplified from Burkholderia pseudomallei strain D286 genomic DNA by 
PCR. Reactions of a total volume of 25 µl were set up for each condition containing 1 µl 
genomic DNA (provided by Professor Rahmah Mohamed, University Kebangsaan, 
Malaysia), 10 pmol of forward and reverse primers, 12.5 µl BioMix Red (Bioline) and 0, 2.5 
or 5 % (v/v) DMSO. The reaction mixes were subjected to an initial denaturation at 95 ºC for 
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5 minutes before thirty cycles of denaturation at 95 ºC for 30 seconds, annealing at 58 ºC for 
30 seconds and elongation at 72 ºC for 60 seconds before a final elongation at 72 ºC for 5 
minutes. 
13.2.3 Polymerase chain reaction product purification 
PCR products were run on a 1 % (w/v) TAE agarose gel containing GelRed at 100 V for 45 
minutes to allow separation of DNA. Bands were visualised on a UV light box and those of 
the correct length were removed from the gel using a scalpel. DNA was extracted from the 
gel using a QiaQuick® Gel Extraction Kit (Qiagen) and the standard protocol. All 
centrifugation was done at 17,000 g in a benchtop centrifuge for 60 seconds. Gel slices were 
weighed in mg and the weight was taken to be equivalent to 1 gel volume in µl. The pieces 
were first suspended in 3 volumes of buffer QG and incubated at 50 ºC for 10 minutes. Once 
the gel pieces had dissolved 1 volume of isopropanol was added to the mixture before it was 
applied to a QIAquick® column. The column was centrifuged and the flow-through was 
discarded before adding 500 µl buffer QG, centrifuging and again discarding the flow-
through. A further wash was carried out using 750 µl buffer PE, centrifuging, discarding the 
flow-through and again centrifuging to ensure all ethanol had been removed from the column. 
The column was then transferred to a clean microcentrifuge tube and the DNA was eluted by 
adding 65 µl water, incubating at room temperature for 2 minutes, and centrifuging. Yields 
varied between 20 and 50 ng µl-1. 
13.2.4 Vector production for pET21a cloning 
A colony of DH5α Escherichia coli cells containing plasmid vector pET21a growing on LB 
agar containing 100 µg ml-1 carbenicillin was picked into 3 ml LB medium containing 100 µg 
ml-1 ampicillin and grown overnight at 37 ºC at 200 rpm. Cells were then harvested by 
centrifugation at 5,000 g for 20 minutes before the plasmids were extracted using a QIAprep 
Spin MiniPrep Kit (Qiagen) and the standard protocol. Cell pellets were resuspended in 250 
µl buffer P1; this buffer contains RNase to degrade any RNA preventing it contaminating the 
purified plasmid. The cells were then subjected to alkaline lysis by the addition of 250 µl 
buffer P2 and mixing by gentle inversion. The solution was neutralised and the salt 
concentration adjusted to allow binding to a QIAprep spin column by the addition of 350 µl 
buffer N3. DNA adsorbs to the silica membrane of the spin column in the presence of high 
concentrations of chaotropic salts at pH below 7.5. The lysate is then cleared of cell debris by 
centrifugation at 17,000 g for 10 minutes in a benchtop centrifuge. All subsequent 
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centrifugation was done at 17,000 g for 60 seconds. The supernatant was applied to a 
QIAprep spin column, centrifuged and the flow-through discarded. A wash was carried out 
using 750 µl buffer PE, which contains ethanol to precipitate the DNA on the column while 
removing the salts. The column was centrifuged, the flow-through discarded and the column 
was again centrifuged to ensure all ethanol had been removed from the column. The column 
was then transferred to a clean microcentrifuge tube and the DNA was eluted by adding 65 µl 
of water, incubating at room temperature for 2 minutes and finally centrifuging to collect the 
pure plasmid DNA. Yields from minipreps typically vary between 10 and 100 ng µl-1. 
13.2.5 Restriction digestion, ligation and transformation for pET21a cloning 
Reactions were set up containing 65 µl purified vector or insert DNA, 40 Units NdeI (NEB) 
and 40 Units BamHI (NEB) or EcoRI (NEB) in 1 x NEB buffer 3 (NEB). Reactions were 
incubated at 37 ºC for 6 hours before increasing the temperature to 65 ºC for 30 minutes to 
denature the restriction enzymes. Digested vector DNA was purified by gel extraction using a 
QiaQuick® Gel Extraction Kit (Qiagen) and the protocol as described previously. Digested 
PCR products were recovered using a QiaQuick® PCR clean up Kit (Qiagen). All 
centrifugation was done at 17,000 g for 60 seconds. Reaction mixtures were mixed with 5 
volumes buffer PB and applied to a QIAprep spin column, centrifuged and the flow-through 
discarded. 750 µl buffer PE were added to the column which was centrifuged, the flow-
through discarded and the column was again centrifuged to ensure all ethanol had been 
removed from the column. The column was then transferred to a clean microcentrifuge tube 
and the DNA was eluted by adding 65 µl of water, incubating at room temperature for 2 
minutes and finally centrifuging to collect the pure digested plasmid DNA. Ligation reactions 
were set up containing 20 units T4 DNA ligae (NEB), 50 ng digested vector and a 3 x molar 
excess of digested insert in 1 x NEB ligation buffer (NEB) and were incubated at 16 ºC 
overnight. Ligation reactions were then used to transform DH5α E. coli cells. Eppendorf 
tubes containing 50 µl aliquots of competent cells were removed from the -80 ºC freezer and 
incubated on ice for 5 minutes. Once defrosted 5 µl of the ligation reaction was added before 
being left to incubate on ice for 30 minutes. The cells were subjected to a heat shock at 42 ºC 
for 30 seconds before being returned to ice for 2 minutes. 500 µl of SOC media was then 
added and the cells were then incubated at 37 ºC at 200 rpm for 60 minutes before plating on 
LB agar containing 100 µg ml-1 carbenicillin to select for transformants. 
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13.2.6 Ligation and transformation for pETBlue-1 cloning   
Ligation reactions were set up containing 2 µl purified PCR product (approximately 50 ng) 
and 50 ng AccepTor vector in ClonablesTM ligation premix buffer (Novagen) and were 
incubated at 16 ºC for 30 minutes. Ligation reactions were then used to transform Novablue 
E. coli cells. Eppendorf tubes containing 50 µl aliquots of cells were removed from the -80 ºC 
freezer and incubated on ice for 5 minutes. Once defrosted 1 µl of the ligation reaction was 
added before being left to incubate on ice for 5 minutes. The cells were subjected to a heat 
shock at 42 ºC for 30 seconds before being returned to ice for 2 minutes. 250 µl of SOC 
media was then added and the cells were then incubated at 37 ºC at 200 rpm for 60 minutes 
before plating on LB agar containing 100 µg ml-1 carbenicillin, 15 µg ml-1 tetracycline, 70 µg 
ml-1 X-gal and 80 µM IPTG for selection and blue-white screening of colonies to select for 
transformants producing white colonies containing an insert in the vector. 
13.2.7 Confirmation of cloning results 
For both pET21a and pETBlue-1 cloning, colonies were picked into 100 µl water and boiled 
at 100 ºC for 10 minutes. Cell debris was removed by centrifugation at 17,000 g for 5 
minutes. Reactions of a total volume of 10 µl were set up for each condition containing 1 µl 
of cell extract, 5 µl BioMix Red (Bioline) and 5 pmol of each of a pair of relevant primers. To 
confirm results from pET21a cloning a single reaction using T7F 
(TAATACGACTCACTATAGGG) and T7R (GCTAGTTATTGCTCAGCGG) primers was 
conducted for each colony. Results from pETBlue-1 cloning were confirmed using a pair of 
reactions for each colony using either bpsl1497F and pETBlueDOWN or pETBlueUP and 
bpsl1497R primers. The reaction mixes were subjected to an initial denaturation at 95 ºC for 
1 minute before thirty cycles of denaturation at 95 ºC for 30 seconds, annealing at 58 ºC for 
30 seconds and elongation at 72 ºC for 60 seconds before a final elongation at 72 ºC for 5 
minutes. PCR products were analysed by electrophoresis on a 1 % (w/v) TAE agarose. 
colonies producing the correct sized band(s) were picked into 3 ml LB containing 100 µg ml-1 
ampicillin and grown overnight at 37 ºC at 200 rpm. The cells were harvested and plasmids 
were purified using a QIAprep Spin MiniPrep Kit (Qiagen) and the same protocol as before. 
Purified plasmids were sent for sequencing using T7F and T7R primers (SourceBioscience or 
Geneservice). 
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13.2.8 Site directed mutagenesis 
Mutations were created in genes using a QuikChange site-directed mutagenesis kit 
(Stratagene). The strategy involves a PCR amplification of a template plasmid containing the 
gene of interest using mutagenic primers before a DpnI restriction digest and transformation 
into competent cells. Template plasmid DNA must come from a dam+ strain of bacteria to 
ensure it is methylated as DpnI is a restriction enzyme that is specific for methylated DNA. 
Therefore the template DNA will be digested leaving behind the newly synthesised mutated 
plasmids. Primers were designed to be between 24 and 45 base pairs in length with the 
desired mutation roughly in the centre and a melting temperature above 78 ºC with a GC 
content above 40 % and terminating in a C or G base. PCR reactions of a total volume of 25 
µl were set up for each mutation containing 5 ng template DNA, 75 ng of forward and 
reverse primers, 0.5 µl dNTP mix and 0.5 µl (1.25 U) PfuTurbo DNA polymerase in reaction 
buffer. The reaction mixes were subjected to an initial denaturation at 95 ºC for 5 minutes 
before eighteen cycles of denaturation at 95 ºC for 30 seconds, annealing at 55 ºC for 30 
seconds and elongation at 68 ºC for 10 minutes before a final elongation at 68 ºC for 10 
minutes. 5 µl of the PCR was taken for analysis by agarose gel electrophoresis, 0.5 µl (5 U) 
DpnI was added to the remaining 20 µl and it was incubated at 37 ºC for 2 hours. 5 µl of the 
DpnI digest was taken for analysis by agarose gel electrophoresis and 5 µl was taken for 
transformation into XL1-Blue competent cells using the same protocol as for DH5α cells. 
Transformants were selected by plating on LB agar containing 100 µg ml-1 ampicillin and 
grown overnight at 37 ºC before being picked into LB containing 100 µg ml-1 ampicillin and 
grown again overnight at 37 ºC at 200 rpm. The plasmids were recovered using a QIAprep 
Spin MiniPrep Kit (QIAGEN) and the same protocol as before. Purified plasmids were sent 
for sequencing using T7F and T7R primers (SourceBioscience or Geneservice) to confirm the 
mutations had been achieved. 
13.3 Protein overexpression 
13.3.1 Transformation 
Plasmids, containing the correct inserts, were transformed into BL21 (DE3), Tuner (DE3) or 
Tuner (DE3) pLacI competent Escherichia coli cells (Novagen) for overexpression. 
Eppendorf tubes containing 20 µl aliquots of cells were removed from the -80 ºC freezer and 
incubated on ice for 5 minutes. Once defrosted 1 µl of plasmid DNA (approximately 10 ng 
µl-1) was added and the reaction was left to incubate on ice for 15 minutes. The cells were 
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subjected to a heat shock at 42 ºC for 30 seconds before being returned to ice for 2 minutes. 
500 µl of SOC media was then added and the cells were incubated at 37 ºC at 200 rpm for 30 
minutes before plating on LB agar containing 100 µg ml-1 carbenicillin for BL21 (DE3) and 
Tuner (DE3) cells or 100 µg ml-1 carbenicillin and 35 µg ml-1 chloramphenicol for Tuner 
(DE3) pLacI cells  to select for successful transformants. 
13.3.2 Small-scale overexpression trials 
An initial overnight culture grown in LB containing 50 µg ml-1 ampicillin for BL21 (DE3) 
and Tuner (DE3) cells or 50 µg ml-1 ampicillin and 35 µg ml-1 chloramphenicol for Tuner 
(DE3) pLacI cells was used to provide a 2 % (v/v) inoculation of 500 ml LB containing 50 µg 
ml-1 ampicillin for BL21 (DE3) and Tuner (DE3) cells or 50 µg ml-1 ampicillin and 35 µg ml-
1
 chloramphenicol for Tuner (DE3) pLacI cells. The cultures were grown at 37 ºC and 200 
rpm until the optical density at 600 nm reached 0.8 at which point the culture was split into 
50 ml aliquots in 250 ml conical flasks. Each individual culture was induced by the addition 
of IPTG and subjected to a different post-induction environment. Conditions tested to provide 
a soluble overexpressed protein were temperature (4 – 37 ºC), time (1 – 30 hours) and IPTG 
concentration (0.1 – 1 mM). Prior to induction and throughout the trials 1.5 ml samples were 
taken and the cells were pelleted by centrifugation at 17,000 g for 5 minutes in a bench top 
centrifuge. Samples were stored at -20 ºC before cell lysis using BugBuster® (Novagen) and 
PAGE analysis. Cell pellets were resuspended in 100 µl BugBuster® A with the addition of 1 
µl BugBuster® B and incubated at room temperature for 15 minutes. Cell debris and insoluble 
protein were removed by centrifugation at 17,000 g for 10 minutes and the supernatant was 
taken as the soluble fraction. The pellet was resuspended in 100 µl 4 % (w/v) SDS and 
incubated at room temperature for 15 minutes. The sample was centrifuged at 17,000 g for 10 
minutes and the supernatant was taken as the insoluble fraction. The overexpression was then 
analysed by running fractions from the various conditions on a suitable polyacrylamide gel to 
determine the optimum post-induction conditions. 
13.3.3 Large scale overexpression 
Once successful conditions had been found for each target the growth was scaled up to 
between 2 and 4 l of media in 500 ml aliquots in 2 l conical flasks. Following overexpression 
cells were harvested by centrifugation at 5,000 g for 45 minutes before resuspension in 
approximately 100 ml LB. The cells were split between 50 ml Falcon tubes and repelleted by 
196 
 
centrifugation at 5,000 g for 30 minutes. The supernatant was discarded and the cell pellets 
were stored at -20 ºC until required. 
13.3.4 Production of seleno-L-methionine incorporated proteins 
An initial overnight culture grown in LB containing 50 µg ml-1 ampicillin was used to 
provide a 2 % (v/v) inoculation of 2.5 l LB containing 50 µg ml-1 ampicillin in 500 ml 
aliquots within 2 l conical flasks. Cultures were grown at 37 ºC and 200 rpm until the optical 
density at 600 nm reached 0.6 at which point the cells were harvested by centrifugation at 
5,000 g for 45 minutes before resuspension in approximately 100 ml minimal media. 
Minimum medium contains K2HPO4 10.5 g l-1, (NH4)2SO4 1 g l-1, KH2PO4 4.5 g l-1, 
Na3C6H5O7·2H2O  500 mg l-1, Glycerol 5.0 g l-1, Adenine 500 mg l-1, Guanosine 500 mg l-1, 
Thymine 500 mg l-1, Uracil 500 mg l-1, MgSO4·7H2O 1.0 g l-1, Thiamine 4 g l-1, L-lysine 100 
mg l-1, L-phenylalanine 100 mg l-1, L-threonine 100 mg l-1, L-isoleucine 50 mg l-1, L-leucine 
50 mg l-1 and L-valine 50 mg l-1. The cells were repelleted by centrifugation at 5,000 g for 30 
minutes before being resuspended in 2.5 l minimal medium containing 40 mg l-1 seleno-L-
methionine and split between five 2 l conical flasks. The cells were incubated at 37 ºC and 
200 rpm until the optical density at 600 nm reached 0.8 at which point the cells were induced 
with IPTG under the same conditions as for native protein production but with the time of 
overexpression doubled to allow for the slower production of protein. Following 
overexpression the cells were harvested and stored as for native proteins. 
13.4 Protein purification techniques 
X-ray crystallography requires large amounts of pure (preferably greater than 95%), 
homogeneous (not suffering from degradation), concentrated (typically between 5 and 30 mg 
ml-1) protein. In order to obtain a suitable purity a number of techniques can be used to 
separate the protein of interest from contaminating proteins and molecules. The theory behind 
the purification techniques used in this thesis is described here with the details for each 
individual target found in the relevant results section. 
13.4.1 Cell disruption 
For all targets the first step in the purification was to lyse the cells containing the desired 
protein. This was achieved by the process of sonication which employs the use of high 
frequency sonic pulses to break down the bacterial cell walls and membranes. Cell pellets 
were removed from the freezer, defrosted and resuspended in an appropriate buffer before 
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homogenization by sonication using three 16 micron pulses of 20 seconds on, 20 seconds off. 
The crude cell extract was cleared of cell debris and insoluble protein by centrifugation at 
70,000 g for 15 minutes before purification. 
13.4.2 Ion exchange chromatography 
The net surface charge of a protein can be used to separate it from a mixture by using its 
relative affinity for charged groups displayed on the surface of beads. The surface charge of a 
protein is dependent upon the amino acids present on its surface and the pH of its 
environment. If the pH of a solution is at the isoelectric point (pI) of a protein there is no 
overall charge on its surface. At a pH below the pI of a protein the net surface charge will be 
positive and at a pH above the pI of a protein the net surface charge will be negative. Ion 
exchange chromatography can be split into two main types; cation exchange chromatography 
uses negatively charged functional groups to bind positively charged cations while anion 
exchange chromatography uses positively charged functional groups to bind negatively 
charged anions. Protein solutions are loaded onto a column in a low molarity buffer allowing 
oppositely charged proteins to adsorb to the beads. The ionic strength of the buffer is then 
increased by the addition of sodium chloride which competes for the charged groups causing 
proteins to desorb and elute from the column with the more highly charged proteins eluting 
later than those with a lesser charge (figure 14.4). DEAE sepharose is an example of anion 
exchange chromatography and consists of a matrix of cross-linked sepharose forming beads 
with DEAE exposed on its surface. This technique is used as an initial purification step for all 
the target proteins in this thesis. 
13.4.3 Ammonium sulphate cut 
The solubility of a protein is a function of its concentration, and the pH and ionic strength of 
the solution of its environment. The surface of a protein contains hydrophobic patches caused 
by the presence of exposed hydrophobic residues. The addition of anti-chaotropic salts, such 
as ammonium sulphate, to a solution will cause a protein to precipitate once a threshold 
concentration is reached as water is removed from the cages around these patches which can 
then associate with each other. Using this technique a protein can be purified by first 
precipitating contaminants that drop out of solution at a lower salt concentration threshold 
which can be removed by centrifugation. The supernatant can then be taken and the salt 
concentration further increased to above the threshold for the target protein. This can then be 
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Figure 13.4 Anion exchange chromatography. Schematic representation of the separation of three proteins from 
a mixture displaying different charge properties. Protein A (light green) is the least negatively charged, protein 
B (intermediate green) is more negatively charged and protein C (dark green) is the most negatively charged that 
interacts with the beads. In the sample there are also other contaminants that are even less negatively charged 
and do not bind the column (grey). Traces show conductivity to follow salt concentration (blue) and UV 
absorption to follow protein elution (grey (for equilibration and sample application), light green (for protein A), 
intermediate green (for protein B), and dark green (for protein C)). First the column is equilibrated in a low salt 
buffer (1) before the sample is applied (2). Once this has run through the column a gradient of increasing salt 
concentration is applied (3-5) causing proteins to elute once a threshold level is reached. Finally the column is 
washed with a high salt buffer to remove any strongly bound contaminants (6). Figure adapted from GE 
Healthcare manual: Ion exchange chromatography and chromatofocusing, principles and methods. 
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Figure 13.5 Hydrophobic chromatography. Schematic representation of the separation of three proteins from a 
mixture displaying different hydrophobicity properties. Protein A (green) is the least hydrophobic, Protein B 
(yellow) is of intermediate hydrophobicity and protein C (orange) is the most hydrophobic. In the sample there 
are also other contaminants that are even less hydrophobic and do not bind the column (blue). Traces show 
conductivity to follow salt concentration (red) and UV absorption to follow protein elution (blue (for 
equilibration and sample application), green (for protein A), yellow (for protein B), and orange (for protein C)). 
First the column is equilibrated in a high salt buffer (1) before the sample is applied (2). Once this has run 
through the column a gradient of decreasing salt concentration is applied (3-5) causing proteins to elute once a 
threshold level is reached. Finally the column is washed with water to remove any strongly bound contaminants 
(6). Figure adapted from GE Healthcare manual: Hydrophobic interaction and reversed phase chromatography, 
principles and methods. 
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pelleted by centrifugation and the pellet resuspended in a low molarity buffer leaving further 
contaminants in the supernatant. 
13.4.4 Hydrophobic chromatography 
Differences is surface hydrophobicity can be exploited to separate a mixture of proteins by 
using their relative affinity for hydrophobic groups. The presence of anti-chaotropic salts 
allow hydrophobic patches on the surface of a protein to interact with hydrophobic groups 
attached to a matrix by competing for solvation. Protein samples are loaded onto a column in 
a high molarity buffer allowing hydrophobic patches on proteins surfaces to interact with 
hydrophobic groups on the beads resulting in adsorption. The molarity of the buffer is then 
decreased causing proteins to desorb and elute from the column with the more hydrophobic 
proteins eluting last (figure 14.5). Phenyl toyopearl is an example of hydrophobic 
chromatography and consists of a matrix of cross-linked toyopearl forming beads with phenyl 
groups exposed on its surface. 
13.4.5 Size exclusion chromatography 
Gel filtration is a technique that separates a mixture of proteins based on their size and shape 
by passing them through a column filled with porous beads. The volume inside the column is 
in two parts, the excluded volume outside the beads, and included volume inside the beads. 
Molecules larger than the pores are unable to enter the beads and can therefore only occupy 
the excluded volume whereas molecules that are small enough to enter the beads are able to 
occupy both the included and excluded volumes. Therefore larger molecules will elute first 
from the column, and as the size of a molecule decreases it can enter a larger proportion of 
the beads, retarding its progress down the column and causing it to elute later, until finally 
proteins that can enter all beads elute last (figure 14.6). Assuming a protein is globular there 
is a linear relationship between the elution volume of a particular molecule from a given 
column and the logarithmic value of its molecular weight based on its partition coefficent 
(equation 13.1).  
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Therefore gel filtration can also be used to estimate the molecular weight of a protein by 
comparing its partition coefficient, Kav, to a calibration curve of partition coefficient plotted 
against the log of molecular weight for a particular gel filtration column determining its 
oligomeric state. In this thesis two separate gel filtration columns were used, a 120 ml 
Superose 6 column (figure 13.7a) and a 120 ml Superdex 200 column (figure 13.7b) 
 
 
 
Figure 13.6 Size exclusion chromatography. The diagram shows the separation of three proteins of different 
sizes, including the ability of them to enter beads due to size and an elution profile. The large protein (red) is 
unable to enter any beads and elutes first in the excluded volume. The small protein (yellow) is able to enter all 
the beads and elutes at the end of the total volume. The intermediate protein (orange) is able to enter some but 
not all beads and elutes between the large and small proteins. Figure adapted from GE Healthcare manual: Gel 
filtration, principles and methods. 
 
13.4.6 Protein concentration 
Concentrated protein solutions are required for use in crystallographic studies and throughout 
the purification process it is often necessary to reduce the volume of a protein sample before 
application to a column. Concentration was performed using Vivaspin sample concentrators 
(GE Healthcare) which consist of two chambers separated by a polyethersulfone membrane 
containing pores of a controlled size. Concentration is achieved by forcing a solution through 
the membrane by centrifugation, allowing solvent and small molecules to pass through, 
leaving larger molecules trapped above the membrane.  Concentrators were also used for 
exchanging buffers prior to crystallisation trials by a series of concentrations and dilutions 
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with the desired buffer. Vivaspin concentrators are available in a range of sizes to deal with 
volumes between 20 ml and 50 µl and molecular weight cut offs from 100,000 to 3,000 Da. 
  
       
 
Figure 13.7 Calibration curves for the gel filtration columns used in this study. 
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14.0 Crystallisation to structure determination 
The section includes a discussion of the theory behind techniques used in this thesis. It also 
describes in detail the laboratory techniques used to crystallise and solve the structures for 
target proteins from Burkholderia pseudomallei.  
14.1 Crystals, space-groups and symmetry 
Crystals are orderly arrays of individual molecules packed together to form a repeating 
lattice. In protein crystals, the molecules are held together by non-covalent interactions. 
These typically consist mainly of hydrogen bonding networks, involving the protein residues 
and ordered water molecules inside the crystal, and some ionic interfaces between protein 
residues and charged buffer components. Each identical repeating unit can contain multiple 
copies of the protein and is termed a unit cell. They consist of a volume defined by three 
lengths, a, b and c, and three angles, α, β and γ. The arrangement of unit cells within the 
crystal and any internal symmetry within the unit cell can be described in terms of the 
crystals space-group. There are a total of 230 possible space-groups for simple non-chiral 
molecules created using combinations of rotational, translational, inversion and reflectional 
symmetry operators. The chiral nature of protein molecules limits the functions that can be 
used to create symmetry elements to rotations and translations leaving 65 possible space-
groups found in protein crystals. The space-group is defined by its lattice type, providing the 
arrangement of lattice points in three dimensions, and crystal system which determines 
symmetry operators inside the unit cell. There are 14 Bravais lattice types made up of the 7 
crystal systems (triclinic, monoclinic, orthorhombic, tetragonal, trignal, hexagonal and cubic) 
determined by the unit cell lengths and angles, coupled with the five lattice centering 
operations (primitive, centred, face centred, internal and rhomohedral). There are only four 
possible rotational symmetries allowed in three dimensions, producing 2-fold (180º), 3-fold 
(120º), 4-fold (90º) and 6-fold (60º) related molecules, as three dimensional space is limited 
to these packing constraints. There are a further eleven possible screw axes, where rotational 
symmetry is coupled with a translation along the rotation axis. These symmetry elements are 
represented by the numbers following the letter denoting lattice type, with each axis with a 
symmetry element greater than 1 listed in order. The four rotational symmetries are 
designated 2, 3, 4 and 6 with the possible screw axes of 21, 31, 32, 41, 42, 43, 61, 62, 63, 64, and 
65. The asymmetric unit (ASU) is the smallest unit within the crystal that contains all the 
information, that when coupled with the symmetry operations defined as part of the space 
group, is able to reproduce the entire crystal lattice structure. A unit cell may also contain 
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additional symmetry elements that are not defined by the space group. Non-crystallographic 
symmetry arises when there are additional symmetry operators present between molecules in 
the ASU that are not aligned with the other operators of the unit cell.  
14.2 Producing protein crystals 
Small molecules are relatively easy to crystallise, however, obtaining protein crystals is a 
complex and time consuming process. The difficulty in forming protein crystals is due to 
their size, complexity, surface mobility, complex electrostatic nature and the chemical and 
physical stability of protein molecules. The process requires the use of chemical precipitants, 
these are molecules that are good at driving the precipitation of proteins without denaturing 
them. Common precipitants include salts, high molecular weight straight chain polymers 
(such as PEGs) and organic solvents. The wide range of protein characteristics make it 
impossible to predict suitable conditions for any given protein therefore requiring screening 
of a large array of possible conditions. There are many variables for crystallisation trials 
including some commonly changed parameters, such as the components, their concentration 
and the overall pH of the crystallisation solution, alongside the protein concentration and 
temperature of crystallisation experiment. There are also other factors that are harder to 
control, such as vibration and sound, convection rates, protein sample age and consistency 
with previously used samples, and general cleanliness of equipment. 
 
The process of protein crystallisation is a phase transition phenomenon which can be 
represented by a phase diagram (figure 14.1). The experiment is initially set up with a protein 
in an aqueous solution alongside other precipitant molecules at concentrations unable to drive 
protein precipitation. As the experiment progresses, protein and precipitant concentrations 
increase as water is lost, typically through evaporation or dialysis, ultimately pushing the 
protein out of solution as either ordered crystals or amorphous precipitant. The first stage in 
crystal growth is achieved once concentrations reach the nucleation phase during which small 
clusters of precipitated protein form reducing the overall concentrations. Crystal growth then 
occurs spontaneously once the concentration of protein and precipitants are at the reduced 
supersaturated level that allows the protein to precipitate at a rate which allows individual 
protein molecules to aggregate together in an orderly manner. In the ideal situation the 
protein solution will reach the nucleation stage and then quickly enter the growth stage 
preventing further nucleation leading to a smaller number of larger crystals. Crystal growth 
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Figure 14.1 Protein crystallisation phase diagram. The blue zone represents an unsaturated solution where 
crystallisation will never occur. The three red zones represent increasingly unstable supersaturated solutions 
with deepening shade, where protein molecules can be spontaneously driven out of solution. 
Sitting drop                                                        Hanging drop 
                                        
 
Figure 14.2 Vapour diffusion crystallisation techniques. In the sitting drop technique, as used for initial robot 
screening, the drop containing a mixture of protein and precipitant solutions is placed in a small well on a shelf 
above a well containing a large volume of precipitant solution before the system is sealed by the addition of 
clear tape. In the hanging drop technique, as used for optimisation screening, the drop containing a mixture of 
protein and precipitant solutions is suspended on the underside of a siliconised coverslip which is placed on top 
of a well containing a large volume of precipitant solution with vacuum grease providing an airtight seal to the 
system.   
Pr
o
te
in
 
co
n
ce
n
tr
a
tio
n
Precipitant concentration
Protein crystallisation phase diagram
Amorphous precipitation Nucleation Growth Unsaturated
Nucleation 
Growth 
Tape 
Protein and precipitant drop  
Vacuum grease 
Precipitant reservoir  
Coverslip 
206 
 
ceases once either the concentration of protein is no longer supersaturated or the growing 
crystal faces are poisoned effectively ending the ordered array. Poisoning can occur by a 
protein molecule being added in the incorrect orientation, the addition of a damaged protein 
molecule or the incorporation of a different molecule. 
14.2.1 Vapour diffusion 
The most commonly used method and the one used in this thesis for the production of protein 
crystals is vapour diffusion. The method involves creating a drop of protein solution with a 
precipitant concentration lower than that of a reservoir in a sealed system. Evaporation can 
then occur allowing diffusion of water between the drop containing the protein and the large 
reservoir of precipitant solution increasing the concentration of protein and precipitant in the 
drop until equilibrium is reached. There are two main methods of setting up vapour diffusion 
experiments, using either a hanging drop or a sitting drop technique (figure 14.2). 
14.2.2 Robot screens 
Initial screens to find conditions that yield crystals were conducted using a Matrix Hydra II 
PlusOne robot (Thermo Scientific). This allowed a large number of conditions to be tested 
quickly using relatively small volumes of purified protein solution. Screens containing 96 
different conditions (Qiagen) were put down in sitting drop plates. Details of the screens 
conducted for each target can be found in the relevant results section. 
14.2.3 Optimisation 
The parameters of the initial crystallisation hit can be manipulated in an attempt to produce 
larger better quality crystals. Parameters of the experiment that can be changed include 
protein concentration, precipitant concentration, size of drops, ratio of precipitant to protein 
solution in drops, pH, temperature and addition of additives etc. Optimisation experiments 
were conducted by hand using the hanging drop technique. Again details for individual 
targets can be found in the relevant sections. 
14.3 Principles of diffraction 
Diffraction of electromagnetic radiation is dependent upon both the size of the object and the 
wavelength of the radiation. In order for diffraction to occur the wavelength of the light must 
be smaller than the distance between the objects one wishes to resolve. As the aim of X-ray 
crystallography is to produce an atomic model of a proteins structure, electromagnetic 
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radiation corresponding to inter-atomic distances, typically between 1.5 and 3.5 Å, must be 
used. Electromagnetic radiation of this type falls within the X-ray range, 0.1 – 100 Å, of 
wavelengths. 
14.3.1 Diffraction from crystals 
The internal symmetry and repeating nature of crystals leads to the production of distinct 
patterns of spots in a diffraction image. The unit cell of a crystal can be divided up by planes 
that cut across the unit cell axes defined by Miller indices. These have three components, h, 
k, l and determine the number of times the planes intersect the unit cell axes a, b and c 
respectively. Bragg’s law (equation 14.1) describes the conditions under which a set of these 
planes inside a crystal produce a reflection in the diffraction image (figure 14.3). 
 
2
 =  (equation 14.1) 
 
The law states that when the angle of incidence, , has the properties that the difference in 
distance travelled by X-rays diffracting from successive planes of given spacing, 
, is 
equal to an integral number of the X-rays wavelength, , the diffracted X-rays will be in 
phase and interfere constructively producing a spot, or reflection, in the diffraction image. 
Under conditions that do not satisfy Bragg’s law, diffracted X-rays are not in phase with each 
other and therefore cancel each other out by destructive interference. 
 
 
Figure 14.3 Schematic representation of Bragg’s law. 
θ 
dhkl 
dhkl sin θ 
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14.3.2 Mosaicity 
The mosaicity of a crystal is a measure of the misalignment between domains containing 
several unit cells in the crystal. The degree of mosaicity found in diffraction experiments is 
also dependent upon the X-ray beam parameters. A perfect crystal in which all the unit cells 
are perfectly aligned, positioned in a point source X-ray beam, would have a mosaicity value 
of zero and the spots in a diffraction image would be infinitesimally narrow. Crystals with a 
high degree of mosaicity, typically greater than 1.5º, are useless for data collection. The 
resultant diffraction images from a highly mosaic crystal contain smeary reflections that 
bleed into each other preventing the accurate assignment of an intensity to the reflection. 
14.3.3 Analysis of diffraction data 
The diffraction pattern can be used to determine the unit cell lengths and angles, and the 
space group, including the presence of rotational symmetry elements, and screw axes. The 
unit cell lengths are inversely proportional to the spacing between reflections in the 
diffraction pattern and can therefore be directly measured. There are in total 11 Laue groups 
that describe the symmetry found in crystal diffraction patterns. Friedel’s law states that 
because of the centrosymmetry of the reciprocal lattice, centrosymmetrically related pairs of 
structure factors, h, k, l and -h, -k, -l, possess identical amplitudes but opposite phases as they 
originate from opposite sides of the same crystal plane. Therefore all diffraction data possess 
an intrinsic symmetry (in the absence of anomalous diffraction) with further symmetry 
between reflections indicating the presence of rotational symmetry within the unit cell. Screw 
axes can be determined by the presence of systematic absences, repeating patterns along an 
edge where one term has an intensity of zero. As the hand of the screw axis is not resolved it 
is not possible to distinguish between the four enantiomorphic pairs (31 and 32, 41 and 43, 61 
and 65, 62 and 64) of screw axis as they produce an identical pattern of systematic absences. 
14.4 Data collection apparatus 
Diffraction images are collected by placing crystals in an X-ray beam and rotating them so 
that all the diffraction data can be collected, using a detector, from the different planes present 
within the crystal. 
14.4.1 X-ray sources 
In X-ray crystallography two distinct techniques are commonly used to produce X-ray 
radiation. The first method involves bombarding a rotating metal anode with electrons. 
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Electrons are released from a heated filament and accelerated towards a metal anode inside an 
electric field. These high energy electrons are capable of colliding with and displacing 
electrons in the target atoms. If an electron is displaced from a low lying orbital, an electron 
from a higher energy orbital will drop down, emitting a photon as it does. The wavelength of 
the resultant electromagnetic radiation is dependent on the metal it is emitted from, as a result 
of unique energy spacing between electron shells for different elements. For protein 
crystallography the commonest metal target is made of copper and emits two distinct energies 
of radiation. CuKα radaition is produced when electrons drop from the L to the K shell and 
has a wavelength of 1.54 Å, while CuKβ radaition is produced when electrons drop from the 
M to the K shell and has a wavelength of 1.39 Å. For crystallography a single wavelength of 
radiation is required so the CuKβ wavelength is removed by absorption by nickel or through 
the use of a monochromater. Initial crystal testing and some data collection for this thesis, 
was conducted at Sheffield, using a Rigaku MM007 copper rotating anode generator.  
 
Synchotron light sources represent the second common source of X-ray radiation used in 
protein crystallography. A synchotron consists of a particle accelerator that injects electrons 
into circular particle storage ring. Inside the ring electrons travel at close to the speed of light 
driven by radio transmitters and maintained in a circular motion by powerful magnets. 
Electrons forced to follow a curved path are constantly changing velocity and therefore emit 
radiation at a tangent to the curve. The intensity of the resultant radiation is increased by the 
presence of two forms of accessory device. Wigglers and undulators increase the intensity of 
the emitted radiation by changing the direction of the electrons multiple times over a short 
distance. Beamlines are placed tangentially around the storage ring at intervals providing X-
ray beams in which crystals can be mounted in for data collection. The principal advantages 
of synchrotron lightsources are the intensity of the radiation allowing data to be collected 
over much shorter exposure times, and the ability to select the wavelength of the X-ray beam 
therefore allowing anomalous dispersion phasing experiments to be conducted. Data 
collection for this thesis was primarily conducted at the Diamond synchrotron lightsource in 
Oxford on the I02, I03, I04 and I24 beamlines. 
14.4.2 Detectors 
Once the diffracted pattern of X-rays has been produced it must be recorded to be of any use; 
this is achieved through the use of detectors. The intensity and direction of the diffracted X-
rays can be recorded, but unfortunately the phase information is lost and must be 
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subsequently determined using other methods (section 14.10). Image plate detectors consist 
of a sheet of plastic coated in thin layer of a phosphor, typically crystals of BaFEu. X-rays are 
able to interact with the Eu2+ causing it to become excited and lose an electron producing 
Eu3+. Following exposure the image plate is read using a fine red laser (λ = 633 nm), which 
causes the transition of Eu3+ back to Eu2+ and the resultant emission of light (λ = 390 nm) 
which can be detected by a photomultiplier. Initial crystal testing and some data collection for 
this thesis, was conducted at Sheffield, using a MarResearch MAR345 image plate detector 
system. The detector systems on the beamlines at the Diamond synchrotron lightsource are 
not image plates but charged-coupled device (CCD) detectors or Pilatus detectors. CCD 
detectors consist of a phosphor screen linked to a CCD by fibre optic cables. Diffracted X-
rays strike the phosphor and are converted into photons of visible light that are directed 
towards a pixel on CCD sensor chip through the fibre optic cable. Following exposure the 
pixels are read and the data is recorded. The Pilatus system is a single photon counting pixel 
array where the incoming photons are directly measured allowing data to be collected 
continuously. The principle advantage of the Pilatus system over CCD detectors, and CCD 
detectors over image plate detectors, is the reduced read-out time, reducing the data 
collection experiment time and therefore the amount of radiation damage sustained by the 
sample. The Pilatus detector can also produce a greater signal to noise ratio by applying an 
energy threshold to the photons that are counted. 
14.5 Cryoprotection and radiation damage 
Protein crystals typically contain only 25 to 70 % protein by volume, with the remaining 
space made up from solvent filled channels running throughout the crystal. Coupled with the 
weak nature of the interactions holding the lattice together, often including water molecules 
and other buffer components, this means crystals are fragile and must be kept hydrated at all 
times. During data collection protein crystals are susceptible to damage from the X-ray 
radiation used in the experiment. This can either be direct damage from the interaction of X-
ray photons with atoms in the protein structure, or indirect damage from reactive radical 
species created following interaction of an X-ray photon with a buffer component. In order to 
reduce the effect of indirect damage, data is collected from samples kept at 100º K, 
effectively preventing the diffusion of reactive radicals through the crystal. The temperature 
is achieved by placing the crystal in a stream of gaseous nitrogen on the collection apparatus, 
flash freezing the crystal and surrounding buffer. Prior to freezing the crystal must be placed 
in a cryoprotectant solution, containing anti-freeze agents, in order to reduce the formation of 
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ice crystals. If ice crystals are present they produce a distinctive pattern of rings in the 
diffraction images, potentially obscuring reflections and can also potentially disrupts the 
crystal lattice. In order to collect the required diffraction data from a crystal it must be 
supported and rotated about an axis perpendicular to the incident X-ray beam.  
14.6 Crystal mounting 
Crystal manipulation is typically carried out using thin nylon loops, with diameters 
appropriate to the crystal size, attached to metal pins on magnetic bases that can be easily 
mounted onto the data collection apparatus. Crystals are removed from a drop by sliding the 
loop into the solution beneath the crystal and lifting with an upward movement resulting in 
the crystal being held by surface tension in a small volume of the drop solution inside the 
loop. Crystals are typically removed from the crystallisation solution to another drop, for 
soaking experiments or cryoprotection, before looping for attachment to the data collection 
apparatus and freezing in the cryostream. The magnetic base of the pin is attached to the 
goniometer, which allows the crystal to be rotated during data collection and for the precise 
alignment of the crystal in the X-ray beam. 
14.7 Data collection  
A preliminary analysis of the protein crystal properties is conducted by collecting a small 
number of diffraction images, with a small rotation, from different angles, typically two or 
three images with ϕ start angles of 0º, 45º and 90º. These images can be indexed to allow the 
space group, unit cell dimensions and mosaicity to be determined (section 14.3) and the 
overall quality of diffraction to be judged. A data collection strategy is then developed to 
allow all the required data for a complete dataset to be collected taking these factors into 
account.  
14.7.1 Data collection strategy variables 
The three main variables to decide are the degrees of data collected, the increment angle and 
the X-ray dose. The required wedge of diffraction data is determined by Friedel’s law and the 
overall symmetry of the crystal. As a result of Friedel’s law the maximum overall rotation of 
the crystal in the beam (for a non-anomalous dispersion experiment) is 180º in order to detect 
all the unique reflections. The space group of the unit cell further reduces the required angle 
based on which of the 11 Laue groups to which they belong. However it is usually 
advantageous to collect a larger dataset, to increase redundancy in the data, unless the sample 
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begins to suffer from radiation damage. The increment in the rotation angle over which 
images are recorded is decided upon based on the level of mosaicity in the crystal and the 
lengths of the unit cell axes. A crystal with a high degree of mosaicity, in which the unit cells 
are relatively poorly aligned, will produce broad reflections in the recorded diffraction 
images. The distance between reflections is inversely proportional to the unit cell axes 
lengths. Crystals with large unit cell axes therefore produce closely packed reflections and in 
order to distinguish between them the angle of rotation must be kept low. The X-ray dose a 
crystal receives for each diffraction image depends upon the strength of the beam and the 
length of exposure. A larger X-ray dose will produce a better signal to noise ratio as 
reflections get stronger and can increase the higher resolution limit of the data collected, up to 
the limit capable from a specific crystal. Unfortunately a large X-ray dose also has two 
unfavourable results reducing the completeness of the data. An increase in the amount of 
radiation damage suffered by the crystal leads to a loss of high resolution data over time, and 
reflections becoming too strong and overloading the detector can cause problems particularly 
with the stronger low resolution data. The X-ray dose must therefore be balanced between 
obtaining high resolution and completeness of the data.  
14.8 Data processing 
Once diffraction images have been collected the data must be indexed and integrated together 
to produce a complete dataset. Indexing is a process that estimates the dimensions and 
spacegroup of the unit cell by using the distances between reflections and the symmetry of 
the diffraction pattern. The solvent content of the crystal and number of molecules in the 
asymmetric unit can then be predicted based on the molecular weight of the protein and the 
unit cell dimensions and space group [197] (equation 14.2). 
 
 =   (equation 14.2) 
 
The Matthews coefficient of a crystal, , is calculated by dividing the volume of the unit 
cell, , by the molecular weight of the protein, , multiplied by the number of equivalent 
positions in the space group,	 , and the number of molecules in the ASU,	 . The  can be 
calculated for different numbers of proteins in the ASU and compared to a database 
containing values derived from other protein crystals to provide an estimate of the most likely 
number of protein molecules in the ASU. Once a complete dataset has been collected and the 
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unit cell parameters have been determined the data is integrated together to produce a file 
containing all the data found during the experiment. The dataset can then be scaled to account 
for discrepancies in the data caused by external influences and equivalent reflections are 
merged. Following scaling the quality of the data can be assessed using a number of 
measures, most importantly, the completeness of the data, the signal to noise ratio (I/σI), the 
merging R-factor (Rmerge) (equation 14.3) and the precision-indicating merging R-factor 
(Rpim) (equation 14.4). 
 
!"#" = ∑ ∑ %&.( − 〈&〉%
+(,-
∑ ∑ &.(+(,-  (equation 14.3) 
 
!./ =
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(equation 14.4) 
 
Rmerge and Rpim both provide a measure of the agreement between symmetry related 
reflections in a dataset. They differ in the application of a correction factor in Rpim that takes 
the multiplicity of the data into account. As would be expected the greater the number of 
measurements of a symmetry related reflection, the greater the discrepancy between them 
when summed together despite the increase in accuracy that comes from increased data. 
14.9 Diffraction data to electron density 
Each reflection in a diffraction image contains contributions from every atom within the unit 
cell and can be described by a structure factor (equation 14.5).  
 
5 =	67(	89/(;<=><=?<)
+
(,-
 
(equation 14.5) 
 
The structure factor, 5, is a Fourier sum of the contributions of each individual atom, j, to 
the reflection with indices, h, k, l, in the reciprocal lattice. The term, 7(, provides the 
scattering factor of the atom, 4, treated as a sphere of electron density, giving the amplitude of 
its diffracted wave contribution, within the Fourier sum, dependent on the number of 
electrons present in the atom. The exponential component represents a simple three-
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dimensional periodic function with both sine and cosine components. It relates to the position 
of atoms within the unit cell as xj, yj, zj are the real space co-ordinates of atom, 4, within the 
unit cell expressed as fractions of axis length. Alternatively 5 can be described as the 
contributions from volume elements, centred on co-ordinates x, y, z, (equation 14.6), or more 
simply as part of the unit cell (equation 14.7), of the electron density, A, within the unit cell.  
 
5 =	B B BA(C, E, F)	89/(;=>=?)
C	
E	
F?>;  (equation 14.6) 
 
5 =	BA(C, E, F)	89/(;=>=?)
G  (equation 14.7) 
 
The values of these elements are equal to the average electron density within the specified 
volume, so by decreasing the size of each individual volume element a value more exactly 
represents the true electron density at that point. As each term in a Fourier sum would 
represent an average electron density, the Fourier sum is instead described in terms of 
integrals in order to make the volume elements infinitely small and the corresponding 
electron density values reflect reality over the whole unit cell.  Fourier transforms represent a 
reversible operation and the electron density can therefore be derived from a set of structure 
factors (equation 14.8). 
 
A(C, E, F) = 	 16665	H89/(;=>=?)
 (equation 14.8) 
 
As the hkl values represent discrete entities, the equation contains a triple sum instead of the 
triple integral required for the continuous data of the previous equation (equation 14.7). 
Using this equation, an electron density map can be constructed provided the required 
information is available. Structure factors are periodic functions that possess an amplitude, 
frequency and phase and in order to calculate each structure factor, these three properties 
must be known. The amplitude is proportional to the square root of the intensity of each 
reflection, Ihkl, and the frequencies are provided by the values of h, k, l, and are therefore 
recorded in the diffraction image data. Unfortunately the phase information is lost during data 
collection and must be calculated using other methods. 
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14.10 Obtaining phases 
A structure factor can be thought of in terms of a complex vector which can be split into 
amplitude, |Fhkl|, and phase, αhkl, components. This allows the expression of the electron 
density in terms of structure factors (equation 14.9) where the phases have separate explicit 
values to the amplitudes (equation 14.9). 
 
A(C, E, F) = 	 1666|5|	H89/(;=>=?)=/JKLM
 (equation 14.9) 
 
Three methods were used to calculate phases in the work described in this thesis. 
Isomorphous replacement and anomalous dispersion are experimental techniques that involve 
the determination of a substructure of certain marker atoms. The experimental amplitudes and 
calculated phases of the substructure are then combined with the experimental amplitudes of 
the protein diffraction data to calculate phases for the protein structure. Molecular 
replacement represents a theoretical technique that relies on the availability of a previously 
solved structure for a highly similar protein. The known structure is positioned in the unit cell 
and the phases are then calculated from the model. All three of these methods rely on the use 
of the Patterson function in some form. 
14.10.1 The Patterson function 
The Patterson function (equation 14.10) is a Fourier sum without phases using amplitudes 
that relate directly to reflection intensities in diffraction data. The function can therefore be 
used for diffraction data, despite the lack of phase information attached to each reflection. 
 
 
N(, , O) = 	 1666|5|8	H89/(P==Q)
 (equation 14.10) 
 
Each structure factor amplitude is squared, |Fhkl|2, making it proportional to the measured 
intensities in diffraction data. The equation produces a Patterson map with its own co-
ordinate system, u, v, w, representing vectors between atoms in the real space structure. If the 
structure of the unit cell is relatively simple, consisting of a small number of atoms, the 
Patterson function can therefore be used to determine the location of individual atoms in real 
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space based on the presence of vectors between them. However as the vectors found by 
Patterson methods are of an unknown direction, there are two possible solutions to the 
structure of atoms located using Patterson methods, typically referred to as the original and 
inverted hands. The atomic model produced can be used to calculate phases for the structure 
factors of the model (equation 14.5). Unfortunately the amount of information relating to 
vectors between atoms in a protein is huge as the number of atoms in even a relatively small 
protein of 20 kDa is in excess of 2,500 atoms meaning Patterson methods cannot be directly 
applied to entire protein structures. 
14.10.2 Single isomorphous replacement and multiple isomorphous replacement 
Isomorphous replacement represents one technique to effectively simplify the results of the 
Patterson function by reducing the number of atoms for which vectors are produced. The 
technique involves producing isomorphous crystals, identical to the native crystals, but for 
the addition of a small number of heavy atoms. This is achieved through co-crystallisation in 
the presence of heavy atoms, or through soaking crystals in a solution similar to the 
crystallisation condition but with added heavy atoms prior to mounting onto the data 
collection apparatus. Heavy atoms used in protein crystallography typically include iodine, 
mercury, gold or platinum which can bind to specific residues in the proteins structure. The 
native and derivative data can then be compared and if the native data is subtracted from the 
isomorphous derivative data an estimated diffraction pattern of the added heavy atom(s) 
within the unit cell is effectively produced (equation 14.11). 
 
FS = FTS − FT (equation 14.11) 
 
This process is combined with the Patterson function (equation 14.10) to create the difference 
Patterson function (equation 14.12). 
 
∆N(, , O) = 	 1666∆58 	H89/(P==Q)
 (equation 14.12) 
 
The difference in the intensities of each reflection, ∆F, effectively	(|5TS| − |5T|), are used to 
create a Patterson map for the heavy atom component, FH, of the derivative data. The 
resulting simple Patterson map can be used to solve a model of the positions of the heavy 
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Figure 14.4 A graphical representation of phase calculation using isomorphous replacement. The green dotted 
lines, dashed arrows, arrow, circles and angle α represent |FP|. The dark and light red arrows represent |FH| with 
both amplitude and calculated phases for derivatives one and two respectively. The dark and light blue dotted 
lines and circles represent |FPH| for derivatives one and two respectively. Solid arrows represent structure factors 
with known amplitude and phase; dashed arrows represent structure factors with known amplitude but of two 
possible phases; circles and dotted lines represent structure factors of known amplitude and unknown phase; and 
the angle α represents the desired protein phase information. a shows a vector diagram representing a solution 
for a single isomorphous derivative. The structure factors for the protein data, |FP|, have known amplitude 
(dotted green line) but unknown phase. They can therefore be represented as a circle, centred on the origin, 
when plotted on axes representing the real and imaginary components of the structure factor (green circle). The 
heavy atom structure factor, FH1, has a known amplitude and phase and is placed at the origin of the two axes 
(dark red arrow). A circle can be drawn around the end of the FH1 vector representing |FPH1| (dark blue circle) as 
these structure factors have a known amplitude (dark blue dotted line) but unknown phase. This provides two 
possible values for the phase of the protein structure factor, where the two circles intersect. b shows the same 
vector diagram including a second isomorphous derivative. Phases for the protein structure factor are derived 
using the same method, this time the heavy atom structure factor, FH2, (light red arrow) is placed at the origin, 
and the derivative amplitudes |FPH2|are plotted around its end (light blue circle). The location where the three 
circles intersect provides the correct phase, α, for the protein structure factor, FP. 
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atom(s) within the unit cell. This model, complete with experimental amplitudes and 
calculated phases, coupled with the native and derivative experimental amplitudes from the 
diffraction data, can then be used to calculate phases for the protein structure. If the heavy 
atom structure factors, FH, are subtracted from the derivative structure factors, FPH, the 
resulting structure factors belong to the protein, FP (equation 14.13). 
 
FT = FTS − FS (equation 14.13) 
 
The phases of the protein structure can therefore be calculated, either diagrammatically using 
Harker constructs (figure 14.4) or computationally using X-ray crystallography software. A 
single derivative data set provides two possible estimates of the phase, α, for each structure 
factor, FP (figure 14.4 a). To reach a single isomorphous replacement solution the value of the 
protein phase is taken as the centroid between the two possible values to provide a rough map 
of electron density that may be improvable by certain density modification techniques. 
Alternatively the phase ambiguity can be removed by using the multiple isomorphous 
replacement technique providing much better initial protein phases. Datasets are collected 
from different crystals with heavy atoms bound in different positions within the unit cell. In 
the simplest form a second derivative can be used to calculate a further two estimates for the 
protein phase. One of which should correspond to one of the phase estimates from the first 
derivative solving the ambiguity and providing a reasonable estimate for the phase of the 
reflection (figure 14.4 b). 
14.10.3 Anomalous dispersion 
The incorporation of atoms capable of anomalous dispersion in the unit cell allows for a 
further method to determine phases for the experimental data. Anomalous scattering occurs 
when the incident X-ray photon is absorbed by atoms in the crystal, causing a transition 
between electron orbitals, and reemitted with a different amplitude and phase as the energy is 
lost from the atom. The absorption of incident X-rays by an element is wavelength dependent 
with sharp rises at absorption edges equivalent to the energy required to effect specific 
electronic transitions (figure 14.5). Therefore overall scattering from the crystal has both a 
wavelength independent, but scattering angle dependent, contribution of every atom to 
diffraction, 7V, but also a wavelength dependent, but scattering angle independent, 
contribution from the anomalously scattering atoms, in the unit cell, 7′ and 7′′ (equation 
14.14). 
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Figure 14.5 X-ray absorption edges of commonly used phasing elements. The figure shows the theoretical f’ 
and f’’ values for a single atom of an element at the given X-ray wavelength or energy for selenium, iodine and 
mercury. The figure was produced using the SSRL Absorption Package. 
 
 
Figure 14.6 Anomalous scattering causes Friedel’s law to breakdown. The green arrows represent the scattering 
from the non-anomalously scattering atoms (the protein) and are equal in amplitude but opposite in phase. The 
light orange and dark orange arrows represent the normal and dispersive scattering from the anomalously 
scattering atoms respectively. The purple arrows represent the phase shifted anomalous component of the 
scattering from the anomalously scattering atoms and it is this component that causes Friedel’s law to 
breakdown. The p ink arrows are the structure factors for the combined scattering of the non-anomalously and 
anomalously scattering atoms and it is the amplitudes of these that are directly measured in the diffraction data. 
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7+ZZP[ =	7V +	7] +	7]] (equation 14.14) 
 
The real dispersive difference component, 7′, alters the amplitude of the normal scattering 
while the imaginary anomalous difference component, 7′′, has a phase that is shifted by 90º 
to the normal, 7V, and dispersive, 7′, scattering. The effect of the anomalous 7′′ component of 
the scattering means that Friedel’s rule is broken and Friedel pairs no longer have equal 
amplitudes and opposite phases becoming Bijovet pairs with values F+ and F- (figure 14.6). 
14.10.4 Single-wavelength anomalous dispersion 
In single-wavelength anomalous dispersion experiments the anomalously scattering atom 
substructure can be determined using Patterson methods. A difference Patterson function 
(equation 14.2) can be conducted using the amplitudes of the two members of the Bijovet 
pair, where ∆F, is effectively	(|FT=^ | − |FTH^ |), to locate the positions of the anomalously 
scattering atoms. The substructure model can be used to generate structure factors with an 
amplitude and phase for the normal scattering component from anomalously scattering atoms, 
X^ . This can then be combined with the phase shifted anomalous component of the scattering 
from the anomalously scattering atoms and the two amplitudes of the members of a Bijovet 
pair to calculate two possible phases for the other non-anomalously scattering atoms in the 
crystal for each reflection (equation 14.15). 
 
XT^ = XT + X^ + X^]] (equation 14.15) 
 
The total scattering of the protein and anomalously scattering atoms, FPA, is the sum of the 
protein scattering, FP, with the collinear normal, f0, and real dispersive, f’, elements from the 
anomalously scattering atoms, FA, and the imaginary anomalous component phase shifted by 
90º,	X^]]. Two possible protein phases can therefore be calculated in a similar fashion to that 
used in isomorphous replacement, either graphically (figure 14.7) or computationally using 
X-ray crystallography software. 
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Figure 14.7 A graphical representation of phase calculation using single anomalous dispersion. This diagram is 
analogous to that for the isomorphous replacement solutions. The green dashed arrows represent possible values 
of |FP|. The orange arrow represents |FA| with both amplitude and calculated phase. The pink dotted lines and 
circles represent |FPA+| and |FPA-|. The vector diagram represents a solution for a SAD dataset. The normal 
scattering structure factors for the anomalously scattering atoms, FA, has a known amplitude and phase and is 
placed at the origin of the two axes (orange arrow). The anomalous scattering contributions are also known, 
F’’A+ and F’’A-, are also known and plotted towards the origin. The structure factors for the combined 
anomalous and non-anomalously scattering atoms, |FPA+| and |FPA-|, have known amplitude (dotted pink lines) 
but unknown phase. They can therefore be represented as a circle, centred on the end of the corresponding 
anomalous vector (pink circles). This provides two possible values for the phase of the non-anomalously 
scattering atoms structure factor, where the two circles intersect, with the structure factor being measured from 
the end of the anomalously scattering atom structure factor to the circles intersection. 
FA
 
F’’A
+ 
F’’A
- 
FPA
+ 
FPA
- 
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Figure 14.8 A graphical representation of phase calculation using single isomorphous replacement with 
anomalous scattering. This diagram is analogous to that for the SAD and isomorphous replacement solutions 
and is effectively constructed by overlaying figure 14.4 a with figure 14.7. This vector diagram provides a single 
value for the phase of the non-anomalously scattering atoms structure factor, where the three circles now 
intersect. 
F’’A
+ FA
+ 
F’’A
- 
FPA
+ 
FPA
- 
|FPH| |FP| 
FH 
FP 
 
14.10.5 Single isomorphous replacement with anomalous scattering 
SIR and SAD can be combined to form the single isomorphous replacement with anomalous 
scattering (SIRAS) technique in order to solve the phase ambiguity that arises from the two 
techniques. The possible protein phases found by SIR are symmetrical about the heavy atom 
phase, while protein phases found by SAD are symmetric perpendicular to the heavy atom 
phase. The two possible phases found using SIR and the two possible phases calculated by 
SAD should therefore have one solution in common (figure 14.8).  
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14.10.6 Multi-wavelength anomalous dispersion 
The phase ambiguity from a SAD experiment can also be resolved by incorporating 
additional datasets collected at different wavelengths. This provides further information as 
different datasets will have different f’ and f’’ values, as these are wavelength dependent, but 
the same f0, as this is wavelength independent. This information allows a single protein phase 
for each structure factor to be calculated (equations 14.16 and 14.7) [198]. 
 
|5=|8 = |5_|8 + |5^ |8 + `|5_||5^ | cos ∆d + e|5_||5^ | sin ∆d (equation 14.16) 
 
|5H|8 = |5_|8 + |5^ |8 + `|5_||5^ | cos ∆d − e|5_||5^ | sin ∆d (equation 14.17) 
 
The constants, a, b and c (equations 14.18, 14.19 and 14.20) are dependent on the scattering 
contributions from the anomalously scattering atoms. 
 
 = 7
]8 + 7]]8
7V8  ` =
27]
7V  e =
27]]
7V  
(equation 14.18) (equation 14.19) (equation 14.20) 
 
The phase angle that is derived, ∆d, is not the phase angle of the protein, α or d_, but the 
difference between the phase of the scattering from the non-anomalously scattering atoms, 
d_, and the anomalously scattering atoms, d^. Providing data is available for multiple 
wavelengths containing an anomalous diffraction contribution there are sufficient data to 
directly derive protein phases. In multi-wavelength anomalous dispersion experiments, three 
wavelengths are typically collected and are referred to as the peak, inflection and remote 
datasets. The peak and inflection are close to the absorption edge and are collected to 
maximise f’’ and minimise f’ respectively with the remote dataset distant to the edge in order 
to maximise ∆f’ with respect to the inflection. 
14.10.7 Molecular replacement 
The final technique used in attempts to provide initial phases for structure solution in this 
thesis is molecular replacement. In order for molecular replacement to be successful a 
structure must already have been determined for a protein with a similar three dimensional 
fold. The known structure is used as a search model in order to obtain the phase information 
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for the target structure. Structure factors with both an amplitude and phase can be calculated 
for the search model. The phases from the model are then used as the initial estimate of the 
phases for the structure factors of the target protein alongside the experimentally determined 
amplitudes allowing an electron density map to be produced. The first step in solving a 
structure by molecular replacement is to create a suitable search model. This is usually 
achieved by finding a structure in the protein data bank with a high degree of sequence 
similarity before editing the model to better resemble the target protein. The second step 
requires the search model to be correctly positioned inside the unit cell of the target protein in 
order to calculate useful phases. Placing the model is further divided into two steps, the first 
is a search based on the orientation of the molecule(s) in the unit cell followed by a second 
search based on the location of the correctly orientated molecule(s) inside the unit cell. The 
rotation search is achieved through the use of Patterson functions which can be calculated for 
both the experimental amplitudes and the amplitudes of the known structure factors of the 
search model.  The Patterson map from the experimental data is superimposed with maps 
created for the search model in a number of orientations, differing by small increments in the 
rotation of the molecule within a unit cell (equation 14.21).  
 
!(h, d, i) = B Nj(, , O)Nk(, , O)(h, d, i)l	
	
	
O
P,,Q
 (equation 14.21) 
 
The orientation of the search model,	h, d, i, that provides the greatest consensus between 
peaks in the experimental,	Nj, and model, N, Patterson maps,	!(h, d, i), is then taken for 
the translation search. This is performed by comparing the experimental amplitudes directly 
with calculated amplitudes from the correctly orientated model in the unit cell placed in a 
number of locations differing by small increments in their translations about the unit cell. 
One method of is to use the translation correlation function (equation 14.22). 
 
m() = 	 ∑(|XZ|
8 − |XZnnn|8) o|Xp()|8 − %Xp()nnnnnnn%8q
0(|XZ|8 − |XZnnn|8)8 o|Xp()|8 − %Xp()nnnnnnn%8q
8 (equation 14.22) 
 
Structure factors are calculated for the protein, in the orientation found from the rotation 
search, in all positions,	, inside the cell on a small spaced grid. The correlation, m, between 
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the observed, XZ, and calculated, Xp, structure factors is then compared to find the best 
possible location within the unit cell. Finally the location that provides the highest degree of 
consensus is taken and the predicted phases of the model are combined with the experimental 
amplitudes to produce initial estimate for the protein structure factors.  
14.10.8 Density modification 
Initial calculated phases can be improved by applying prior knowledge about the density 
found in protein crystals and known or predicted properties specific to the crystal being 
studied. There are four main techniques that can be used for density modification procedures, 
solvent flattening and flipping, histogram matching and averaging the density around non-
crystallographic symmetry elements. 
14.11 Data processing, estimating phases and initial model production 
Once a dataset was collected it was integrated using either XDS [199] or Mosflm [146] 
before scaling using the programmes XSCALE [199] or SCALA [188]. Phasing was 
attempted using a number of programmes and techniques for the work included in this thesis. 
Details of the techniques and programs used for each target are described in the relevant 
results sections. Experimental phasing by SIR, SAD, SIRAS and MAD were conducted using 
either the SHELX package of programmes (SHELXC, SHELXD and SHELXE with 
autotracing), the AutoSol programme of the Phenix suite [158] or the crank pipeline which 
uses programmes (AFRO/CRUNCH, BP3, SOLOMON, PARROT  and Buccaneer) from the 
CCP4 suite of programmes [156]. Molecular replacement was conducted using Phaser [151] 
from the CCP4 suite [156]. Initial model building was done by the Buccaneer programme 
[187] of the CCP4 suite [156], or the Autobuild programme of the phenix suite of 
programmes [158]. 
14.12 Model rebuilding, refinement and validation 
After initial phases for the protein have been calculated, and a starting protein model 
produced, the model is improved by iterative rounds of rebuilding and refinement. The aim of 
this process is to build the model that best describes the experimental data. The agreement 
between the model and the diffraction data is calculated by comparison of the observed 
structure factor amplitudes, from the experimental data, with a calculated set of structure 
factors amplitudes created from model to produce an R-factor, R (equation 14.23).  
 
226 
 
R = 	∑ %|5Zs[| − 3|5pp|% ∑ |5Zs[|  (equation 14.23) 
 
The calculated structure factors are adjusted by a scaling factor, k, to relate them to the same 
scale as the experimental data. A low R-factor is desirable meaning the model corresponds 
well with the data, with a value of zero meaning the model agrees perfectly with the data. In 
reality, due to errors in data collection and the limits of resolution, it is not possible to 
accurately determine the exact position of all the atoms in the unit cell. A free R-factor, Rfree, 
is also calculated using a small random subset of the diffraction data that is excluded from the 
refinement process in order to monitor and guard against any incorporation of bias by 
overfitting. The R-factor and free R-factor should be a close to each other as possible as a 
difference of more than 5 % suggests the model has been over fitted to the data and become 
biased. Known structural parameters, based on theoretical and observed values from other 
high resolution structures, can also be used to gauge the quality of a model. These include 
chemical properties, such as bond lengths and angles, stereochemical properties, such as 
chirality, and conformational properties, such as atom clashes. Model improvement is 
achieved by cycles of adjusting the model to best fit an electron density map, followed by 
refinement and production of a new electron density map, which is in turn used to adjust the 
model. The progress while building a structure is monitored by a comparison of the R and 
Rfree values from subsequent steps alongside analysis of the models geometry. The process of 
refinement makes small changes to the model, adjusting the positioning of atoms and their 
associated B-factors in order to reduce the overall R-factor. Refinement can be conducted 
with varying degrees of external restraints placed upon the model. The application of these 
restraints is decided based on the resolution of the data and the progress of model building. 
Generally, the lower the resolution of the data and the earlier in the model building process, 
the greater the number of these restraints that are applied. 
14.13 Producing the final model 
Refinement and rebuilding of models in this thesis were conducted using REFMAC5 [152], 
from the CCP4 programme suite [156], and COOT [159] respectively. The initial phased 
model was first examined in COOT and rebuilt to best fit the current electron density map 
while maintaining appropriate geometry between the atoms in the model. Rebuilding includes 
making alterations to existing components, and adding atoms corresponding to unbuilt parts 
of the protein and molecules from the surrounding buffer for which there is definitive density 
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in the map. Once the model could not obviously be further improved it was input alongside 
the original data into REFMAC5 [152] for refinement. Each refinement stage consisted of 10 
cycles of maximum likelihood refinement provided with various external restraints. Two 
maps and an adjusted model were output at the end of each refinement stage. The model 
contains the minor adjustments made as part of the refinement process. The two maps are a 
weighted map of	2|XZs[| − t|Xpp|, where the weights are dependent on the quality of the 
current model, and |XZs[| − |Xpp|. The two maps were used in the COOT programme 
alongside the refined output model to guide further modification of the model before further 
refinement in an iterative process that finished when the model could not be improved 
further. During model building, the structural parameters were examined using the structure 
analysis tools within the COOT. Once a final structure had been completed, the geometry was 
analysed using PROCHECK [160] and the Molprobity server [161]. Molprobity also 
calculates a score based on the quality of the model geometry and compares this to other 
models in the PDB of a similar resolution in order to gauge the relative quality of the model. 
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15.0 Abbreviations and symbols 
 
15.1 Crystallographic 
Å Angstrom (10-10 m) 
a, b, c, α, β, γ Real space unit cell dimensions and angles 
ASU Asymmetric unit 

  Inter-planar spacing in the reciprocal lattice 
X Structure factor 
X] Structure factor arising from the dispersive scattering from an atom 
X]] Structure factor arising from the anomalous scattering from an atom 
XV Structure factor arising from the normal scattering from an atom 
X  Structure factor for the reflection with indices hkl 
X^  Structure factor arising from the anomalous contribution of all atoms 
XS Structure factor arising from the atoms in a heavy atom substructure 
XT Structure factor arising from the atoms in a protein structure 
XTS Structure factor arising from a protein structure containing heavy atoms 
X_  Structure factor arising from the total contribution of all atoms 
|X=|, |XH| Structure factor amplitudes for reflections in a Bijovet pair 
|X| Structure factor amplitude for the reflection with indices hkl 
|X| Structure factor for the reflection with indices hkl 
|Xpp[| Calculated structure factor amplitude 
|XZs[| Observed structure factor amplitude 
&  Intensity of the reflection with indices hkl 
&/v& Signal to noise ratio 
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7] Dispersive form factor from an atom 
7]] Anomalous form factor from an atom 
7V Normal form factor from an atom 
7+ZZP[ Atomic scattering from an anomalously scattering atom 
hkl Miller indices 
MAD Multiple-wavelength anomalous dispersion 
MIR Multiple isomorphous replacement 
MR Molecular replacement 
R R-factor 
Rw"" Free R-factor 
R"#" Merging R-factor 
R./ Precision-indicating merging R-factor 
SAD Single-wavelength anomalous dispersion 
SIR Single isomorphous replacement 
SIRAS Single isomorphous replacement with anomalous scattering 
u, v, w co-ordinates in Patterson space 
V Matthews coefficient 
x, y, z co-ordinates in real space 
Z Number of equivalent positions in the unit cell 
λ Wavelength 
φ^ The phase of the structure factors from the anomalously scattering atoms 
φ_ The phase of the structure factors from all atoms 
α Phase angle of the structure factors from the protein molecule. 
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15.2 Biological and chemical 
AHL N-acyl-homoserine lactones 
CPS Capsular polysaccharide structure 
DEAE Diethylaminoethyl 
DMSO Dimethyl sulphoxide 
DNA Deoxyribonucleic acid 
dNTP Deoxyribonucleotide 
EDTA Ethylenediaminetetraacetic acid 
EMTS Sodium ethylmercuric thiosalicylate 
HMAQ 4-hydroxy-3-methyl-2-alkylquinolones 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
LPS Lipopolysaccharide 
MES 2-(N-morpholino)ethanesulfonic acid 
mRNA Messenger ribonucleic acid 
NADPH Nicotinamide adenine dinucleotide phosphate 
PEG polyethylene glycol 
RNase RNA nuclease 
SDS Sodium dodecyl sulfate 
T3SS Type 3 secretion system 
T6SS Type 6 secretion system 
TRIS TRIS(hydroxymethyl)aminomethane 
Trx Thioredoxin 
X-gal 5-bromo-4-chloro-indolyl-β-D-galactopyranoside 
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15.3 Miscellaneous 
AU Absorbance unit 
bp Base pair (of nucleic acid) 
CCD Charge coupled device 
Kav Partition coefficient in gel filtration 
LB media Lysogeny broth media: 1 % (w/v) tryptone, 0.5 % (w/v) yeast extract, 1 % (w/v) NaCl 
OD Optical density 
PAGE Polyacrylamide gel electrophoresis 
PCR Polymerase chain reaction 
PDB Protein data bank 
pI Isoelectric point 
RMSD Root mean square deviation 
SOC media Super optimal brother with catabolite repression media: 2% (w/v) bacto-tryptone, 0.5% (w/v) Yeast extract, 10 mM NaCl, 2.5mM KCl 
TAE buffer TRIS acetate EDTA buffer 
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